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Age-related macular degeneration (AMD) is the leading cause for visual impairment and 
blindness registration in the developed world. Globally, 8.7% of the population has AMD 
and it has been projected that the number of people afflicted with AMD by 2020 will be 
196 million, increasing to 288 million by 2040.  
AMD is multi-factorial and the key pathogenesis of AMD is not known, but it has been 
postulated to be related to oxidative stress. As there is no known treatment for atrophic 
AMD, many researchers have investigated the modifiable risk factors such as smoking 
and diet to prevent progression to neovascular AMD. Following large clinical trials such 
as AREDS and AREDS 2, many supplements to support eye health emerged in the 
market. With such a large selection of products and various information, this could be 
confusing for the patients and even eye care practitioners.  
 
This doctorate programme consists of three distinct studies (chapters three to five) and 
the first objective of this research was to evaluate the nutritional and smoking advice for 
patients with or at risk of AMD by optometrists in Singapore. This objective was achieved 
via a questionnaire (online and hardcopy) (chapter three) as well as face-to-face in-depth 
interviews (chapter four).  
 
The questionnaire consisted of 41 questions and participants received the hardcopies 
through mail or an online link through social media or email to complete the questionnaire 
electronically. The questionnaire elicited demographic information, frequency of dietary 
advice to patients with early, advanced or at risk of AMD, as well as smoking advice to 
AMD patients.  
The response rate of the questionnaire was 18.2%. 52.9% of the respondents provide 
dietary advice to patients with advanced AMD most of the time, and 31.7% of the 
respondents provide dietary advice to patients at risk of AMD most of the time. 
Optometrists in Singapore advise AMD patients to consume green leafy vegetables and 
oily fish but seldom advise on the amount to consume. Slightly more than one-third of 
the optometrists in Singapore will inform smokers of the link between smoking and AMD 
and slightly more than half will advise AMD patients to stop smoking.  
From the face-to-face in-depth interviews, Singapore optometrists do believe that 
nutrition are beneficial for the eye but they need more knowledge and a guideline in this 
area to be more confident when providing nutritional advice for AMD patients.  
 
The second objective of this research was to evaluate a Clinical Decision-Making Aid 
(CDMA) in the form of a flowchart to determine its impact on the self-efficacy of qualified 
and student optometrists in providing dietary advice regarding risk or progression of AMD 
(chapter five). The results show that the self-efficacy scores increased after using the 
CDMA for both qualified and student optometrists and the number of correct answers for 
five simulated clinical scenarios also increased after using the CDMA.  
 
Despite some conflict regarding nutritional research for AMD, provision of appropriate 
nutritional and smoking advice is important with regard to reducing risk of progression to 
sight loss related to AMD. Moreover, optimising nutritional intake and avoiding smoking 
are beneficial for general well-being. This thesis shows that, with the CDMA, eye care 
practitioners are able to provide more accurate and research-based nutritional 
information to their AMD patients with more confidence.  
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Chapter One: Introduction 
1.1. Background to the research  
Classification of age-related macular degeneration  
Age-related macular degeneration (AMD) is an eye condition affecting the macula of the 
retina that is responsible for central vision. This condition was originally described by 
Haab in 18851, but the modern era of AMD began during the 1960s when Gass2 
described in details the clinical findings associated with AMD in which he believed that 
the source of pathology for AMD was at the level of the choroid. Though the exact 
pathogenesis of AMD is still unclear, the retinal layers that are affected in this condition 
also include the retinal pigmented epithelium (RPE) and Bruch’s membrane.  
There are several different AMD classification systems in place from previous large 
population-based studies such as the Beaver Dam Eye Study3 (BDES) (The Wisconsin 
Age-Related Maculopathy Grading System) and the Age-Related Eye Disease Study4 
(AREDS) (AREDS Grading System).  The AREDS classified AMD with the following 
system: 
Category 1: No AMD. No drusen, or a few small drusen (£ 63 µm in diameter). 
Category 2: Early stage AMD. Any or all of the following: multiple small drusen or a few 
intermediate drusen (63-124 µm in diameter) in one or both eyes, or RPE abnormalities. 
Category 3: Intermediate AMD. Any or all of the following: extensive intermediate drusen 
and at least one large drusen (³ 125 µm in diameter) in one or both eyes, or geographic 
atrophy not involving the center of the fovea.  
Category 4: Advanced AMD. Geographic atrophy (GA) involving the fovea or abnormal 
and fragile blood vessels under the retina (neovascular form). 
In 2013, Ferris et al.5 proposed a unified classification scheme which achieved 
consensus among AMD experts: 1) No apparent aging changes (No drusen and no AMD 
pigmentary abnormalities), 2) Normal aging changes (Only drupelets (small drusen (£ 
63 µm) and no AMD pigmentary abnormalities, 3) Early AMD (Medium drusen >63 µm 
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and £ 125 µm and no AMD pigmentary abnormalities, 4) Intermediate AMD (Large 
drusen >125 µm and/or any AMD pigmentary abnormalities, 5) Late AMD (Neovascular 
AMD and/or any geographic atrophy) 
Alternatively, AMD can be simply divided into the non-exudative or atrophic type and the 
exudative or neovascular type, and in addition to simplicity, the two types also offer a 
natural division in prognosis, as up to 88% of vision loss attributed to AMD is found in 
the exudative form6. Non-exudative AMD often occurs during the early stage of AMD and 
is characterized by the deposition of basal laminar deposits (BLD) debris at the level of 
Bruch’s membrane and this debris is thought to originate from incomplete metabolism of 
degenerating RPE cells. The clinical manifestations of AMD is defined by the 
degeneration of RPE and the accumulation of metabolic byproducts from RPE 
dysfunction7. The earliest stage of dry AMD begins when the BLD have formed a thin 
continuous layer, and as AMD progresses, the RPE layer continues to degenerate, and 
two other hallmark findings, drusen and retinal thinning, become manifest clinically8.  
Drusen are localized deposits of membranous deposits that lie between the RPE 
basement membrane and the remainder of Bruch’s membrane. Drusen can be divided 
clinically into hard or cuticular drusen, soft or granular drusen, and diffuse or confluent 
drusen. Drusen has long been associated with AMD and the type of drusen can 
determine if the patient is at risk of exudative AMD9. Hard drusen are thought to represent 
a localized area of RPE dysfunction, are usually smaller than fifty microns in size and 
have been shown to be unrelated to increasing age3. In addition, the presence of small 
drusen does not increase the risk of progression to late maculopathy3. Soft drusen 
display ill-defined borders, tend to be variable in size and shape, are larger than fifty 
microns, increases with age and can coalesce to become confluent drusen10. The clinical 
finding of confluent drusen is thought to represent a more diffuse pattern of RPE 
dysfunction, and Green highlighted that the coalescence of several soft drusen could 
alter the clinical diagnosis of drusen to serous RPE detachment or exudative AMD9. 
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Reticular pseudodrusen, also known as subretinal drusenoid deposits, represent a 
morphological change to the retina. Histologically, reticular pseudodrusen have been 
shown to have distinct compositions in comparison to typical drusen and are located 
above the level of the RPE11.  It is highly related to later stages of AMD such as choroidal 
neovascularization and geographic atrophy, but also other diseases such as Sorby’s 
fundus dystrophy, pseudoxanthoma elasticum and acquired vitelliform lesions11.  
Geographic atrophy (GA) of the RPE is the end-stage maculopathy in non-exudative 
AMD12, and retinal function in the area of GA is severely compromised. However, the 
loss of visual acuity is variable as the area of fixation is sometimes spared, even when 
large areas of atrophy are present. GA accounts for 12% to 21% of legally blind eyes in 
AMD13.  
Exudative AMD is distinguished from non-exudative AMD when the integrity of the 
Bruch’s membrane or RPE complex separates and forms a pigment epithelial 
detachment (PED)7. When this occurs, the sub-RPE and sub-retinal potential spaces are 
exposed to the rich vascular milieu of the choriocapillaris and the result is the formation 
of a pigment epithelial detachment (PED) and exudative AMD. PEDs come in various 
clinical appearance such as confluent drusen, serous, hemorrhagic and vascular 
pigment epithelial detachments14. Once a PED forms, there are four potential outcomes: 
persistent PED, spontaneous flattening of the PED, spontaneous RPE tear, or choroidal 
neovascularization (CNV)7. Spontaneous flattening of PEDs has been reported to lead 
to GA15,16. The most common complication of PED is the formation of CNV, which occurs 
frequently with all of the PED groups except confluent drusen17. CNV develops when a 
defect occurs in the Bruch’s membrane and new capillaries from the choriocapillaris grow 
towards the pigment epithelium18. Type I CNV occurs when the neovascularization is 
confined to the sub-RPE space and Type II occurs when the neovascularization 
penetrates the RPE to enter the sub-retinal space19. CNV can also be classified into 
classic, occult and disciform scar7.       
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Causes and risk factors of AMD  
Similar to many other chronic degenerative diseases, AMD is multifactorial. The known 
factors are environmental, genetic, and sometimes concomitant systemic disease. The 
term AMD has itself suggested that aging is associated with a higher incidence, and in 
fact, age is the primary risk factor for AMD. The free radical theory of aging identifies 
reactive oxygen intermediates (ROIs) as causing cumulative damage to DNA and other 
macromolecules, leading to senescence, cell death, disease, and ultimate organism 
death20. Oxygen is essential for aerobic activities in living things, but is potentially toxic 
when harmful molecules known as ROIs are being formed. ROIs can be formed 
endogenously through normal metabolism and they can destruct many cellular 
components such as lipids, proteins and nucleic acids7. Lipid peroxidation can be 
initiated by hydroxyl radical (formed as a result of hydrogen peroxide obtaining another 
electron), hydroperoxyl radical, or singlet oxygen, and toxic compounds that result from 
lipid peroxidation, such as malondialdehyde (MDA), can cause inflammation either at the 
site of formation or at other sites via diffusion7. ROIs can cause DNA damage or inhibition 
of transcription and translation through base hydroxylation and cross-linking of DNA 
strands21.  
 
Potentially Harmful ROI Sources 
Superoxide anion radical, O2-- Auto-oxidations, oxidases, electron 
transport chain, respiratory burst, light 
and lipofuscin 
Hydrogen peroxide, H2O2 Electron transport chain, light and 
lipofuscin 
Hydroxyl radical, OH- Fenton reaction, Haber-Weiss reaction 
Peroxide radical, ROO- Hydroxyl attack of rod and cone 
polyunsaturated fatty acids after RPE 
phagocytosis 
Singlet oxygen, 1O2 Light acting on molecular oxygen in the 
presence of photosensitizers such as 
lipofuscin 
Table 1.1: Most common ROI and their possible production sites7.  
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Oxidative stress occurs when there is an excess generation of oxidants through essential 
biologic functions, or an imbalance between oxidants and antioxidants. Besides AMD, 
oxidative stress contributes significantly to other age-related diseases such as 
atherosclerosis, chronic lung disease and Alzheimer’s disease22–24. The eye is highly 
susceptible to oxidative processes due to its function; it is subjected to high light 
incidence and in conjunction with photosensitizers such as melanin, rhodopsin and 
lipofuscin, it has the ability to produce a multitude of ROIs7. As oxidative stress has been 
identified as one of the main causes for AMD, the use of antioxidants such as vitamin C, 
vitamin E and carotenoids in protecting against development of AMD or limiting its 
progression have been studied extensively by researchers.  Environmental factors such 
as cigarette smoke contains an extremely high concentration of free radicals25, causing 
an increased state of oxidative stress in the body. A meta-analysis of three large 
population-based studies on three different continents found an odds-ratio for all types 
of AMD of 3.12 for current smokers compared to non-smokers, and it was concluded that 
smoking is the main preventable risk factor associated with AMD26.  
AMD is believed to be a genetic condition and over the past few years, many studies 
were conducted in identifying causative and protective genetic variants associated with 
AMD, and the discoveries of the complement factor H (CFH) gene and the chromosomal 
10q26 locus, which contains the LOC387715/ARMS2 and HTRA1 genes are one of the 
major breakthroughs27,28. Other established genetic risk markers identified include 
complement component 3 (C3), complement component 2 (C2) or complement factor B 
(CFB), complement factor I (CFI) and apolipoprotein E (ApoE) 29–32. Further details will 
be discussed in the section “Pathogenesis of age-related macular degeneration” in 
chapter two. In general, the non-modifiable risk factors of AMD are age and genetics, 
while the modifiable risk factors are lifestyle modifications such as to quit smoking for 





Singapore has a population of approximately 5.6 million and 9.72% are aged 65 years 
and above33; the life expectancy at birth for males is 80.7 years and 85.2 years for 
females34. With the rapidly greying population, the prevalence of AMD in Singapore will 
most likely increase concurrently35,36. Singapore is a multi-racial country and the three 
main races are Chinese, Malays and Indians. The age-standardized prevalence of early 
and late AMD in Singapore is 5.1% and 0.5% respectively, with no racial predilection, 
although early AMD is more common in Chinese and Indians compared to Malays37.  
Additionally, the study by Cheung et al. highlighted that the prevalence of bilateral AMD 
between Singapore Malays and Caucasians is comparable37.  
AMD causes a huge impact on society, and Brown and colleagues found that mild AMD 
caused a 17% decrease in quality of life of the average patient, moderate AMD caused 
a 32% decrease in the average patient’s quality of life, severe AMD caused a 53% in 
quality of life and very severe AMD caused a 60% decrease in the average AMD patient’s 
quality of life (QoL), similar to that encountered with end-stage prostate cancer or a 
catastrophic stroke38. Similarly as demonstrated by more recent studies, the vision and 
health-related QoL scores in AMD patients are reduced significantly39,40. It has also been 
established that early AMD lesions are associated with lower self-reported vision-specific 
health-related QoL but not general health-related QoL, and the severity and bilaterality 
of AMD are associated with lower health-related QoL scores40. As AMD affects the 
central vision, the QoL reduces concurrently with the severity of the condition. Therefore 
those who are visually impaired experience significantly reduced QoL, which manifests 
as greater social dependence, difficulty with daily living, higher rates of clinical 
depression, increased risk of falls, premature admission to nursing homes and suicide41. 
Unsurprisingly, the economic burden of AMD in Singapore is high as well and it has been 
proven by Saxena and co-workers that the medical cost of treating a cohort of patients 
with category 3 and 4 AMD ranged from Singapore dollars (SGD) 282.8 million to SGD 
510.7 million for a period of five years depending on the type of treatment42. In view of 
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the society impact and financial burden that AMD will bring, Singapore initiated the AMD 
awareness week from 2005. Since then, this public health campaign is organized 
annually, with the main objective to generate awareness and understanding of AMD, 
including the modifiable risk factors, through education, early detection and knowledge 
of treatment and rehabilitation options for the disease. This campaign encourages those 
above 50 years of age to go for regular eye examinations, and it hopes to preserve vision 
and improve quality of life of individuals with AMD43. The activities of this campaign 
include educational health talks on AMD, eye screenings for the public above 50 years 
of age, smoking cessation campaigns and educational and art exhibitions on AMD. This 
national campaign has produced satisfying results as through a telephone survey 
conducted in 2006 and 2011, it showed that the awareness of AMD have increased four-
fold from 7.3% to 28.1%44. Additionally, among the respondents who were surveyed in 
2011, 84.1% were aware that smoking is a risk factor of AMD, compared to 45.9% who 
were aware in 2006.  
This public health campaign is indeed necessary as it has been estimated that there will 
be a growth of 42% in the number of wet AMD cases by 2030, and the estimated 
economic burden of wet AMD by then is SGD 203.1 million if patients were not taking 
preventive antioxidant vitamins45. On the other hand, if AMD patients were taking 
preventive antioxidant vitamins, the estimated economic burden would be SGD 162.9 
million45. In a study by Saxena and colleagues on a hypothetical cohort of category 3 
and 4 AMD patients from Singapore, it was found that more than 5400 patients could be 
prevented from progressing to wet AMD if AREDS formulation were prescribed42.  
From a national perspective, Singapore has recognized AMD to be one of the health 
conditions that will have a social impact and economic burden to the country in the near 
future. Hence efforts have been made to increase the awareness of AMD to the public 
through the national health campaign, AMD awareness week, that is being held annually, 
and still ongoing till today. Additionally, it hoped that Singaporeans who are aged 50 
years and above will go for their annual eye examinations so that AMD could be 
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diagnosed early, and AMD patients could be more conscious of the modifiable risk 
factors such as smoking and dietary modification. The role of optometrists is vital as they 
will most likely be the first health care practitioner to diagnose AMD through a 
comprehensive eye examination, especially when the patient has no symptoms during 
the early stages. On top of that, their advice to AMD patients, such as to quit smoking if 
they are current smokers, to make some changes to their diet, or to take supplements is 
also important as it could help to prevent their AMD conditions from worsening.  
 
1.2. Scientific justification for the research  
Age-related macular degeneration (AMD) is the leading cause of visual impairment and 
blindness registration in the developed world46 and it accounts for 8.7% of all causes of 
blindness globally47. As discussed in the previous section, AMD is classified into non-
exudative and exudative forms, and to date treatment is only available for the exudative 
form. Therefore, researchers are investigating the modifiable risk factors for AMD such 
as smoking and dietary modification that includes intake of antioxidant micronutrients 
and/or polyunsaturated fatty acids, and exploring the possibilities of preventing or 
reducing the risk of progression from non-exudative to exudative AMD, which usually 
has the worse visual prognosis among all the AMD stages.   
Smoking increases the risk of AMD as it increases retinal oxidative stress, decreases 
choroidal blood flow, stimulates choroidal neovascularization and reduces the amount of 
antioxidants in the blood48. AMD has also been shown to be positively correlated with 
the duration of smoking and the number of cigarettes49. Cross-sectional studies that 
showed a relationship between smoking and AMD include the Beaver Dam Eye Study50, 
Beaver Dam Offspring Study51, Rotterdam Study52, Blue Mountains Eye Study53, Age-
related Eye Disease Study4, Eye Disease Case-Control Study54 and POLA study55. The 
above-mentioned studies highlight that current smokers have a higher risk of early51 and 
neovascular AMD50,52-53, and the Rotterdam study52 found that the increased risk of 
neovascular AMD was present up to twenty years after cessation of smoking. 
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Longitudinal studies with a follow-up period between five and ten years also proved that 
current smokers have a higher risk of AMD56–60.  
The first piece of evidence to suggest the association between antioxidant micronutrients 
in the diet and AMD is from the first National Health and Nutrition Examination Survey 
that was conducted in the United States back in 198861. With oxidative stress being 
identified as one of the key pathogenesis of AMD, antioxidant micronutrients in the diet 
have been of particular interest to many researchers as antioxidants have been known 
to remove reactive oxygen intermediates (ROIs) in the body62. The Age-related Eye 
Disease Study (AREDS)63 was the first large clinical trial that evaluated the effectiveness 
of high-dose antioxidant supplementation in decreasing progression of AMD and 
associated vision loss. In this trial, the participants in the treatment group received the 
AREDS formulation consisting of 500mg of vitamin C, 400IU of vitamin E, 80mg of zinc, 
2 mg of copper and 28,640IU of vitamin A. The results from the AREDS showed that the 
AREDS formulation is beneficial for patients with AMD of category 3 or 463; at five years, 
the estimated probability of progression to advanced AMD was 28% for those assigned 
to placebo, 23% and 22% for those assigned to antioxidants and zinc, respectively, and 
20% for those assigned to antioxidants and zinc. Estimates of risk reduction from odd 
ratios suggest risk reductions for those taking antioxidants alone or zinc alone of 17% 
and 21%, respectively, and the risk reduction for those taking antioxidants plus zinc was 
25%. In addition, compared with the placebo group, AMD patients in categories 3 and 4 
assigned to antioxidants and zinc had a statistically significant reduction in the odds of a 
15-letter or greater visual acuity decrease (p = 0.008). There is an estimated 27% odds 
reduction in the visual acuity outcome for this group who are taking antioxidants and zinc. 
It has been suggested that the reduction in risk of visual acuity loss observed with the 
antioxidant plus zinc formulation may be a result of the reduction in risk of progression 
to advanced AMD.   
Out of 10 years of follow-up, there were no serious adverse effects and no significant 
effect on mortality was seen among participants randomized to antioxidant vitamins. 
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However, there were some concerns on the AREDS formulation for smokers as it was 
highlighted by other researchers that beta-carotene in the formulation could increase the 
risk of lung cancer in smokers. Therefore in AREDS 264, beta-carotene was replaced by 
other carotenoids, lutein and zeaxanthin, to establish the efficacy of the new formulation. 
Besides that, the AREDS 2 evaluated if the addition of omega-3 long-chain 
polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid 
(EPA) and lowering the dosage of zinc from the original AREDS formulation would affect 
the progression of AMD. From the AREDS 2, 10mg of lutein and 2mg of zeaxanthin 
reduced the risk of progression of AMD, as compared to the group not receiving this 
combination. Seddon et al. found that 6mg of lutein and zeaxanthin can also be beneficial 
to AMD patients as it reduces the risk of advanced AMD65. Unfortunately, only 1 to 3 mg 
of lutein and zeaxanthin are obtained from the typical American diet daily65. The intake 
of lutein and zeaxanthin has been found to reduce the risk of late AMD66, neovascular 
AMD67,68, as well as any form of AMD55,69. Macular pigment levels have recently been 
used as an indicator for macular health, hence some studies evaluated the macular 
pigment optical density (MPOD) following the intake of lutein and zeaxanthin. The 
studies that revealed increased MPOD following intake of lutein and zeaxanthin include 
studies conducted by Johnson et al.70, Zeimer et al.71, Richer et al.72 and Huang et al.73. 
Besides increased MPOD, studies such as the Carotenoids in Age-Related Maculopathy 
in Italians Study74 (CARMIS) and the Lutein Antioxidant Supplement Trial75 (LAST) also 
showed improved visual acuity, contrast sensitivity, Amsler grid results and glare 
recovery following supplementation of lutein and/or zeaxanthin.  
More recently, it was discovered that a deficiency in polyunsaturated fatty acids (PUFAs) 
would increase the risk of AMD, and this could be because DHA accounts for 50 to 60% 
of the total fatty acid content of the photoreceptor outer segments76. The US Twin Study 
of Age-related Macular Degeneration77 and AREDS78 found that those consuming the 
highest amount of omega-3 fatty acids had a reduced risk for any stage of AMD and 
neovascular AMD respectively. Furthermore, they found that the intake of omega-6 fatty 
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acids had an influence on the results. Prospective studies that showed participants with 
a high intake of fatty acids have a reduced risk of AMD include the Nurses’ Health Study 
and the Health Professionals’ Follow-Up Study79, Blue Mountains Eye Study80 and 
EUREYE81.   
Nevertheless, not all studies on nutrition and AMD showed positive results. There are 
some evidence suggesting that dietary modification are not beneficial for AMD 
progression, and a few studies even show that it could cause AMD to progress faster. 
These studies will be discussed under section 2.3 “Age-related macular degeneration 
and nutrition” in chapter two. However these studies are only a minority and many 
researchers still do believe that dietary modification such as increasing intake of 
antioxidants, lutein, zeaxanthin and polyunsaturated fatty acids are beneficial for AMD 
patients. Moreover, currently this seems like the most feasible approach as it has proven 
to be relatively effective and does not cause much damage to the human body, but to be 
more wary if the AMD patient has other systemic conditions, or is taking other 
medications.  
 
1.3. Purpose and objective of research  
This thesis consists of three different research studies and each has its own purpose 
and objective. The first study titled “Nutritional and smoking advice to patients with or at 
risk of AMD by optometrists in Singapore” aims to understand the nutritional and smoking 
advice that optometrists in Singapore are providing to their patients who have AMD, or 
are at risk. The second study “What do Singapore optometrists feel about providing 
nutritional advice to patients with or at risk of AMD?” complements the first through 
qualitative methods in order to gain a deeper understanding of optometrists’ views on 
nutrition and the eye. The third study “Evaluation of a clinical decision-making aid for 
qualified and student optometrists when providing nutritional advice for patients with or 
at risk of age-related macular degeneration” evaluates the efficacy of a clinical decision-
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making aid (CDMA) when providing nutritional advice to patients with or at risk of AMD. 
The following sections will explain in details the purpose and objective for each study.  
 
Study 1: Nutritional and smoking advice to patients with or at risk of AMD by optometrists 
in Singapore (Chapter 3)  
As there is no known treatment for non-exudative AMD, the modifiable risk factors such 
as smoking and diet modification have been identified to prevent AMD from progressing 
to exudative AMD or vision from deteriorating. In the early stages of AMD, patients could 
be asymptomatic and diagnosed of AMD following a routine eye examination. Since 
there is currently no treatment for non-exudative AMD, patients, particularly those with 
early stage AMD are usually not referred to the ophthalmologist and instead are asked 
to self-monitor their central vision at home with an Amsler grid and annual review. 
Patients who are being referred to the ophthalmologists are usually also being reviewed 
on a yearly basis, depending on the severity of the condition. Meanwhile, AMD patients 
could be advised to quit smoking if they are currently smoking, or to increase their intake 
of certain antioxidants such as vitamin A, C, E and/or lutein and zeaxanthin as well as 
polyunsaturated fatty acids as these could reduce their risk of exudative AMD. The intake 
of these micronutrients could be via their diet or nutritional supplements. Therefore, AMD 
patients may be asked to increase the intake of certain foods in their diet such as green 
leafy vegetables as they contain high amounts of lutein, or oily fish such as salmon, 
which is a source of PUFAs. Alternatively, some optometrists may ask AMD patients to 
get supplements that contain the above-mentioned antioxidants or nutrients which are 
beneficial for their condition. With the modifiable risk factors being the most feasible 
management option for patients with non-exudative AMD, the nutritional and smoking 
advice given by their optometrists is crucial as it could help to prevent a patient’s current 
AMD condition from advancing to later stages and prevent their vision from worsening, 
especially when there is a family history of AMD or patient is more than 85 years old82. 
In Singapore, there has been no previous research done on this area and not much is 
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known on the advice optometrists are providing to their AMD patients. In this study, the 
aim is to understand the smoking and nutritional advice given by optometrists in 
Singapore to their patients who are at risk or have AMD via a questionnaire, and this aim 
is achieved via the following objectives:  
• To establish the frequency and dietary advice given to patients with early (category 
1 or 2) AMD 
• To establish the frequency and dietary advice given to patients with established 
(category 3 or 4) AMD 
• To establish the frequency and dietary advice given to patients considered to be at 
risk of AMD 
• To establish the frequency of taking a smoking history in new and review patients 
• To establish the frequency of informing smokers of the link between smoking and 
AMD and advising patients to stop smoking 
• To establish the nutritional supplements recommendations to patients with 
established AMD or at risk of developing AMD 
• To establish the confidence level of Singapore optometrists when providing 
nutritional advice to patients with or at risk of AMD 
 
Study 2: What do Singapore optometrists feel about providing nutritional advice to 
patients with or at risk of AMD? (Chapter 4)  
In order to have a deeper understanding on optometrists’ views regarding nutrition and 
the eye, one-to-one interviews were conducted with fully registered optometrists working 
in different practices: retail optical shops, clinical optical shops, teaching institutions and 
eye hospitals or eye clinics; details on the different practices will be elaborated further in 
chapter four. Singapore optometrists are not legalised to use diagnostic drugs in their 
practice, hence in this study, one of the objectives is to understand from the participants 
whether they think diagnostic drugs are beneficial in diagnosing AMD. The other 
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objectives of this study are as follows: 
• To understand optometrists’ views on nutrition and the eye, and the eye conditions 
that they think will benefit from nutrition 
• To understand their patients’ receptiveness when they provide nutritional advice to 
them 
• To understand how they feel about providing nutritional advice to their patients in 
their practice, the factors that influence whether or not to provide nutritional advice, 
and the challenges when doing so 
• To establish if they routinely screen for AMD in their practice for patients aged 50 
years and above, and whether they think the use of diagnostic drugs will aid in their 
diagnosis of AMD 
• To understand what can be done to support optometrists in their professional 
development relating to nutrition and the eye 
 
Study 3: Evaluation of a clinical decision-making aid for qualified and student 
optometrists when providing nutritional advice for patients with or at risk of age-related 
macular degeneration (Chapter 5)  
There are currently various supplements available in the market that are marketed to 
preserve and/or improve eye health, including AMD. This could be confusing for 
patients83,84 and even optometrists, as they are often unsure of the indications to 
consume them, or which supplements are most beneficial for AMD patients. Hence the 
aim of this study is to evaluate the efficacy of a clinical decision-making aid (CDMA) that 
can assist optometrists in providing the most accurate and evidence-based nutritional 
advice to patients who are at risk, or with AMD. This CDMA is in the form of a flowchart 
and designed according to the results of AREDS 14 and 285. The aim is achieved by 
investigating if there is a difference in confidence levels via self-efficacy surveys and 
number of correct answers before and after using the CDMA when providing nutritional 
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advice for five hypothetical clinical case scenarios. This study is conducted on fully 
registered optometrists as well as student optometrists to compare the results between 
the two groups. 
 
This chapter highlighted  AMD classification, including the clinical appearance and retinal 
layers involved at different stages of AMD, the causes and risk factors of AMD, along 
with the AMD situation in Singapore. In addition, the scientific justification of this research 
was discussed, together with the objective of each study. In the next chapter, a thorough 
literature review of the research will be discussed, which includes the epidemiology of 
AMD in different geographic locations of the world, the more well-known pathogenesis 
of AMD such as genetic factors and oxidative stress, as well as nutrition and smoking 
and AMD. To conclude the next chapter, studies that evaluated the nutritional and 
smoking advice by eye care practitioners to AMD patients will also be reviewed. 
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Chapter Two: Literature review 
In the previous introductory chapter, AMD classification, causes and risk factors were 
explained. In this chapter, there will be a discussion on the epidemiology and 
pathogenesis of AMD, including a literature review on nutrition and smoking and AMD. 
Moving on to the next chapter, details of the first study “Nutritional and smoking advice 
to patients with or at risk of AMD by optometrists in Singapore” will be discussed.  
 
The Aston Library’s Smart Search allows its users to access to a wide range of resources 
via several databases such as the Cochrane Library, Ovid Journals, ScienceDirect, 
SpringerLink, Wed of Science and Wiley Online Library, and the relevant journal articles 
in this literature review was obtained via this system. The Google Scholar was the next 
platform to gain access to a journal article should it be unavailable in Aston Library. In 
the event that a journal article was not available from both platforms, it was requested 
via the Aston Library’s Inter-Library service.  
The search strategy to identify relevant journal articles used the terms and combination 
searches outlined in the box below. There were duplications arising from the combination 
searches and further suitable articles were identified for this review through references 




Terms used in initial searches: 
1. Age-related macular degeneration  
2. Pathogenesis 
3. Nutrition  
4. Nutritional advice 
5. Smoking 
6. Singapore  
 
Combination searches Hits Relevant articles 
[terms #1] AND [terms #2]  174 50 
[terms #1] AND [terms #3] 87 48 
[terms #1] AND [terms #5] 224 14 
[terms #1] AND [terms #4] 18 6 
[terms #1] AND [terms #6] 40 8 
 
 
2.1 Epidemiology of age-related macular degeneration  
As the term suggests, AMD is associated with age and with an increasing ageing 
population worldwide, the prevalence of AMD will increase exponentially. In 2017, 12.7 
per cent of the global population is aged 60 years or over and by 2050, this figure is 
expected to almost double and rise to 21.3 per cent86. Globally, 8.7% of the population 
has AMD and it has been projected that the number of people afflicted with AMD by 2020 
is 196 million, increasing to 288 million by 204047.  
Colijn and colleagues studied the prevalence of early and late AMD across ten countries 
in Europe from 1990 to 2013 and found that the prevalence of early AMD was 3.5% in 
those aged 55 to 59 years and 17.6% in those aged 85 years and above; whilst the 
prevalence for late AMD was 0.1% and 9.8% respectively87. It was projected that by 2040, 
the number of individuals in Europe with early AMD will range between 14.9 and 21.5 
million and between 3.9 and 4.8 million for late AMD87. In Australia, the prevalence of 
early AMD among nonindigenous Australians was 14.8% and 13.8% among indigenous 
Australians. Late AMD was found in 0.96% of nonindigenous participants and 0.17% of 
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indigenous participants and the prevalence of late AMD increased to 6.7% in 
nonindigenous participants 80 years or older 88. The Irish Longitudinal study on Ageing 
estimated the prevalence of early AMD in the population aged 50 years or older to be 
6.6% and the prevalence of late AMD was 0.6%89. In the capital of Iceland, the 
prevalence of early AMD was 12.4% for those aged between 66 and 74 years and 36% 
for those aged 85 years or older, and the prevalence of exudative AMD and pure 
geographic atrophy was 3.3% and 2.5% respectively82. Jonasson et al. concluded that 
persons aged 85 years or above have a ten-fold higher prevalence of late AMD than 
those aged 70 to 74 years82. In a systematic review by Kawasaki et al. from four Asian 
populations, they found that the pooled prevalence estimates of early and late AMD in 
Asian populations aged 40 to 79 years were 6.8% and 0.56% respectively. However, 
they were not able to establish the prevalence estimates of AMD in Asians aged 80 years 
and above due to the small number of subjects in this age category90.  
Historically, AMD has been known to affect whites more than blacks91, indicating that 
there is a genetic predisposition for this condition. Genes and age are the two main 
factors that are linked to AMD, in which most studies showed a common trend that the 
prevalence of late AMD increases with age 82,87,88. Over the years, other factors such as 
smoking has been established to be linked to AMD and details of these factors will be 
discussed in the next section. Through further research, AMD has now seem to be 
multifactorial and this could explain the differences in prevalence in various global 
locations. In addition, the different age groups of the sample population, as well as the 
different AMD classification systems used in the studies could also affect the prevalence 
of AMD discussed previously. However globally, there is an increasing prevalence of 
AMD due to the ageing population in developed countries.  
 
2.2 Pathogenesis of age-related macular degeneration  
The exact pathogenesis of AMD may be unknown but through decades of research it 
has been found to include drusen genesis, lipofuscin genesis, local inflammatory state 
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genesis and angiogenesis92. Druses are clusters of retinal metabolites between the RPE 
and the Bruch’s membrane, impeding the transport of nutrients and metabolites. 
Immune-chemical examinations have shown that druses contain plasma proteins, 
lipoprotein (apolipoprotein E), cholesterol-rich lipids, polysaccharides, glycoprotein and 
plasma amyloid P, responsible for complement inactivation and membrane attack 
complex (MAC) formation93. Further details on the complement system and MAC will be 
discussed under the section “Immune system-related genes”. Lipofuscin, also known as 
cell-aging factor, is a product of incomplete metabolism of external segments of 
photoreceptors by phagolysosomes. Due to loss of the protein-lipid membrane tightness, 
liposome lipofuscin gets into cytoplasm and then to extracellular areas, forming druses 
as an end result92. Lipofuscin has been suggested to be involved in AMD pathogenesis 
as its molecule contains hybrid flurophor A2-E, a substance that is active in 
photoreceptors’ apoptosis92. Excessive levels of lipofuscin and A2-E (a toxic vitamin A 
dimer) can also damage photoreceptors and choriocapillaris, leading to geographic 
atrophy92. Besides being toxic to the RPE, A2-E has also been shown to activate the 
complement cascade94,95.  
The pathogenesis of non-exudative AMD is not completely understood and it is 
suggested that oxidation and inflammation play important roles in the pathogenesis of 
the disease. The retinal tissue is one of the tissues with the biggest oxygen needs due 
to the complexity of its metabolism processes. The human antioxidative system consists 
of enzymatic and non-enzymatic divisions; the enzymatic system includes catalase, 
glutathione peroxidase and reductase and superoxide dismutase96. Zinc, selenium, 
copper and manganese ions ensures that this enzymatic system is functioning well96. 
The non-enzymatic part of this system includes vitamins E and C, glutathione as well as 
carotenoids, and especially lutein and zeaxanthin, which are natural components of the 
macula97. Nowak and colleagues highlighted that oxidative stress could be one of the 
factors involved in the pathogenesis of AMD and suggested the possible protective effect 
of antioxidants supplementation98. The rods and cones in the retina are replaced every 
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ten days but their outer segments may be at particular risk of oxidative damage because 
of high concentration of polyunsaturated fatty acids in the photoreceptor outer segment 
membrane. Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is a primary 
structural component of the human retina, comprising 50 to 60 per cent of the 
polyunsaturated fatty acids in the retina, and is found in the membrane of the outer 
segment of the photoreceptors76. Inflammation has been hypothesized to have a role in 
the pathogenesis of AMD99, and Medzhitov first introduced the idea of para-inflammation 
as a tissue adaptive response to noxious stress or malfunction that has characteristics 
intermediate between basal and inflammatory states100. In the aging retina, oxidized 
lipoproteins and free radicals are major causes of tissue stress and serve as local 
triggers for retinal para-inflammation. Drusen have been shown to contain proteins 
associated with immune-mediated processes and inflammation, and inflammatory cells 
have been found on the outer surface of Bruch’s membrane in AMD eyes101. The main 
genetic changes (polymorphism) associated with AMD were found to be genes that 
regulate inflammation, most notably Complement Factor H (CFH), a circulating protein 
that inhibits directly or indirectly the three complement activation pathways102. In patients 
with early and late AMD, many CFH polymorphisms have been described103. With 
abnormal CFH, complement system downregulation is defective and excess 
inflammation may result. Additionally, histological analysis of drusen revealed the 
presence of complement factors and the terminal membrane attack complex104. Chronic 
subclinical local inflammation of the retina in AMD patients may trigger and/or sustain 
the damaging process99,100.  
Angiogenesis is the development of new blood vessels from pre-existing vessels and 
whilst being a crucial process in normal physiology, it is an important pathogenic process 
in both benign and malignant disease105. Abnormal angiogenesis is a hallmark of 
diseases such as cancer, chronic inflammation and also the neovascular form of 
AMD106,107. Choroidal neovascularization (CNV) represents the growth of new blood 
vessels from the choroid into the subretinal pigment epithelium. Several proangiogenic 
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factors are consistently upregulated during CNV formation, particularly two members of 
the vascular endothelial growth factor (VEGF) family, VEGF-A and placental growth 
factor (PIGF)106. These factors activate quiescent endothelial cells and promote cell 
proliferation, migration and vascular permeability106.  
 
Genetic factors 
Studies have shown that there is a strong correlation between a family history of AMD 
and the subsequent development of both early and late forms of the disease. This is 
proven by higher concordance rates among monozygotic twins when compared with 
dizygotic, and segregation analyses comparing first degree relatives of affected 
individuals as compared with the general population108,109. The study by Smith and 
Mitchell showed that the risk of developing late AMD was increased nearly four-fold for 
those with a family history of AMD, particularly in cases of neovascular AMD109. This risk 
is amplified when immediate family members have the disease, with one study 
estimating a 27.8 times increase in risk with an affected parent and 12 times increase in 
risk for those with an affected sibling110. As AMD is a multifactorial disease, it is 
challenging to identify specific genes that are responsible for causing the symptoms of 
AMD. Despite this challenge, researchers have identified approximately forty genes that 
may be associated with the development of AMD, and some of these genes fall into 
broad groups based on their function: genes with retinal-specific function, immune 
function, neovascularization, or lipoprotein-related function111.  
 
Genes with retinal-specific function 
Unlike retinitis pigmentosa (RP) and other early onset retinal degenerations, retinal 
specific genes have minimal impact on AMD susceptibility and only three monogenic 
macular dystrophy-related genes, ABCA4, apolipoprotein E (ApoE) and Tissue inhibitor 
of matrix metalloproteinase-3 (TIMP-3) show any association with AMD risk111. Of these 
genes, only ABCA4 expression is restricted to the retina while ApoE and TIMP-3 have 
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additional systemic functions. ABCA4 is a specific marker for photoreceptor cells and 
found in the outer segment disks of this retinal layer. Its function involves the 
transportation of N-retinylidene phophatidylethanolamine (PE) across membranes in 
photoreceptor cells112. In the absence of functional ABCA4, a N-retinylidene PE complex 
accumulates, leading to a buildup of lipofuscin fluorophore A2E113. Retinal degeneration 
in those with compromised ABCA4 may result from loss of the ability to transport N-
retinylidene PE out of photoreceptor cells, or RPE toxicity associated with A2E buildup112.   
ABCA4 mutations cause a range of retinopathies such as Stargardt disease and 
autosomal recessive RP that vary in severity related to the degree of residual retinal 
function. Despite this, they are not a common cause of AMD114 and more research is 
needed to clarify its actual roles in AMD development.  
 
Immune system-related genes  
Immunological responses have long been implicated in AMD progression but the 
pathways involved have remained unclear. The complement cascade can be activated 
by a number of triggers, usually related to infection, and aids in the destruction of foreign 
pathogens. The complement system is a crucial component of the body’s innate immune 
system against antigens and it consists of the classical, lectin and alternative cascades 
115–118. These three cascades eventually result in the formation of membrane attack 
complexes (MAC) that cause cell lysis and inflammation through chemokine release and 
increased capillary permeability116,117. Homeostasis of the complement system is 
achieved via various proteins and disruption of this balance leads to sustained activation 
of the complement system, resulting in chronic inflammation and forming druses119. 
Besides the formation of drusen which is a clinical hallmark of early AMD, studies have 
also shown that the complement system predisposes to choroidal neovascularization 
(CNV) by increased vascular-endothelial growth factor (VEGF) expression120,121. 
Different components of the complement pathways have been associated with AMD, 
namely factor H (CFH), factor H-related complement, factor B, factor D, and factors 2, 3 
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and 5111. CFH is a key regulator and major inhibitor of the alternative complement 
pathway and is found within drusen 115,122, and Y402H is one of the high-risk CFH variants 
strongly associated with AMD, especially in Western Europeans123,124. CFH can be found 
in the RPE of the retina and the Y402H variant has been found to be associated with the 
presence of complement proteins in drusen122,125. Early genetic studies identified a 
susceptibility locus on chromosome 10q26 for the development of AMD126. Further 
genomic studies of this chromosome demonstrated two AMD susceptible loci: one is 
known as rs10490924, which lies within the gene LOC387715/ARMS2, now known as 
Age-Related Maculopathy Susceptibility 2 (ARMS2), and the other, rs11200628, lies 
within the promoter region of the gene known as High Temperature Requirement Factor 
A1 (HTRA1) gene. The precise function of ARMS2 in AMD is largely unknown, but 
findings have suggested that mitochondrial dysfunction results in AMD, and smokers are 
at a higher risk of AMD via this gene127,128. Therefore this suggests that mitochondrial 
function is disrupted by ARMS2, leading to the formation of reactive oxygen 
intermediates (ROIs), apoptosis and AMD62. HTRA1 has been shown to be associated 
with an increased risk of wet AMD in certain populations126,129; HTRA1 binds to and 
inhibits transforming growth factor-beta (TGF-b), a factor known to play a crucial role in 
extracellular matrix deposition and angiogenesis. Therefore, it is possible that HTRA1 
may play a role in the regulation of Bruch’s membrane and growth of vessels into the 
RPE126. The two other immune-related genes that are related to AMD are the epidermal 
growth factor (EGF) containing fibulin-like extracellular matrix protein (ECM) 1 (EFEMP1), 
also known as fibulin 3, and Hemicentin-1 (HMCN-1). The actual attributable risk of 
EFEMP1 on AMD development is not known, but its role in extracellular matrix protein 
alteration and retinal deposits make it a likely player in AMD pathogenesis and further 





Genes related to neovascularization 
VEGF, TIMP-3 and fibulin 5 are genes producing proteins that directly or indirectly 
influence the growth of new blood vessels111. Of these, VEGF is the most important and 
it is the target of current anti-AMD therapy ranibizumab (Lucentis) and bevacizumab 
(Avastin). AMD development can be influenced by genes that directly or indirectly 
influence the levels of VEGF. Vascular endothelial cell growth factor (VEGF) is a member 
of the platelet-derived growth factors and it plays an important role in maintaining a 
healthy retina. There are five different retinal cell types that produce VEGF and they 
include vascular endothelium, retinal pigmented epithelium, Muller cells, ganglion cells 
and astrocytes130,131. There are seven biologically active isoforms in the VEGF family, 
but VEGF-A is thought to be most critical in the angiogenesis process111. VEGF-A has 
been linked to many ocular neovascular diseases132 and previous studies have 
demonstrated that patients with wet AMD, diabetic retinopathy, retinopathy of 
prematurity, retinal vein occlusion and neovascular glaucoma133 have an increased 
intraocular levels of VEGF. All of these ocular diseases share a similar pathological 
process: vascular permeability and neovascularization. VEGF is released by the retina 
and RPE in response to tissue hypoxia111. Increased VEGF production results in 
subsequent upregulation of endothelial nitric oxide synthase, metalloproteinases and 
decreased tissue inhibitors of metalloproteinase expression, which together enhance 
choroidal neovascularization111. Single nucleotide polymorphisms at the genetic level are 
presumed to contribute to altered VEGF and VEGF-2 expression, leading to the 
pathogenesis of AMD and even diabetic retinopathy. Tissue Inhibitor of Matrix 
Metalloproteinase (TIMP) refers to a group of proteins that inhibit matrix 
metalloproteinases (MMPs), a group of proteins involved in extracellular matrix (ECM) 
degradation. Macular Bruch’s membrane concentrations of Tissue Inhibitor of Matrix 
Metalloproteinase-3 (TIMP-3) appear to be age-dependent134. Additionally, patients with 
AMD often have supra-normal levels of TIMP-3 both in macular Bruch’s membrane and 
in macular drusen. As TIMP-3 inhibits MMPs, excess TIMP-3 may retard Bruch’s 
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membrane renewal and result in the thickening of Bruch’s membrane. By reducing 
Bruch’s membrane permeability, the trafficking of metabolites and nutrients between the 
choroid and RPE is also reduced, ultimately resulting in RPE and photoreceptor 
atrophy134. TIMP-3 acts as a local inhibitor of VEGF thus limiting CNV135. Mutations 
leading to decreased activity in TIMP-3 result in increased VEGF levels and a 
subsequent increase in the growth of pathological blood vessels in the eye. Many 
hypotheses have been proposed regarding the direct mechanism and causative 
relationship between TIMP-3 and AMD development, the direct mechanistic relationship 
remains unknown and more research is needed to address the mechanistic relationship 
between these associative findings. The fibulin 5 gene is a member of the same family 
as EFEMP1/Fbln3. As properly functioning fibulin 5 strengthens cell adhesions, down-
regulates VEGF and controls choroidal endothelial cell proliferation, mutations leading 
to misfolding and subsequent dysfunction of this protein confer an increased risk of AMD 
development136.  
 
Lipoprotein-related genes  
Hepatic Lipase (LIPC) is responsible for lipoprotein production and the presence of an 
HDL-elevating allele of the LIPC gene was found to be associated with decreased risk 
of AMD137–139. While high HDL levels are protective against AMD, individuals with high 
LDL counts have a significantly higher risk of developing AMD138. The discovery of LIPC, 
a genetic variant in the HDL pathway, may serve as a potential marker to be used in 
laboratory testing and individual risk analysis for the development of AMD138. 
Apolipoprotein E (ApoE) is a plasma protein and regulates the transport of lipid and 
cholesterol in the central nervous system by serving as a ligand for low density 
lipoprotein (LDL) receptors140. ApoE is found in the liver, brain and in various parts of the 
eye such as the RPE, Bruch’s membrane, photoreceptor cells, retinal ganglion cell layer, 
choroid, as well as in drusen in early AMD141. ApoE consists of three major variants: E2, 
E3 and E4; the E4 isoform is associated with neurodegenerative diseases such as 
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Alzheimer’s disease142. The ApoE4 isoform is also associated with a reduced risk of AMD 
development, and it has been postulated that this is achieved by suppressing the 
expression of the chemokine CCL2 (C-C motif ligand 2) and VEGF expression143. On the 
other hand, more studies are necessary to establish the relationship between cholesteryl 
ester transfer protein (CETP), CD36 and AMD. CD36 is expressed in the RPE and may 
participate in phagocytosis of photoreceptor outer segments144,145. Basal laminar 
deposits that are found in the early stage of AMD have been shown to contain oxidized 
LDL, to which CD36 binds111. Increases in oxidized plasma LDL are observed with age 
and high cholesterol diet, and CD36 serves as the primary receptor in RPE cells for 
oxidized plasma LDL111.  
As a positive family history of AMD increases a patient’s risk of getting AMD, it may seem 
more imperative to provide nutritional and smoking advice to such patients. Whilst 
genetic factors can provide an indication to practitioners on providing nutritional and 
smoking advice, previous reports have suggested that genetic testing for AMD may have 
a role because of potential harmful genetic interaction with specifically the zinc 
component in the AREDS supplements146,147. However, the American Academy of 
Ophthalmology recommended that genetic testing for AMD should not be conducted 
prior to considering treatments for AMD such as the AREDS supplements148.  
 
Oxidative Stress 
The aging process occurs as a main result of the free radical reactions that are going on 
continuously in the cells of the human body20. “Oxidative stress refers to cellular damage 
caused by reactive oxygen intermediates (ROIs) and the retina is highly susceptible to 
oxidative stress due to its high consumption of oxygen, its high proportion of 
polyunsaturated fatty acids and its exposure to visible light” 62. The retina, especially the 
macula is exposed to a high amount of oxidative stress as it is the highest oxygen-
consuming tissue in the body149 and the high amount of polyunsaturated fatty acids in 
the photoreceptor outer segments and lipofuscin makes the retina prone to the 
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generation of ROIs150,151.  ROIs cause lipid peroxidation of the RPE cell membrane, 
which may trigger the complement system and lead to chronic inflammation151, as 
discussed earlier. It has also been postulated that CFH synthesis and/or secretion is 
impaired by oxidative stress152. Superoxide dismutase, catalase and glutathione 
peroxidase are antioxidant enzymes and they remove ROIs enzymatically. Vitamins and 
other carotenoids can also ‘scavenge’ ROIs either directly or non-enzymatically62.  
 
Smoking  
As mentioned earlier, smoking is one of the modifiable risk factors for AMD and it has 
been shown to be positively correlated with the duration of smoking and the number of 
cigarettes49. AMD could result from oxidative stress in the retina and smoking exacerbate 
the condition through further oxidative insults to the retina, decreased choroidal blood 
flow, increased ischaemia, hypoxia and micro-infarctions, stimulation of CNV and 
reduction of serum antioxidants48. The toxic effect of hydroquinone on retinal cells 
includes the accumulation of VEGF and the reduction of macular pigment153,154. Authors 
have also found that cigarette smoking causes inflammation by activating complement 
C3 and other inflammatory mediators and reducing serum levels of CFH155.  
 
Other systemic risk factors  
A higher body mass index (BMI) is another modifiable risk factor that is implicated in the 
pathogenesis of AMD. Studies such as the Los Angeles Latino Eye Study (LALES) and 
the Blue Mountains Eye Study (BMES) showed that persons with a high BMI were at 
greater risk of early AMD, but no significant associations were seen with late AMD156,157. 
The Age-related Eye Disease Study (AREDS) found significant associations between a 
higher BMI and both subtypes of late AMD4,158. It has been postulated that obesity 
increases the risk of AMD through changes in the lipoprotein profile or an increase in 
oxidative damage and inflammation as obese persons generally have a diet low in 
antioxidants and polyunsaturated fatty acids or even an overall unhealthy lifestyle159. 
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Besides obesity, hypertension has also been hypothesized as a risk factor for AMD due 
to its effect on the choroidal blood flow160,161. In the Bam Deaver Eye Study (BDES), 
hypertension was associated with a ten-year incidence of late AMD, in particular CNV 
162, and in the Rotterdam Study, a clear dose-dependent association was found between 
elevated systolic blood pressure and increased risk of incident AMD163. On the other 
hand, the BMES indicated that neither pressure, systolic or diastolic blood pressure, or 
presence of hypertension at baseline were associated with incident AMD58.  
 
2.3 Age-related macular degeneration and nutrition 
The first National Health and Nutrition Examination Survey conducted in the US provided 
the first piece of evidence that the intake of fruits and vegetables high in vitamins A and 
C is associated with the risk of AMD61. Since then, researchers work intensively in this 
area as currently there is no treatment for atrophic AMD and GA, and if AMD progresses 
to the exudative form, it will have the worst visual prognosis among the other forms. 
Additionally, oxidative stress has been postulated as one of the more viable 
pathogenesis for AMD, therefore introducing antioxidants in the form of vitamins or 
carotenoids would seem promising for AMD patients to prevent their condition from 
getting worse.  
 
Age-related Eye Disease Study (AREDS)  
The first controlled oral intervention study for AMD patients was performed by Newsome 
et al. where oral zinc was administered in subjects with drusen or macular degeneration 
164. The study showed positive results but oral zinc was not widely used at that time due 
to the possible toxic effects and complications of oral zinc. The main side effect 
associated with high doses of zinc is mineral absorption disturbances, and the most 
serious interactions are with cooper and iron165. Therefore there have been reports of 
cooper deficiency following oral use of high doses (more than 220 mg) of zinc for a period 
of time (more than ten months)166. Other symptoms reported to be associated with high 
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zinc intake include nausea, vomiting, headache, abdominal cramps, epigastric pain, loss 
of appetite, lethargy and fatigue. About ten years later, a large clinical trial, the Age-
Related Eye Disease Study (AREDS) was conducted with the key aim of determining 
the effect of high-dose antioxidant supplementation in decreasing the progression of 
AMD and associated vision loss. AREDS was a multicentred, double-blind placebo-
controlled trial involving 3640 subjects aged between 55 and 80 years of age167. The 
AREDS formulation consists of 500mg of vitamin C, 400IU of vitamin E, 80mg of zinc, 2 
mg of copper and 28,640IU of vitamin A. A statistically significant reduction in the odds 
of developing advanced AMD was found in patients receiving antioxidant vitamin 
supplementation plus zinc, compared with placebo (OR: 0.72; 99% CI: 0.52-0.98). A 
statistically significant odds reduction was not seen in participants receiving antioxidants 
and vitamins alone or zinc alone. After removing participants from Category 2 AMD 
(extensive small drusen, pigment abnormalities, or at least one intermediate size druse), 
odd reduction estimates reached statistical significance in patients receiving antioxidants 
and vitamins plus zinc (R:0.66; 99% CI: 0.47-0.91) and in those receiving zinc alone (OR: 
0.71; 99% CI 0.52-0.99). Statistically significant odds reduction in vision loss (of 15 or 
more letters) occurred in patients receiving antioxidants and zinc, (OR: 0.73; 99% CI: 
0.54-0.99) and the risk of serious adverse events did not reach statistical significance in 
any treatment groups of the study. 2% of the study participants discontinued the 
supplementation as reports from other investigators highlighted the increased risk of lung 
cancer in smokers taking beta-carotene168,169.  
 
AREDS 2 
In AREDS 2, one of the goals was to determine the effect of the addition of lutein and 
zeaxanthin, as these carotenoids were not commercially available when AREDS was 
conducted, as well as the addition of omega-3 long-chain polyunsaturated fatty acids 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Another goal was to 
assess the effect of the removal of beta-carotene, and lowering the dosage of zinc from 
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the original AREDS formulation. No statistically significant reduction in risk of 
progression to advanced AMD was observed beyond the effects of AREDS formulation; 
however, in secondary exploratory analyses, when patients receiving lutein and 
zeaxanthin were compared with those not receiving this combination, an added 10% 
reduction in risk was noted, which was statistically significant (HR: 0.90; 95% CI: 0.82-
0.99). In addition, when lutein plus zeaxanthin was substituted for beta-carotene, a 
significant reduction in risk of progression was observed compared with the original 
AREDS formulation (HR: 0.82; 95% CI: 0.69-0.96). Last but not least, beta-carotene 
supplementation was found to be associated with an increased risk of lung cancer in 
former smokers (2.0% versus 0.9%, P=0.04)64.  
Despite the promising results of AREDS and AREDS 2, a recent review by Macdonald170 
on five randomized clinical trials (RCTs) highlight that antioxidant vitamin or mineral 
supplements do not prevent age-related macular degeneration. In fact, a multivitamin 
combination increased the risk of AMD. However, unlike the AREDS or AREDS 2 where 
a combination of antioxidant vitamins and minerals were evaluated, the RCTs in 
Macdonald’s review evaluated the vitamins (vitamin A or C or E) and minerals (zinc) on 
its own. Moreover, there was no mention of the ingredients that were in the multivitamin 
combination, which makes it prejudiced to conclude that multivitamin combination 
increased the risk of AMD.   
 
Lutein and Zeaxanthin  
More than 600 carotenoids are found in nature and lutein is found in greatest percentage 
in human serum (20%)171. Lutein and zeaxanthin are found in the human retina and they 
form the retinal macular pigment (MP)172. Besides improving visual performance, MP 
also protects the retina against the damaging effects of light and MP levels are used as 
an indicator of macular health, particularly to predict the likelihood of developing AMD 
172. As discussed in AREDS 2, the beneficial effects of lutein and zeaxanthin may be 
their ability to protect the retina by absorbing the short-wavelength blue light and 
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ultraviolet radiation and reducing oxidative stress64.  There is a huge variety of food that 
contain lutein and zeaxanthin and the foods that are high in lutein and zeaxanthin include 
but not limited to, green leafy vegetables such as kale and spinach, egg yolk, broccoli, 
pumpkin and corn173. From the AREDS 2 study, the benefits of lutein and zeaxanthin 
were from consuming 10 mg of lutein and 2 mg of zeaxanthin daily64 but consuming 6mg 
per day of lutein and zeaxanthin has also been found to reduce the risk of advanced 
AMD65.  
Besides AREDS 2, there were other studies that have been conducted to evaluate the 
association between intake of lutein and zeaxanthin and risk of AMD, and the results 
vary among studies. In a secondary analysis of the AREDS 2, lutein and zeaxanthin on 
top of the original AREDS formulation lowered the progression to advanced AMD, but 
only in persons with low dietary lutein and zeaxanthin85. A systematic review and meta-
analysis of six longitudinal cohort studies with a total of 123,178 participants in the British 
Journal of Nutrition examined the effects of lutein and zeaxanthin on AMD and found a 
significant risk reduction only in late AMD with an increased dietary intake of these 
carotenoids (RR: 0.74; 95% CI: 0.57, 0.97)66. Another systematic review and meta-
analysis  by Chong et al. on nine prospective studies involving 149,203 participants 
showed a statistically significant inverse association between the intakes of lutein and 
zeaxanthin and neovascular AMD risk. (RR:0.68; 95% CI: 0.51, 0.92)67. Case-control 
studies by the Eye Disease Case-Control Study Group174 and Snellen at al.68 involving 
132 subjects found that high intakes of lutein were protective against neovascular AMD.  
Cross-sectional studies found that high plasma levels of zeaxanthin have a reduced risk 
of any stage of AMD55,69; and the combination of lutein and zeaxanthin from the POLA 
study that recruited 2584 subjects showed the same trend55. A cross-sectional analysis 
of the third cohort of the National Health and Nutrition Education Evaluation Survey 
(NHANES III) showed that those aged between 40 and 59 and consuming highest levels 
of dietary lutein and zeaxanthin had less risk for pigment abnormalities compared to 
those consuming the lowest amounts (OR=0.10; 95% CI: 0.10, 0.30). Additionally, 
 44 
among those aged between 60 and 79, those consuming the highest level of lutein and 
zeaxanthin have a reduced risk for late AMD (OR=0.10; 95% CI: 0.00, 0.90). A small 
interventional study on 150 participants by Bucheli and colleagues showed that elderly 
supplemented with 13.7g per day of lacto-wolfberry, a potent source of zeaxanthin, for 
ninety days has increased serum zeaxanthin levels and antioxidant capacity in serum, 
and their retina showed reduced pigment changes and soft drusen accumulation relative 
to the placebo group175. As mentioned earlier, MP levels are used as an indicator for 
macular health, hence some studies evaluated the macular pigment optical density 
(MPOD) following intake of lutein and/or zeaxanthin. Placebo controlled trials revealed 
that 12mg of lutein a day or a combination of 12mg lutein and 1mg zeaxanthin a day for 
a period of four months and six months respectively significantly increased macular 
pigment optical density (MPOD)70,71. In a one-year randomized double-blinded placebo-
controlled study by Richer and colleagues, 60 patients were divided into three groups: 1) 
8mg zeaxanthin a day; 2) 9mg lutein a day; 3) combination of both carotenoids. After a 
year, MPOD increased in all three groups, and was not different among the groups72. In 
another randomized, double-blinded and placebo-controlled trial on 112 patients with 
early AMD, it was found that after two years of supplementation with lutein, serum lutein 
concentration, MPOD and visual sensitivities was increased 73. In addition, it was 
concluded that 10mg of lutein daily might be an advisable long-term dosage for early 
AMD. In a more recent clinical trial on 64 subjects, lutein complex, consisting of marigold 
(lutein) and wolfberry (zeaxanthin) was found to reduce oxidative stress index and 
inflammatory markers, and best-corrected visual acuity was lowered in subjects when 
treated for five months176. This suggests that consumption of lutein complex suppresses 
the oxidative stress and therefore reduce the incident of AMD. Studies such as the 
Carotenoids in Age-Related Maculopathy in Italians Study (CARMIS) and the Lutein 
Antioxidant Supplement Trial (LAST), involving 145 and 90 participants respectively, 
combined lutein and zexanthin with antioxidants and they showed positive results such 
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as elevated MPOD, improved visual acuity, contrast sensitivity, Amsler grid results and 
glare recovery74,75.  
However, despite the positive results discussed, there were few studies that did not find 
any effect of lutein and zeaxanthin on risk for AMD. They include cross-sectional study 
by Michikawa et. al and cross sectional analyses of the BDES and European Eye Study 
177–179. In the study conducted by Michikawa et. al179, there was no significant difference 
in the serum lutein and zeaxanthin levels between normal patients and patients with early 
or late AMD; and this could be because of the low sample size: 32 early AMD patients 
and 8 late AMD patients. A few prospective studies also reported the same findings that 
lutein and zeaxanthin have no effect on AMD risk and they include studies by van 
Leeuwen et al. (4179 participants), Flood et al. (2335 participants), and 
VandenLangenberg et al. (1709 participants)180–182. In these studies, food frequency 
questionnaires (FFQs) were used to assess nutrient intakes and this could be a possible 
source of confounding bias as AMD patients tend to be older and they might not recall 
correctly and accurately their daily diet intake. Moreover, the follow-up period for the 
studies conducted by Flood et al.180 and VandenLangenberg et al.182 was five years, 
which could be slightly short for conditions like AMD. Another prospective study that 
showed lutein or zeaxanthin intake was associated with an increased risk of AMD is a 
study done on 254 patients by Robman and co-workers 183. Similar to other prospective 
studies, this study utilised FFQs to assess patients’ nutrient intakes and they used a 
different AMD classification system other than the ones used in the BDES, AREDS and 
Rotterdam Eye Study. Robman and colleagues concluded that the AMD patients in their 
study were aware of their condition before and during the study and hence improve their 
lifestyle by increasing their intake of carotenoids and PUFAs. As a result, the high levels 
of carotenoids switched from antioxidant to pro-oxidant, thereby increasing their risk of 
AMD. On top of that, from the retrospective analysis of the NHANES III cohort that 
consisted of 8222 participants, it was observed that those who consumed the highest 
amounts of lutein and zeaxanthin had a slightly increased risk for the appearance of 
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drusen184. In spite of this, the authors concluded that the relation of lutein and zeaxanthin 
to AMD may be influenced by age and race, therefore require further evaluation in 
separate populations and in prospective studies.  
Lutein and zeaxanthin form the retinal macular pigment and consuming foods high in 
these carotenoids will serve to protect the macula, and AMD. Most studies, particularly 
the clinical trials, have shown that lutein and zeaxanthin reduced the risk of AMD, 
increased MPOD and improved visual acuity.  
 
Polyunsaturated fatty acids 
The photoreceptor outer segments are constantly replenishing and DHA accounts for 50 
to 60% of the total fatty acid content of the photoreceptor outer segments76. Therefore, 
supplementation of omega-3 long chain polyunsaturated fatty acids (PUFAs) would 
seem helpful in AMD patients. Additionally, a review by Evans and Lawrenson 
highlighted that a deficiency in PUFAs would increase the risk of AMD76.  Omega-3 long-
chain PUFAs also play a role against oxidative stress, inflammation and vascular 
dysfunction, which have been shown to be closely associated to the pathogenesis of 
AMD185.  
The Nutritional AMD Treatment 2 study that was conducted on 263 subjects found that 
administering 350mg of EPA and 650mg DHA daily for three years lower the risk of CNV 
in patients with early lesions of AMD186. Red blood cell membranes are long-term 
biomarkers of omega-3 long-chain PUFAs and they have been found to be strongly 
associated with neovascular AMD after dietary oily fish and seafood intake187. The US 
Twin Study of Age-Related Macular Degeneration, involving 681 twins, is a cross-
sectional study that compared those consuming the least amount of omega-3 fatty acids 
to those consuming the highest amount of omega-3 fatty acids. In this study, they found 
that those consuming the highest amount had a reduced risk for any stage of AMD 
(OR=0.55; 95% CI: 0.32, 0.95) and this effect was driven mostly by those with a low 
linoleic acid and omega-6 fatty acid intake (p<0.001), as the effect vanished in those with 
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an intake of linoleic acid above the median77. The AREDS found that compared to those 
in the lowest quintile of intake, those in the highest quintile of intake for EPA, DHA and 
total long-chain omega-3 fatty acids were at a reduced risk for neovascular AMD. 
However, when the cohort was separated by intake of arachidonic acid, a type of omega-
6 fatty acid, the reduction of risk for neovascular AMD became insignificant78. A 
prospective analysis of AREDS revealed that increasing intake of DHA and EPA was 
associated with a decreased rate of progression to central GA over 12 years (p=0.026). 
Increasing intakes of DHA alone (p=0.001) or DHA and EPA (p=0.032) were also 
associated with a decrease in risk of progression to neovascular AMD (p=0.001)188. 
However, from the AREDS 2 study, a daily dose of EPA and DHA together with the 
AREDS formulation did not offer an additional advantage in reducing the risk of 
developing advanced AMD64. An increased intake of DHA and EPA daily is associated 
with a reduced risk for progression to advanced AMD and participants who were healthy 
at baseline benefited from a diet high in DHA as there was a markedly reduced 
progression of early AMD in these patients189. Prospective studies such as the Nurses’ 
Health Study (NHS) and the Health Professionals’ Follow-Up Study, BMES and 
EUREYE also showed participants with a high intake of fatty acids have a reduced risk 
of AMD 79–81. Chiu et al. showed that in the AREDS participants, there was no association 
between DHA intake and risk for drusen (R=0.94; 95% CI: 0.77, 1.16) or late AMD 
(OR=0.82; 95% CI: 0.59, 1.13); there was also no association between intake of EPA 
and risk for drusen (OR=0.96; 95% CI: 0.84, 1.15)190. There was also no association 
between intake of EPA, DHA or alpha-linolenic acid and risk for early or late AMD in the 
Melbourne Collaborative Cohort of 6734 participants191. Conversely, some prospective 
studies showed deleterious effects of omega-3 fatty acid intake on risk for AMD, and 
they include the Carotenoids in Age-Related Eye Disease Study (CAREDS)192, 
consisting of 1787 women, as well as a study by Robman et al183.  In the CAREDS192, 
the fat intake was estimated using FFQs and the AMD patients were followed through 
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for only four years. The study design by Robman et al. was discussed in the previous 
lutein and zeaxanthin section.  
In 2017, Evans and Lawrenson conducted a review on antioxidant and mineral 
supplements for slowing the progression of AMD193. This review consisted of three large 
trials with reasonably long treatment duration and follow-up of four to six years (AREDS 
2001194; AREDS 2 201364; VECAT 2002195), and sixteen smaller trials (ranging from 20 
to 400 participants) and shorter duration of treatment and follow-up (6 to 24 months). 
The results of AREDS and AREDS 2 have been discussed previously. The VECAT 2002 
study suggested that the general population should not take vitamin E with a view to 
preventing the incidence or progression of AMD. However, the study was underpowered 
to answer the question about whether people with signs of AMD should take vitamin E.  
The other trials of multivitamin preparations such as Ocuguard196, Ocupower75, 
Visaline197 and lutein or antioxidant198 were too small to provide evidence in either way. 
Pooling results, where possible, did not provide evidence of any benefit of 
supplementation. However, these trials were of relatively short duration. Newsome 
1988164 found a reduction in the risk of visual acuity loss with zinc supplementation over 
12 to 24 months. However, Stur 1996199 found no effect of zinc treatment. Newsome 
2008200 found that zinc-monocysteine had beneficial effects on visual acuity and contrast 
sensitivity.  
The main evidence that antioxidant vitamin and mineral supplementation was of benefit 
came from the AREDS trial, and potential biases have been minimised as it was a large, 
well-conducted randomised study. Other than the AREDS, pooling data from other trials 
revealed little evidence for effectiveness of antioxidant vitamin and mineral supplements 
on preventing visual loss or progression of the disease. However, the other studies 
encompassed many different formulations and in general, were rather small and of short 
duration, which may explain the lack of effect.  
In conclusion, from the AREDS and AREDS 2 results, AMD patients may experience 
modest delay in progression of the disease with antioxidant vitamin and mineral 
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supplementation. However, as these two large trials were conducted in a relatively well-
nourished American population, we will not know whether these findings can be applied 
more generally until it is replicated by other large-scale trials in other populations. In 
addition, this review shows little effect, if any, of supplements containing lutein and 
zeaxanthin on the progression of AMD but the evidence was low-certainty. Generally, 
AMD patients should take antioxidant vitamins and zinc at the levels described in this 
review, and smokers and people with vascular disease should be wary of the harmful 
effects associated with long-term vitamin supplementation as smokers who take beta-
carotene may be at an increased risk of developing lung cancer and among people with 
vascular disease and diabetes, vitamin E supplementation was associated with a higher 
risk of heart disease.  
 
2.4 Age-related macular degeneration and smoking 
According to World Health Organisation (WHO), the projected prevalence of smokers in 
Asian countries such as China, South Korea and Singapore in 2025 will be 43.3%, versus 
Western countries, with a projected prevalence of 16.3%201. With the increasing number 
of smokers, the prevalence of AMD will increase as well as smoking has been shown to 
be associated with AMD in the following studies. Cross-sectional studies such as the 
Beaver Dam Eye Study50, Beaver Dam Offspring Study51, Rotterdam Study52, Blue 
Mountains Eye Study53, AREDS4, Eye Disease Case-Control Study54 and POLA study 
202 showed a relation between smoking and AMD. The Beaver Dam Eye Study50, 
Rotterdam Study52 and Blue Mountains Eye Study53 proved that current smokers had a 
higher risk of neovascular AMD. Additionally, the Rotterdam Study52 found that the 
increased risk of neovascular AMD was present up to twenty years after cessation of 
smoking. In the Beaver Dam Offspring Study51, current smoking and greater number of 
pack years were associated with early AMD. In the POLA study, current and former 
smokers had an increased prevalence of late AMD and the risk is higher if patients 
smoked twenty pack-years and more202.  
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After five years, the Beaver Dam Eye Study concluded that men who smoked greater 
number of cigarettes were more likely to develop early AMD, and a ten-year follow-up 
confirmed that their AMD were also more likely to progress56,203. The longitudinal analysis 
of the Blue Mountains Eye Study after five years concluded that current smokers had an 
increased risk of incident GA and any late lesions204. After ten years, results show that 
current smokers had a four-fold increase in the risk of late AMD compared with never-
smokers, and former smokers had a three-fold higher risk of GA205. Current or former vs 
never smoking participants was associated with a 30% (95% CI, 10-70%) increased risk 
for progression to either subtype of late AMD in one or both eyes after a mean follow-up 
of 6.3 years59. In a more recent longitudinal study performed on 64,560 South Koreans, 
it was shown that cigarette smoking is associated with a strong risk of neovascular AMD 
and the duration of smoking and daily cigarette consumption was associated with the 
incidence of neovascular AMD in a dose-dependent manner60. It has also been 
established that current cigarette smoking in exudative AMD patients is associated with 
poor visual acuity improvement following intravitreal anti-VEGF therapy206.  
 
2.5 Age-related macular degeneration and nutrition and smoking advice 
Currently there is still no treatment available for early and atrophic AMD, and despite 
conflicting results from nutritional research, to advise patients on their diet or 
supplements, as well as to quit smoking if patients are smokers seem to be the most 
viable option. Patients should be well-informed of all the possible options to treat or delay 
the progression of their disease, including lifestyle changes. If feasible, most patients will 
be most willing to make these changes in order to preserve their vision, as through a 
survey, loss of sight is the sense that people in the UK fear losing the most207. Moreover, 
the intake of antioxidants is also beneficial to the human body in general, not only to the 
eye, therefore it is unlikely that it will do any harm to the patient unless the patient has 
other systemic conditions, which he or she should seek medical advice before 
 51 
consuming such supplements. As a result, it is important that AMD patients are being 
advised about the importance of diet.  
To date, there are only a few, if not limited studies that evaluate the nutritional and 
smoking advice that are provided to patients with or at risk of AMD. The most recent 
study was conducted by Martin and Lene208 whereby 371 optometrists and 
ophthalmologists were questioned on the use of nutritional supplements, changes in diet 
or smoking cessation to patients who are at risk or with signs of AMD in Sweden. From 
this study, it was found that optometrists were more likely than ophthalmologists to 
recommend nutritional supplements in AMD patients and they also provided significantly 
more advice about diet than the ophthalmologists. On the other hand, ophthalmologists 
use the AREDS as reference when recommending nutritional supplements and they tend 
to advice smoking cessation more than optometrists.  
In another study conducted in the UK 209 on 1468 optometrists and ophthalmologists, it 
was found that 67.9% of the respondents frequently provide dietary advice to patients 
with established AMD and 53.6% of the respondents frequently provide dietary advice 
to patients who are at risk of AMD. About 93% of the respondents will recommend 
supplementation in a patient who has advanced AMD in one eye and early AMD in the 
other. However, the type of supplement recommended did not comply with the current 
best research evidence, which is the finding from AREDS. Furthermore, as there are no 
strict regulations for nutritional supplements in the UK, many supplements to improve 
eye health is available in the market, even though they have not been tested clinically to 
be effective. Last but not least, in this study, only one in three optometrists regularly 
asked their patients on their smoking statuses and/or advised them to quit smoking.  
In Australia, a study conducted by Downie and Keller on 283 optometrists highlighted 
that fewer than half of the respondents routinely asked their patients about smoking 
status and younger practitioners were significantly (p < 0.05) less likely to enquire about 
patients’ smoking behaviours. Almost two-third of respondents indicated routinely 
counsel their patients about diet, and about half of respondents routinely asked their 
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patients about nutritional supplement intake, especially if the respondent is a female (p 
< 0.05)210. However, another study by Downie et al.211 on 220 patients indicated that 
approximately one-third of patients indicated having been routinely questioned about 
their smoking status, diet and nutritional supplement intake by their optometrist, which 
was lesser than what the optometrists reported in the previous study.  Additionally, 
approximately 75% of the respondents indicated that they feel comfortable talking with 
their optometrist about their lifestyle behaviours that include smoking status, diet and 
nutritional supplement intake.  
A survey conducted in Singapore212 revealed that 66% of practicing optometrists and 
contact lens practitioners were aware that smoking was a risk factor for AMD, and those 
who were aware of the negative ocular effects were more than twice as likely to assess 
the smoking status of their patients, and nearly three times more likely to ask patients to 
quit smoking. Additionally, among the participants who enquired about their patients’ 
smoking status, 62% advised patients to quit smoking if they were known to be current 
smokers. 
In order to encourage eye care practitioners to advice patients with or at risk of AMD on 
diet or nutritional supplementations, efforts have been made to make this process easier 
for them. These include educational intervention in the form of leaflets and prompt cards, 
as well as a clinical decision-making aid in the form of a flowchart. Both methods have 
proved to be easy and helpful for optometrists when providing nutritional advice to 
patients with or at risk of AMD213,214.  
This chapter presented the literature review for this thesis, including the pathogenesis 
and risk factors (modifiable and non-modifiable) of AMD. Studies that evaluated the 
effect of antioxidants, carotenoids such as lutein and zeaxanthin and PUFAs were also 
highlighted. The effect of smoking on AMD was discussed, and nutritional and smoking 
advice to patients with or at risk of AMD by eye care practitioners around the world was 
evaluated. In the next chapter, the first study of this thesis, “Nutritional and smoking 
advice to patients with or at risk of AMD by optometrists in Singapore” will be analysed. 
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Chapter Three: Nutritional and smoking advice to patients with or at risk of AMD 
by optometrists in Singapore  
3.1  Introduction 
Chapters one and two highlighted on the pathogenesis, causes and risk factors of AMD, 
nutrition and smoking and AMD, as well as nutritional and smoking advice to AMD 
patients by eye care practitioners. Though the nutritional results may vary, dietary 
modification and/or nutritional supplementation will remain one of the viable options for 
patients with or at risk of AMD, especially the atrophic type as there is no treatment 
available at the moment. In this chapter, full details of the study “Nutritional and smoking 
advice to patients with or at risk of AMD by Singapore optometrists” will be discussed, 
including the methods and results. This study is important as it will be the first to be 
conducted in Singapore and it is also important as the prevalence of smoking in 
Singapore is higher compared to other countries such as the UK and Sweden who has 
conducted similar studies. With the projected increasing prevalence of AMD due to the 
ageing population, understanding the nutritional and smoking advice that are being 
provided to AMD patients is crucial as it gives an indication as to whether AMD patients 
are receiving the appropriate information on managing their condition. As optometrists 
are usually the first to diagnose patients with AMD, therefore this study will explore 
optometrists’ nutritional and smoking advice to patients with or at risk of AMD.  
 
3.2 Methods  
This study is conducted using a cross-sectional questionnaire to understand the 
nutritional and smoking advice that optometrists in Singapore are giving to their patients 
with or at risk of AMD. A questionnaire is adopted in this study as it is a less expensive 
method of collecting data from a potentially large number of respondents. Most of the 
questions in the questionnaire are close-ended as it is easier for respondents to answer, 
hence increasing the response rate.  
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Validation of questionnaire 
The questionnaire was designed with reference to the one used by Lawrenson and 
Evans209 and modified after validating with ten optometrists who are currently practicing 
in Singapore. Ten optometrists from different practice types (retail optical shops, clinical 
optical shops, hospitals or eye clinics and teaching institutions) were invited to complete 
the draft questionnaire and to provide feedback on it either verbally to the principal 
researcher or indicating on the draft questionnaire. The feedback provided by the 
optometrists were consolidated and the following key changes were made to the draft 
questionnaire: 1) to include highest qualification attained in the field of optometry for each 
participant completing the questionnaire; to determine if there is a difference in nutritional 
and smoking advice between optometrists with different qualifications, 2) location of 
current practice; to establish if geographic location will affect the nutritional and smoking 
advice provided by optometrists, 3) optometric tests that were routinely performed on 
patients aged 50 and above and number of patients aged 50 and above seen per week; 
to provide an estimation of the prevalence of AMD in Singapore, 4) images to illustrate 
Category 1 or 2 AMD and Category 3 or 4 AMD; to assist participants who are not too 
familiar with the AMD classification system, 5) to provide a range in percentage for each 
frequency option, for instance, rarely (10% of the time), often (50 to 70% of the time); to 
allow participants completing the questionnaire to have a clearer idea of the frequency 
terms, 6) to include serving size options for green leafy vegetables and oily fish; to have 
a clearer picture of how much optometrists are advising their patients to consume and 
last but not least, to provide example for oily fish such as salmon.  
 
The demographic information for the final questionnaire include age, gender, number of 
years practicing as a fully registered optometrist, highest qualification attained in the field 




The final questionnaire (Appendix A) consists of nine sections: 
1. Tests routinely performed on patients aged 50 and above (2 questions) 
2. Number of AMD patients seen per year (2 questions) 
3. Perspective on AMD and nutrition (2 questions) 
4. Dietary advice to patients with early (Category 1 or 2) AMD (3 questions) 
5. Dietary advice to patients with advanced (Category 3 or 4) AMD (3 questions) 
6. Dietary advice to patients considered to be at risk of AMD (3 questions) 
7. Smoking and AMD (6 questions)  
8. Recommendations on nutritional supplements in patients with established or at risk 
of developing AMD (5 questions) 
9. Confidence level in classifying AMD and providing nutritional advice to patients with 
or at risk of AMD (7 questions)  
In section eight, three case scenarios were simulated to illustrate patients with 
established or at risk of AMD in order to understand the optometrists’ nutritional advice 
to these patients for each scenario.  
In section nine, respondents were requested to complete a section that evaluates their 
self-efficacy using scales to determine if they are likely to accomplish a task in the future. 
The items in the section were adapted from the study by Stevens et al.213 and the items 
are as follows:  
I am confident that I could classify the type of AMD a patient has based on retinal 
signs. 
I am confident that I can advise a patient with AMD on the relationship between 
AMD and nutrition. 
I am confident that I can advise a patient with AMD on what foods to eat that 
might be beneficial for their condition. 
I am confident that I can advise a patient with AMD on the quantities of food that 
might be beneficial for their eye health. 
I am confident that I can advise a patient with AMD on when nutritional 
supplementation may be beneficial. 
I am confident that I can advise a patient with AMD on what supplements to take 
and what dosage to recommend. 
I am confident with talking about nutrition to those at risk of AMD. 
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For each statement, respondents are required to indicate their confidence level from a 
scale of 0 to 100; 0 being least confident and 100 being most confident. Further details 
of this self-efficacy survey can be found in chapter 5.4, section “Evaluation of the 
flowchart”. 
The questionnaire is available in a hardcopy and an online version. The hardcopy 
questionnaire (Appendix A) together with a return envelope, invitational letter (Appendix 
B) study information sheet (Appendix C), consent form (Appendix D) and an appendix to 
illustrate AMD categories (Appendix E) was mailed to 573 fully registered optometrists, 
with no mention of their names, in December 2017 and they were encouraged to 
complete the questionnaire before 31 March 2018. The questionnaire was designed to 
be as anonymous as possible by not including personal data of the participants, and only 
anonymous data will be used for analysis. Confidentiality was ensured by only allowing 
the principal researcher to have access to all the data collected, and all data are 
password-protected. The contact list of the 573 optometrists was obtained from the 
Optometrists and Opticians Board (OOB). This research study was also being advertised 
on Singapore Optometric groups on Facebook (Appendix F) and members of the 
Singapore Optometric Association (SOA) also received an email to participate in this 
study. The online version of the questionnaire was created using Survey Monkey and 
the link to the questionnaire https://www.surveymonkey.com/r/AMD_advice was 
available in the invitational letters (Appendix B), Facebook advertisement (Appendix F)  
as well as the email that was sent out to the SOA members. Optometrists who received 
the hardcopy questionnaire could opt to complete the questionnaire online using the link 
that was in the invitational letter. Optometrists who are in the Singapore Optometric 
Facebook groups and SOA members were not included in the mailing list to prevent 
optometrists from receiving the invitation twice. It was also highlighted in the invitational 
letters and advertisement that they should only complete the questionnaire once. 
The study information sheet (Appendix C) for this study contained details of the study 
and after participants have read and understood the information in the study information 
 57 
sheet, they will initial on the consent form (Appendix D) and mail it back together with 
the completed questionnaire. If participants are completing the questionnaire online, 
there will be a link for the participants to access the study information sheet and they will 
complete an electronic consent form to acknowledge that they have read and understood 
the study information sheet before they proceed to complete the questionnaire.  
 
The inclusion criteria for this study are:  
• Fully registered optometrist under the Optometrists and Opticians Board (OOB) in 
Singapore 
• Currently practicing in Singapore as an optometrist 
 
The exclusion criteria for this study are: 
• Optometrists under provisional registration 
• Optometrists currently not practicing in Singapore 
 
3.3  Ethics 
This research study has been reviewed and approved by the Aston University Research 
Ethics Committee (AUREC); Application Number 2010 and approved by the Parkway 
Independent Ethics Committee (PIEC) based in Singapore; reference number 
PIEC/2017/004 (Appendix G). Moreover, in order to manage appropriately the ethical 
issues inherent in this study, it is necessary to put the following additional protections of 
the research participants in place. They are that: (1) informed consent is required before 
any information from the optometrists can be analysed; (2) Only the principal researcher 
has access to the information that the optometrists provided; (3) Only anonymous data 






32 completed hardcopy questionnaires were mailed back and the responses of these 
hardcopies were entered manually into the Survey Monkey database by the principal 
researcher. This equates the response rate of the hardcopies to be 5.6%.  
The online version of the questionnaire was created with Survey Monkey (an online 
survey platform that is cloud-based) and the link was circulated to optometrists who are 
members of the Singapore Optometric Association (180 members) as well as the 
Facebook Group, SG OPTOMS (399 members). SOA members who were also members 
of the SG OPTOMS Facebook group were taken into consideration to ensure there is no 
duplication. There is a total of 217 (complete and partial) responses via the Survey 
Monkey link, and 111 were complete (response rate of 19.2%). However, only 141 
responses, inclusive of the 32 hardcopy responses will be analysed in this study as 2 
respondents indicated that they are not fully registered optometrists. The total number 
of fully registered optometrists in Singapore is 776 when this questionnaire was 
disseminated; therefore approximately 18.2% of fully registered optometrists responded.  
 
Demographics of respondents 
The mean age of the respondents is 32.1 years; minimum age of 21 and maximum age 
of 71, with a standard deviation of 7.9. 96 (68.1%) of the respondents are female and 45 
(31.9%) are male. The average number of years practicing as a fully registered 
optometrist is 9.3 years, standard deviation of 7.2 years. The number of respondents 
with less than or twelve years of experience is 88, and 53 of them have more than twelve 
years of experience.  
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Figure 3.1 : Respondents’ highest qualification attained in the field of optometry  
 
Most of the respondents have a Bachelor or Diploma in Optometry and there was one 
optometrist who graduated in Chinese Medicine Ophthalmology.  
 
Optometrists in Singapore can be working in different practices: 1) retail optical shop 
whereby optometrists mainly check subjective refraction and anterior ocular health as 
patients usually go to them for vision correction, such as to purchase glasses or contact 
lenses. Therefore optometrists working in retail optical shops generally do not routinely 
perform comprehensive eye examinations on all patients. 2) Clinical optical shop is a 
practice whereby optometrists will perform a comprehensive eye examination on all 
patients even though the location and setting is similar to that of a retail optical shop. 3) 
Hospitals and eye clinics are places where optometrists will perform optometric tests as 
requested by the ophthalmologists.  
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  Independent/ 
Private 
Chain Government Total- 
N (%) 
Retail optical shop 38 (26.6%) 17 (11.9%) 1 (0.7%) 56 
(39.2) 
Clinical optical shop* 26 (18.2%)  2 (1.4%)  2 (1.4%)  30 
(21.0) 
Clinical (Includes hospitals 
and eye clinics) 
27 (18.8%) 0  30 (21.0%) 57 
(39.8)     
143 
*A practice is defined as clinical optical shop if slit-lamp examination and ophthalmoscopy are routinely performed on all 
patients/customers.  
Table 3.1: Respondents’ type of current practice (total is 143 as 2 respondents are working in 
more than one practice)  
 
Based on the data provided by OOB, the percentage of optometrists holding an active 
practicing certificate and working in retail setting is approximately 60%, and this matches 
closely to our respondents working in retail and clinical optical shops (60.2%).  
 












0  22  
(15.6) 
South 3 (2.1%)  0  2 (1.4%) 0  1 (0.7%) 6  
(4.3) 
East 8 (5.7%)  10 (7.1%) 0  0  0  18 
(12.8) 
West 4 (2.8%)  8 (5.7%) 5 (3.5%)  1 (0.7%) 15 (10.6%) 33 
(23.4) 
Central 26 (18.4%) 6 (4.3%) 11 (7.8%) 19 (13.5%) 0  62 
(44.0)  
47 33 22 23 16 141 
Table 3.2: Respondents’ location of current practice  
 
The average number of patients aged 50 years and above seen in the respondents’ 
practice per week is 43.9. The average number of patients seen with Category 1 or 2 
AMD per year is 77.5 and the average number of patients seen with Category 3 or 4 
AMD per year is 19. Based on the numbers reported by the respondents above, the 
estimated prevalence of Category 1 or 2 AMD is 3.4% and Category 3 or 4 AMD is 0.8%, 
whereas the report by Cheung et al. states that the prevalence of early AMD in Singapore 
is 5.1% and late AMD is 0.5%37.  
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Figure 3.2: Tests routinely performed by respondents on patients aged 50 and above  
 
The respondents added the other tests that are routinely performed on patients aged 50 
and above are OCT macular scan, Amsler chart, low vision evaluation and management, 
corneal topography and fundus photography. 46.4% of optometrists in retail optical 
shops routinely perform fundus examination on patients aged 50 and above, while 93.3% 
of optometrists in clinical optical shops routinely perform fundus examination.   
137 (97.2%) respondents are aware of the link between AMD and nutrition, and the 
nutritional advice to patients with or at risk of AMD is restricted for 31 (22.0%) 
respondents.  Respondents working in eye hospitals or clinics can be restricted in terms 
of giving certain nutritional advice to their AMD patients as the ophthalmologists might 
prefer to provide such advice themselves, or, would want the optometrists to provide 
nutritional advice which they believe in. As some retail or clinical optical shops are selling 
a particular product or supplement in the shop, that could also pose a restriction to 
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 62 









Never 8 (14.3) 4 (4.7) 12 (8.5) 
Rarely (10% of the time)  8 (14.3) 7 (8.2) 15 (10.6) 
Sometimes/ Often (20-70% of the time)  21 (37.5) 33 (38.8) 54 (38.3) 
Most of the time/ Always (80-100% of 
the time) 
19 (33.9) 41 (48.2) 60 (42.6) 
Table 3.3: Frequency of dietary advice for patients/customers with early (Category 1 or 2) AMD 
*Clinical includes clinical optical shops, eye clinics and hospitals  
 
Figure 3.3: Main reason(s) for not/rarely advising dietary advice for patients/customers with early 
(Category 1 or 2) AMD  
 
27 respondents indicated that they rarely or do not provide dietary advice to patients with 
early AMD and when asked to indicate their reasons for not doing so, they were able to 
select more than one option from the list provided, as shown in figure 3.3.  
 
Insufficient evidence 
that nutrition is 
beneficial for 
patients/ customers 
with category 1 or 2 
AMD; 7; 18%




with category 1 or 2 
AMD; 0; 0%




with category 1 or 2 
AMD; 4; 10%
Insufficient time; 10; 
26%
Rarely see category 
1 or 2 AMD cases; 
13; 33%
Others ; 5; 13%
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Figure 3.4: Advice to consume leafy green vegetables, oily fish or other foods for 
patients/customers with early (Category 1 or 2) AMD 
 
80 (56.7%) of the respondents advised their patients with early AMD to consume both 
leafy green vegetables and oily fish.  
 
 
Figure 3.5: Frequency to consume green leafy vegetables to patients/customers with Category 1 
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Figure 3.6: Amount of green leafy vegetables to consume for patients/consumers with Category 








































Figure 3.8: Amount of oily fish to consume for patients/consumers with Category 1 or 2 AMD 
(n=85)    
 
 
134 (95.0%) respondents think that optometrists in Singapore should be providing 
dietary advice to patients or customers with early (Category 1 or 2) AMD.  The 
optometrists who indicated that they should not be providing dietary advice to patient  or 
customers with early AMD is because 1) they feel that they can give as general advice, 
but not for main advice to prevent or treat AMD; 2) they are not trained to provide such 
advice; 3) there is no evidence to show that it helps, therefore perhaps to provide dietary 
advice to all patients, including healthy ones; 4) it is not optical related.  
 









Never 10 (17.9) 8 (9.4)  18 (12.8) 
Rarely (10% of the time)  11 (19.6) 8 (9.4) 19 (13.5) 
Sometimes/ Often (20-70% of the time)  13 (23.2) 24 (28.2) 37 (26.2) 
Most of the time/ Always (80-100% of the 
time) 
22 (39.3) 45 (52.9)  67 (47.5) 


















Figure 3.9: Main reason(s) for not/rarely advising dietary advice for patients/customers with 
advanced (Category 3 or 4) AMD 
 
37 respondents indicated that they rarely or do not provide dietary advice to patients with 
advanced AMD and when asked to indicate their reasons for not doing so, they were 
able to select more than one option from the list provided, as shown in figure 3.9. The 
other reasons highlighted by the respondents are patients with advanced AMD are 
usually managed by ophthalmologists, hence they will know the food that are beneficial 
for their condition.  
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with category 3 or 4 
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Do not believe that 
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category 3 or 4 AMD; 
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category 3 or 4 AMD; 
1; 2%
Insufficient time; 8; 
16%
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Figure 3.10: Advice to consume leafy green vegetables, oily fish or other foods for 
patients/customers with advanced (Category 3 or 4) AMD 
 
58.9% of the respondents in this study advised patients with advanced AMD to consume 
both green leafy vegetables and oily fish.  
Figure 3.11: Frequency to consume green leafy vegetables to patients/customers with advanced 
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Figure 3.12: Amount of green leafy vegetables to consume for patients/consumers with advanced 
(Category 3 or 4) AMD (n=110)  
 
 
Figure 3.13: Frequency to consume oily fish to patients/customers with advanced (Category 3 or 


































Figure 3.14: Amount of oily fish to consume for patients/consumers with advanced (Category 3 
or 4) AMD  (n=83) 
 
130 (92.20%) respondents think that optometrists in Singapore should be providing 
dietary advice to patients/customers with advanced (Category 3 or 4) AMD.  The main 
reasons for not advising is that optometrists feel that advanced (Category 3 or 4) AMD 
should be managed by an ophthalmologist, including dietary advice, and optometrists 
are not professionally trained in this area, hence their advice might contradict the 
ophthalmologist’s advice. However, one optometrist mentioned that he or she can 
provide advice as general recommendation and not as a main advice for treatment, and 






























Never 12 (21.4) 9 (10.6) 21 
(14.9) 
Rarely (10% of the time)  6 (10.7) 10 (11.8)  16 
(11.3) 
Sometimes/ Often (20-70% of the time)  21 (37.5) 39 (45.9) 60 
(42.6) 
Most of the time/ Always (80-100% of 
the time) 
17 (30.4) 27 (31.7) 44 
(31.2) 
Table 3.5: Frequency of dietary advice for patients/customers considered to be at risk of AMD 
 
 
Figure 3.15: Main reason(s) for not/rarely advising dietary advice for patients/customers 
considered to be at risk of AMD 
 
37 respondents indicated that they rarely or do not provide dietary advice to patients 
considered to be at risk of AMD and when asked to indicate their reasons for not doing 
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so, they were able to select more than one option from the list provided, as shown in 
figure 3.15. 
  
Figure 3.16: Advice to consume leafy green vegetables, oily fish or other foods for 
patients/customers considered to be at risk of AMD 
 
81 (57.4%) respondents in this study advised patients at risk of AMD to consume both 
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Figure 3.17: Frequency to consume green leafy vegetables to patients/customers considered to 
be at risk of AMD (n=113)  
 
 
Figure 3.18: Amount of green leafy vegetables to consume for patients/consumers considered to 


































Figure 3.19: Frequency to consume oily fish to patients/customers considered to be at risk of 
AMD (n=83)  
 
 
Figure 3.20: Amount of oily fish to consume for patients/consumers considered to be at risk of 
AMD (n=83)   
 
136 (96.5%) respondents think that optometrists in Singapore should be providing 




























not providing dietary advice is that they felt that these patients should see an 
ophthalmologist, and it is not optical related.  
 
Smoking and AMD 
138 (97.87%) respondents are aware that smoking is a risk factor of AMD, and the table 
below depicts the frequency of taking a smoking history in new or first time patients 
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Never/ Rarely (10% of the time)  23 (41.1) 32 (37.6) 55 (39) 474 
(35.6) 
Sometimes/ Often (20-70% of the 
time)  
27 (48.2) 39 (45.9) 66 (46.8) 576 
(43.2) 
Most of the time/ Always (80-100% 
of the time) 
6 (10.7) 14 (16.5)  20 (14.2) 283 
(21.2)  











Never/ Rarely (10% of the time)  17 (30.4) 14 (16.5) 31 (22) 129 (9.7) 
Sometimes/ Often (20-70% of the 
time)  
26 (46.4) 40 (47.0) 66 
(46.8) 
546 (41.0) 
Most of the time/ Always (80-
100% of the time) 
13 (23.2)  31 (36.5) 44 
(31.2) 
658 (49.4) 
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the time)  
14 
(25.0) 





Most of the time/ Always (80-
100% of the time) 
20 
(35.7) 














Never/ Rarely (10% of the time)  20 (35.7) 18 (21.2) 38 (26.9) 
Sometimes/ Often (20-70% of the time)  19 (33.9) 20 (23.5)  39 (27.7) 
Most of the time/ Always (80-100% of the 
time) 
17 (30.4) 47 (55.3)  64 (45.4) 
Table 3.10: Frequency of advising patients/customers at risk of AMD to stop smoking  
  
42.3% of the clinical optometrists in Singapore take a smoking history in new or first time 
patients most of the time, compared with 32.3% of the optometrists in the UK. Almost 
half of the optometrists in the UK inform smokers of the link between smoking and AMD 
most of the time but only 36.5% of optometrists in Singapore does the same. Conversely, 
slightly more than half of the optometrists in Singapore advise AMD patients to stop 
smoking most of the time and 33.7% of the optometrists in the UK advised AMD patients 
to stop smoking most of the time.  
 
Nutritional supplements for case scenarios 
As mentioned under the methods section, three clinical case scenarios are simulated to 
understand the type of supplements that are recommended for these patients by the 
Singapore optometrists, and they are allowed to select more than one option for each 
scenario. The three case scenarios are the same ones used by Lawrenson and Evans209 
and Martin208 in their studies to allow comparison between optometrists in the UK, 
Sweden and Singapore.  
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Scenario 1: 55 year old patient/ customer with no evidence of AMD but with one or 
more parents and/or siblings affected by AMD. 
66.4% of the respondents in this study would recommend supplements compared to 
33.6% in the study by Lawrenson and Evans209 in the UK and 50.1% in the study by 
Martin208 in Sweden.  
 
Figure 3.21: Supplements to recommend to patient in Scenario 1 by respondents 
 
Others include regular monitoring with Amsler chart and annual eye examination, eat 
green leafy vegetables and other foods that are high in lutein or zeaxanthin, to have a 
diet rich in green leafy vegetables, a healthy lifestyle and cease smoking if patient is a 
smoker, to take supplements in consultation with a pharmacist or GP, Ocuvite, 
wolfberries, and to go for eye check annually.  
In the UK study209, 15.6% would recommend an AREDS formula, 62.1% would 
recommend a supplement containing macular carotenoids, 63.0% would recommend a 
supplement containing antioxidant vitamins, lutein and zeaxanthin, and 20.1% would 























Scenario 2: 65 year old patient/ customer with advanced AMD in one eye and early 
AMD in the other.  
92.3% of the respondents would recommend supplements compared to 92.8% in the 
study by Lawrenson and Evans209 in the UK and 73.3% in the study by Martin208 in 
Sweden.  
 
Figure 3.22: Supplements to recommend to patient in Scenario 2 by respondents  
 
Others include regular monitoring with Amsler chart and regular six monthly eye 
examination, diet with green leafy vegetables, to see an ophthalmologist, to have a diet 
rich in green leafy vegetables, to have a healthy lifestyle, to cease smoking and AREDS 
2 if patient is a smoker, to refer to eye clinic, Ocuvite, wolfberries and TCM herbs. 
In the UK study209, 27.5% would recommend an AREDS formula, 64.6% would 
recommend a supplement containing macular carotenoids, 57.2% would recommend a 
supplement containing antioxidant vitamins, lutein and zeaxanthin, and 20.7% would 

























Scenario 3: 75 year old patient/ customer with advanced AMD in both eyes 
88.1%% of the respondents would recommend supplements compared to 44.8% in the 




Figure 3.23: Supplements to recommend to patient in Scenario 3 by respondents  
 
Others include regular monitoring with Amsler chart and regular six monthly eye 
examination, to eat green leafy vegetables, to see an ophthalmologist, to have a healthy 
lifestyle and cease smoking if patient is a smoker, to refer to eye clinic, Ocuvite, 
wolfberries and TCM herbs. 
In the UK study209, 26.8% would recommend an AREDS formula, 65.8% would 
recommend a supplement containing macular carotenoids, 56.7% would recommend a 
supplement containing antioxidant vitamins, lutein and zeaxanthin, and 25.0% would 























111 (78.72%) of the respondents would consider the smoking status or history of their 
patients when recommending nutritional supplements. The figure below shows the 
sources of evidence that respondents use and others include ophthalmologist whom the 
optometrist is working for, Google, Wikipedia and sales representative.  
 
 
Figure 3.24: Sources of evidence that respondents use to obtain information on nutritional 




The Mann-Whitney U test is used to analyse the difference in average self-efficacy 
scores between optometrists with different years of experience, working in different 
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7. I am confident with talking about 




(SD: 20.0)  
0.67 
Table 3.11: Average confidence and self-efficacy scores between optometrists with less than or 
12 years of experience and optometrists with more than 12 years of experience 
 
Out of the seven statements in Table 3.11, there is no item that shows a statistically 
significant difference in scores between those with or less than twelve years of 
experience and those with more than twelve years of experience (all p-values are more 




Statement  Retail Clinical P- 
Value 
1. I am confident that I could classify the 
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7. I am confident with talking about 




(SD: 22.2)  
0.06 
Table 3.12: Average confidence and self-efficacy scores between optometrists working in retail 
and optometrists working in clinical setting (optical shops, clinics and hospitals)  
 
Between optometrists working in retail and optometrists working in clinical setting, the 
score difference was statistically significant for all statements except for statements four 
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with AMD on the quantities of food that 
might be beneficial for their eye health. 
50.0 




5. I am confident that I can advise a patient 
with AMD on when nutritional 






6. I am confident that I can advise a patient 
with AMD on what supplements to take and 






7. I am confident with talking about 
nutrition to those at risk of AMD. 
53.8 




Table 3.13: Average self-efficacy scores between optometrists with a diploma qualification and 
optometrists with a bachelor, masters or PhD qualification. 
 
There is a difference in self-efficacy scores for all statements except statement four 
between optometrists with a diploma qualification and optometrists with a bachelor, 
masters or PhD qualification.  
 
3.5 Discussion 
It is with no doubt that AMD will bring about society impact and economic burden to a 
country in the years to come due to the ageing population. In Singapore, it has been 
estimated that there will be a growth of over 42% in the number of wet AMD cases by 
the year 203045. As AMD affects the patient’s central vision, it will have a significant 
impact on patient’s vision and functionality as the condition progresses, therefore 
compromising patient’s quality of life. In view of the society impact and economic burden 
that AMD will bring in the near future, the Singapore government is taking necessary 
measures to reduce this impact to a minimum, and one of the measures include the AMD 
awareness week that is being held annually since 2005. With no treatment available for 
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atrophic AMD, the modifiable risk factors such as smoking and dietary modification are 
targeted as they are simple and cost-effective215, and are being studied extensively to 
either prevent the development of AMD, or to prevent atrophic AMD from progressing to 
the more advanced forms such as GA or neovascular AMD.  
In Singapore, most optometrists in retail optical shops do not perform a comprehensive 
eye examination on their patients as most practices are operating alike a traditional 
optical shop where prescription of glasses is the main focus of business. However, there 
are some optometrists in retail practice who take reference to the approach optometrists 
in Western countries are practicing, and being equipped with state-of-the-art equipment 
so that a comprehensive eye examination can be performed on all patients. This is 
evident from the results in this study that only 46.4% of the optometrists practicing in 
retail optical shops routinely perform a fundus examination on patients aged 50 and 
above, compared with 93.3% of optometrists practicing in clinical optical shops. While 
more (76.8%) optometrists in retail optical shops routinely perform slit-lamp bio-
microscopy on their patients aged 50 and above, but by not routinely performing fundus 
examination, they could have missed AMD patients especially during the early stages 
when their vision is usually unaffected.  
Though currently there are no large clinical trials to prove that antioxidants or PUFAs are 
beneficial for early AMD, some optometrists in Singapore (42.6%) do frequently provide 
dietary advice for patients with early AMD. 81.6% of the optometrists in Singapore 
advised patients with early AMD to consume green leafy vegetables daily but did not 
mention the amount to consume, and 60.3% of them advised their patients with early 
AMD to consume one serving of oily fish daily.  
In the UK209, 3.7% of the respondents never provide dietary advice, 28.4% of the 
respondents sometimes provide dietary advice, and 67.9% always or most of the time 
provide dietary advice for patients with established AMD. In another similar study done 
in Sweden208, 29% of the optometrists never recommend, 43% sometimes recommend 
and 28% always or very often recommend on diet for patients with established AMD. In 
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comparison with our data in Singapore, 9.4% of the clinical optometrists never provide 
dietary advice, 28.2% sometimes provide dietary advice and 52.9% always or most of 
the time provide dietary advice for patients with established AMD.  
From the study done in the UK209, 38.3% of the optometrists advised patients with 
established AMD to eat plenty of leafy green vegetables, 0.2% advised to eat oily fish at 
least twice per week, 50.7% advised to eat both green leafy vegetables and oily fish and 
10.8% advised to eat other foods. 78.0% of the optometrists in this study advised patients 
with advanced AMD to consume green leafy vegetables, 58.9% advised to consume oily 
fish and 58.9% advised patients with advanced AMD to consume both green leafy 
vegetables and oily fish. One of the reasons to explain the higher percentage (58.9%) of 
Singapore optometrists advising patients with advanced AMD to eat oily fish could be 
because in this study, the respondents are able to select more than one option; whereas 
in the study done in the UK, the respondents are only allowed to select one option out of 
the four options. However, the percentage of optometrists who advised patients with 
advanced AMD to consume both green leafy vegetables and oily fish is comparable 
between Singapore (58.9%) and the UK (50.7%).   
In the UK,209 it was found that 53.6% of optometrists always or most of the time provide 
dietary advice for patients considered to be at risk of AMD, 39.2% sometimes provide 
dietary advice and 7.2% never provide dietary advice for patients considered to be at 
risk of AMD. In Sweden208, 25% of the optometrists always or very often provide 
recommendations on diet, 42% sometimes provide recommendations on diet and 33% 
never provide recommendations on diet for patients who are at risk of developing AMD.  
In Singapore, 31.7% of the clinical optometrists always or most of the time provide dietary 
advice to patients considered to be at risk of AMD, 45.9% sometimes provide dietary 
advice and 10.6% never provide dietary advice to patients considered to be at risk of 
AMD.  
In the UK209 it was established that 38.4% of the optometrists advised patients 
considered to be at risk of AMD to eat plenty of green leafy vegetables, 0.5% advised to 
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eat oily fish at least twice per week, 47.2% advised to eat both green leafy vegetables 
and oily fish and 14.0% advised to eat other foods. In this study, 80.1% of the 
optometrists advised patients considered to be at risk of AMD to eat green leafy 
vegetables, 58.9% advised to eat oily fish and 57.4% advised to consume both green 
leafy vegetables and oily fish.  
Lutein and zeaxanthin are the principal components of macular pigment which plays an 
important role in visual function and also possesses essential antioxidant and protective 
blue-light filtering properties216. These macular carotenoids are not synthesized by the 
body de novo and therefore humans rely solely on dietary intake. The richest sources of 
lutein and zeaxanthin are from leafy green vegetables such as spinach and kale, and 
orange or yellow fruits and vegetables.  A review by Chong et al. suggested that high 
antioxidant levels in the healthy retina do little to prevent the development of early AMD67, 
while a Cochrane review showed that antioxidant supplements may have a role delaying 
the progression of early to late AMD193. This could explain the varying results relating to 
dietary advice for patients who are at risk of AMD between optometrists in Singapore, 
the UK and Sweden.  
The frequency of taking a smoking history in new or first time patients amongst 
optometrists in Singapore was very similar to the study conducted in the UK209 by 
Lawrenson and Evans, with one-third of the optometrists in Singapore frequently taking 
a smoking history, where the proportions of smokers in the UK and Singapore are 
19.9%201 and 28.0%201 respectively. A survey conducted in 2006 on optometrists and 
contact lens practitioners practicing in Singapore revealed that 66% were aware that 
smoking was a risk factor for AMD212, and through this study, more optometrists (97.87% ) 
in Singapore are now aware that smoking is a risk factor for AMD. Despite being aware 
that smoking is a risk factor for AMD, only one-third of the optometrists in Singapore 
would inform AMD patients of the link between smoking and AMD, but almost half will 
advise AMD patients to quit smoking, with only one-third of the UK optometrists209 who 
will do the same. This reveals that Singapore optometrists are more willing to advise 
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AMD patients to quit smoking as compared to the optometrists in the UK, and it is a good 
sign since there are more smokers in Singapore than in the UK. There is increasing 
evidence that smoking is causally linked to the development of AMD217 and smoking 
increases the risk of AMD two-fold218, but public awareness of the link between smoking 
and ocular health is lacking219–221. Therefore, eye care practitioners play a critical role in 
educating the public the link between smoking and AMD as well as encouraging smokers 
to quit. Only one-third of the optometrists in Singapore would inform AMD patients of the 
link between smoking and AMD, but almost half will advise AMD patients to quit smoking 
if they are current smokers. Previous studies that have investigated the attitudes and 
practice of optometrists in this area have reported similar findings222,223. These studies 
also identified a number of barriers to routinely addressing a patient’s smoking behavior 
including time constraints and a perceived need for further training in this area223. The 
challenges that Singapore optometrists face when advising AMD patients to quit smoking 
will be explored in the next chapter, but meanwhile Singapore optometrists should be 
providing smoking advice to more patients.  
With regards to recommending nutritional supplements for AMD patients, similar in the 
UK, the decision was based on the likelihood of disease progression, with 92.3% of the 
optometrists in Singapore providing nutritional supplements in scenario with advanced 
AMD in one eye and early AMD in the other eye. 73.4% of them would recommend an 
AREDS or AREDS 2 formula, compared to only 26% by optometrists in the UK209. 
However, in the scenario where patient had advanced AMD in both eyes, 88.1% of the 
optometrists in Singapore would also recommend nutritional supplements, with 71.3% of 
them recommending the AREDS or AREDS 2 formula. Optometrists in Singapore are 
likely to recommend nutritional supplements in all three scenarios, but the supplement 
that they are most likely to recommend in scenario one (55-year old with no evidence of 
AMD but with one or more parents and/or siblings affected by AMD) are antioxidant 
vitamins, lutein and zeaxanthin (49%). The nutritional supplements that they will 
recommend for scenario two and three are based on the latest clinical research evidence, 
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that is, results from AREDS and/or AREDS 2, and the sources of evidence that they got 
information on nutritional supplements and the eye are articles in professional journals, 
conference presentation such as continuing professional education events and 
references to specific studies such as the AREDS.  
At the end of the questionnaire, participants were asked to indicate their self-efficacy 
score for each statement and comparing the scores between optometrists with less than 
or twelve years of experience and optometrists with more than twelve years of 
experience, there is no significant difference in the self-efficacy scores between the two 
groups of optometrists. This shows that the number of years of experience does not 
influence the self-efficacy scores among optometrists in Singapore. However, when 
comparing the average self-efficacy scores between optometrists working in retail 
practice and optometrists working in clinical setting, there is a statistically significant 
difference (p < 0.05) in the scores between these two groups for all the statements except 
1) I am confident that I can advise a patient with AMD on the quantities of food that might 
be beneficial for their eye health (p = 0.21), and 2) I am confident with talking about 
nutrition to those at risk of AMD (p = 0.06). In addition, when comparing the self-efficacy 
scores between optometrists with diploma qualification and optometrists with higher 
qualification such as Bachelor, Masters or PhD, optometrists with higher qualification 
have a statistically significant higher score for all the statements except for one statement: 
I am confident that I can advise a patient with AMD on the quantities of food that might 
be beneficial for their eye health (p = 0.24). This shows that most optometrists, despite 
working in a clinical setting or have a higher qualification, are not that confident when 
asked to advise their AMD patients on the quantities of food that might be beneficial for 
their eye health.  
In conclusion, more optometrists practicing in retail optical shops should routinely 
perform fundus examination on all patients aged 50 and above so that conditions such 
as AMD could be diagnosed and treatment or appropriate advice can be provided earlier. 
Though the percentage of Singapore optometrists providing dietary advice to patients 
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with advanced AMD is slightly lower as compared to the optometrists in the UK, it is 
higher than the percentage of Swedish optometrists who will always provide dietary 
advice to patients with advanced AMD. For patients considered to be at risk of AMD, 
about one-third of the Singapore optometrists always or most of the time provide dietary 
advice, similar to the percentage in Sweden. Singapore optometrists are comfortable to 
provide general nutritional advice to patients with early AMD, hence they do not and are 
not confident to provide the quantities of food to consume for such patients. In addition, 
Singapore optometrists felt that they lack knowledge in this area, therefore patients with 
advanced AMD should be managed by an ophthalmologist.  
More optometrists in Singapore are willing to advise AMD patients to quit smoking than 
the optometrists in the UK, even though only one-third of the Singapore optometrists 
explain to AMD patients the link between smoking and AMD. Most optometrists in 
Singapore will recommend nutritional supplements based on disease progression and 
their recommendations are based on latest clinical research; AREDS and AREDS 2 
findings. Years of experience practicing as an optometrist does not affect the confidence 
and self-efficacy scores but the type of practice as well as level of qualification does 
affect the confidence and self-efficacy scores for most of the statements.  
The prevalence of AMD in Singapore has been predicted to increase over the next few 
years and with the relatively high prevalence of smokers, the frequency of nutritional and 
smoking advice to AMD patients by optometrists should be higher. In the next chapter, 
Singapore optometrists’ opinions on nutrition and the eye will be explored through face-
to-face in-depth interviews. In addition, the challenges faced and support required by 
optometrists when providing nutritional and smoking advice to AMD patients will be 
discovered in the next chapter. This will complement and provide a clearer picture on the 
statistics presented in this chapter.  
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Chapter Four: What do Singapore optometrists feel about providing nutritional 
and smoking advice to patients with or at risk of AMD?  
In the previous chapter, the frequency of nutritional and smoking advice to patients with 
or at risk of AMD provided by optometrists in Singapore was evaluated and compared 
with results published from the UK and Sweden. In addition, the confidence level of 
Singapore optometrists when providing nutritional and smoking advice to patients with 
or at risk of AMD was assessed using self-efficacy scores. In this chapter, a qualitative 
research of how Singapore optometrists feel about providing nutritional and smoking 
advice to patients with or at risk of AMD will be conducted via in-depth interviews.  
 
4.1  Introduction  
As discussed in earlier chapters, cigarette smoking, diet and nutritional supplementation 
are major modifiable factors that have a strong influence on the long-term risk of 
neovascular AMD. This is align with the hypothesis that oxidative stress plays an 
important role in the pathogenesis of AMD. Thus a diet rich in certain vitamins (A, C and 
E), nutrients such as xanthophyll carotenoids (lutein and zeaxanthin) and omega-3 
essential fatty acids could help to delay a patient with atrophic AMD to neovascular AMD, 
as some of these substances have been shown to scavenge ROIs that were produced 
through oxidative stress. The studies that evaluated the association between nutrition 
and AMD were discussed earlier in Chapter 2.3. Cigarette smoking is generally quite 
well known to the public to be associated with systemic morbidities such as lung cancer, 
cardiovascular disease and stroke, and associations with eye diseases such as AMD 
are less widely recognized224. In order to increase public awareness on the association 
between cigarette smoking and eye diseases, one of the measures was to include eye 
images as graphic warnings on cigarette packaging. Cigarette smoking is also known to 
increase oxidative stress, which can result in an increased risk of AMD, and the details 
on the association between smoking and AMD were highlighted previously in Chapter 
2.4.  
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As the major providers of primary eye care, optometrists are ideally positioned, as part 
of the health care team, to provide patient counselling with regard to these modifiable 
risk factors for AMD. In addition, optometrists could be the first to diagnose AMD in some 
patients through a comprehensive eye examination and could therefore give a timely 
diagnosis and management. In recognition of the important public health role that 
optometrists provide in these areas, there has been interest in understanding current 
optometric practices in these domains, as shown by studies done in the UK209, United 
States225 and Canada223.  
However, there is limited or no qualitative research conducted to explore optometrists’ 
views regarding nutrition and the eye in Singapore, or even other countries. Dietary 
advice and nutritional advice or management are often used interchangeably. According 
to McClinchy et al.226, dietary advice relates to the nutritional care or management of a 
specific disorder such as type 2 diabetes, undernutrition, obesity. Those providing dietary 
advice will need to have some specific knowledge about diet and disease. This is oppose 
to general nutritional advice given as part of life-style related care or health education 
included within a health promotion intervention. In the case of AMD, patients can be 
provided with dietary or nutritional advice depending on the severity of the condition. 
During category 1 or 2 AMD, patients can be advised on general nutritional advice such 
as to increase their intake of lutein and zeaxanthin with green leafy vegetables, and/or 
omega 3 with oily fish such as salmon. However for category 3 or 4 AMD, the AREDS 
and AREDS 2 results show that nutritional supplements containing vitamins A, C, E, 
carotenoids such as lutein and zeaxanthin and minerals such as zinc and cooper could 
prevent the condition from worsening and become neovascular AMD. In this case, 
providing dietary advice will be applicable. “Dieticians are the only qualified health care 
professionals that assess, diagnose and treat dietary and nutritional problems.{Citation}” 
McClinchy et al.227 found that general practitioners (GPs) and practice nurses perceived 
that their role included the delivery of dietary advice and Mitchell et al.228 confirm that 
primary care is an appropriate setting for GPs and practice nurses to deliver dietary 
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advice. Therefore, optometrists are in an ideal position to provide either nutritional or 
dietary advice to AMD patients as they provide primary eye care but no research has 
been done on optometrists to evaluate on how they perceive their role to provide 
nutritional and dietary advice.  
The previous chapter has looked into the nutritional and smoking advice that 
optometrists in Singapore are providing, and it was found that the frequency of Singapore 
optometrists providing nutritional and smoking advice to patients with or at risk of AMD 
is not as high as anticipated. The prevalence of AMD in Singapore has been predicted 
to increase due to the ageing population and with the higher prevalence of smokers 
compared with other Western countries, it is important to understand Singapore 
optometrists’ views about nutrition and the eye, particularly AMD. Following the results 
of the previous study, Singapore optometrists’ perspectives as well as challenges when 
providing nutritional and smoking advice to AMD patients will be further explored in this 
chapter. These will be addressed through a qualitative research presented in this chapter, 
whereby there will be a better understanding on the optometrists’ views regarding 
nutrition and the eye, their perception on this role, the challenges that they face, as well 
as further support in this domain.  
 
4.2  Methods 
Study design 
The main objective of this study is to obtain an in-depth opinion from Singapore 
optometrists on nutrition and the eye through interviews and to further enhance some 
findings that was observed from the previous chapter, such as a lower than anticipated 
frequency of nutritional and smoking advice to patients with or at risk of AMD.  
Qualitative research methods are employed when the researcher is interested in 
understanding the “why” behind peoples’ behaviours and actions. It provides a way to 
get an in-depth understanding of the underlying reasons, attitudes, and motivations 
behind various human behaviours229. Observations, in-depth interviews and focus 
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groups are methodologies in qualitative research that may be used to collect data230. In-
depth interviews involve the posing of open-ended questions and follow-up probes 
designed to obtain an in-depth understanding of participants’ experiences, perceptions, 
opinions, feelings and knowledge231. Interviews are useful for gaining insight and context 
into a topic, in this case, nutrition and the eye, and there is opportunity to probe, to 
encourage more complete and better explained responses. There is total control over 
the environment; the interviewer can ensure that the interview in conducted in private 
such that no other person may constitute bias to the response of the interviewee, and 
the interviewer can also ensure that sufficient information is being collected through the 
interview process232. Focus groups are structurally similar to in-depth interviews in the 
sense that they are comprised of open-ended questions designed to capture the in-depth 
experiences of respondents233. However, focus groups are a distinct data collection 
technique from in-depth interviews, which will provide researchers with data that relies 
upon the interaction of the group members to formulate answers to the researcher’s 
questions230. One-to-one in-depth interviews are preferred over focus groups in this 
study phase as the main objective is to obtain optometrists’ individual views; focus 
groups might result in an imbalance of opinions between optometrists and optometrists 
who are more vocal will share more of their views, whereas optometrists who are more 
reserved might not voice out their views as much. Moreover, any doubts during the 
interview can be clarified immediately and hence interviews are the best option for this 
phase of the study. It was also highlighted by Rosenthal230 that it is not recommended 
that novice researchers undertake focus groups in a first attempt to conduct qualitative 
research.  
In the previous study discussed in chapter three, the questions were mostly closed-
ended with the intention to increase the response rate as well as to enable easier data 
analysis. However, this could also create some questions regarding nutrition and the eye 
to be unanswered but able to be complemented through this study. The questions were 
developed by the principal researcher and were created to answer queries that emerged 
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while analysing the data from the previous study. Some of the queries include how do 
optometrists feel about providing nutritional and smoking advice to their patients, and 
how receptive were their patients when they provide such advice, the challenges that 
they face when providing nutritional and smoking advice and the support that they hope 
to get in this area. There were no previous research conducted in this area on 
optometrists, but a similar study by McClinchy et al226 exploring the views of pharmacists 
and allied health professionals regarding the provision of dietary advice to patients was 
used as a reference while developing the questions.    
The questions of the semi-structured interview are:  
- Do you think nutrition plays a role in preventing or treating certain eye conditions? 
What are the eye conditions that you think will benefit from nutrition? (For each eye 
condition, what nutritional advice/information have you given to patients? Or for each 
eye condition, what kind of nutritional advice/information do you think is appropriate 
for patients?) Where do you get the information regarding nutrition and the eye from?  
- What were your patients’ reactions to you offering this advice/information? (If 
participants have not engaged in this scenario, ask whether participants believe that 
patients would expect optometrists to be involved in this type of activity and why?)  
- How do you feel about including nutritional advice/information within your patient 
management?  
- What factors influence whether or not you give nutritional advice/information to your 
patients? What do you think is most challenging/difficult when providing nutritional/ 
smoking advice to AMD patients?  
- Do you routinely screen for age-related macular degeneration (AMD) in your practice 
for patients aged 50 years and above? (If yes, ask how is AMD diagnosed in your 
practice? If no, ask what is/are the main reasons for not routinely screening?) 
Currently the use of diagnostic drugs has not been legalized in Singapore, but do 
you think the use of these drugs will aid in your diagnosis of AMD?  
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- If you agree that you have an important role to play in the health promotion and 
dietary advice giving to patients, what can be done to support you further in your 
professional development relating to this aspect of your role?  
- Are there any other comments you would like to make in relation to this area of patient 
care and management?  
 
Sample size and data collection 
Optometrists in Singapore typically can work in different settings: 1) retail optical shop, 
2) clinical optical shop, 3) teaching institution or 4) eye clinic or eye hospital. As 
highlighted in chapter three and to re-emphasize, 1) optometrists working in retail optical 
shops mainly only check subjective refraction and anterior ocular health as patients 
usually go to them for vision correction, such as to purchase glasses or contact lenses. 
Therefore optometrists working in retail optical shops generally do not routinely perform 
comprehensive eye examinations on all patients. 2) Optometrists working in clinical 
optical shops will perform a comprehensive eye examination on all patients even though 
the location and setting is similar to that of a retail optical shop. The scope of practice is 
adopted from western countries whereby a comprehensive eye examination is 
performed on all patients. 3) Optometrists working in teaching institutions are lecturers 
who are teaching Optometry in an educational institution such as a polytechnic, and are 
also practising Optometry in the clinic that is usually located within the school compound. 
4) Optometrists working in hospitals and eye clinics will perform optometric tests as 
requested by the ophthalmologists. Data from OOB show that 60% of fully registered 
optometrists work in retail setting (retail optical shops and clinical optical shops) and the 
rest are working in eye clinics or hospitals.  
Optometrists from different settings are recruited for this research to ensure a varied 
opinion from optometrists working in Singapore and the optometrists are recruited from 
the contact list of the principal researcher. A total of fifteen fully registered optometrists 
are recruited for this research; 3 are from retail optical shop, 4 are from clinical optical 
 95 
shops, 5 are from teaching institutions and 3 are from eye clinics or eye hospitals. Data 
collection and analysis were conducted concurrently and participant recruitment ceased 
when data saturation has appeared to have surfaced. Saturation is used in qualitative 
research as a criterion for discontinuing data collection and/or data analysis234. Its origin 
lie in grounded theory235 but it now commands acceptance across a range of approaches 
to qualitative research, and Guest et al.236 refer saturation as having become ‘the gold 
standard by which purposive sample sizes are determined in health science research.” 
A face-to-face interview was arranged with the participants based on their schedules and 
all interviews were conducted by the principal researcher. Prior to each interview, the 
study information (Appendix H) was discussed with the participant, and the consent form 
(Appendix I) signed, should the participant have no further questions on the research. 
The participants are provided with the questions at least a day before the interview so 
that they could have time to think about their answers. They are also informed that the 
interviews will be voice-recorded for data analysis.  
 
Inclusion criteria  
• Fully registered optometrist under the Optometrists and Opticians Board (OOB) in 
Singapore 
• Currently practicing in Singapore as an optometrist, either working in a retail optical 
shop, clinical optical shop, hospital, eye clinic or teaching institution.  
Exclusion criteria  
• Optometrists under provisional registration 
• Optometrists currently not practicing in Singapore 
 
Ethical approval 
This study has been reviewed and approved by the Parkway Independent Ethics 
Committee (PIEC) reference number PIEC/2017/004 (Appendix E) based in Singapore 
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and the Aston University Research Ethics Committee (AUREC) application number 2010 
based in the UK.  
 
Data-analysis 
Material collected through qualitative methods is invariably unstructured and unwieldy; a 
huge proportion of it is text based, consisting of verbatim transcriptions of interviews or 
discussions, field notes or other findings that were documented during data collection. 
Moreover, the internal content of the material is usually in detailed and micro form, such 
as accounts of experiences, descriptions of interchanges, or observations of interactions. 
The qualitative researcher has to provide some coherence and structure to this 
cumbersome data set while retaining a hold of the original accounts and observations 
from which is it derived. Qualitative data analysis is essentially about detection, and the 
tasks of defining, categorizing, theorizing, explaining, exploring and mapping are 
fundamental to the analyst’s role237. The methods used for qualitative analysis therefore 
need to facilitate such detection, and to be of a form which allow certain functions to be 
performed. ‘Framework analysis’ is one of the methods deployed for qualitative analysis 
and is an analytical process which involves a number of distinct though highly 
interconnected stages: familiarization, identifying a thematic framework, indexing, 
charting, mapping and interpretation. In this study, ‘framework analysis’ as described by 
Ritchie and Spencer238 is used for data analysis and unlike quantitative analysis, 
qualitative analysis occurs concurrently with data collection. In addition, this process is 
conducted manually, without the assistance of any software as the amount of data is still 
manageable. The process of data analysis begins during the data collection; with the 
principal researcher skilfully facilitating the discussion, generating rich data from the 
interviews which have been recorded individually, and typing the transcript following 
each interview with the optometrists. This stage is followed by familiarization with the 
data which is achieved by listening to the recorded interviews, reading the transcripts 
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several times in order to immerse in the details and get a sense of the interview as a 
whole before breaking it into parts.  
The next stage involves identifying a thematic framework by writing memos in the margin 
of the text in the transcripts in the form of short phrases, ideas or concepts arising from 
the texts and beginning to develop categories. This stage is also facilitated as the 
interview questions were semi-structured. After manually sorting out the ideas and short 
phrases, the themes or descriptive statements that arise are: 1) Singapore optometrists’ 
perception of nutrition and the eye; 2) Perception of optometrists providing nutritional 
advice – optometrists’ and patients’ view; 3) Factors and challenges faced by Singapore 
optometrists when providing nutritional advice in practice; 4) Further support required by 
Singapore optometrists in the area of nutrition and the eye. The third stage, indexing, 
comprises sifting the data, highlighting and sorting out quotes and making comparisons 
both within and between cases. Each individual transcript was printed on paper and 
analysed thoroughly, and quotes were highlighted with different colours based on the 
optometrist’s practice type. The fourth stage, charting, involves lifting the quotes from 
their original context and re-arranging them under the newly-developed appropriate 
themes. The quotes that were highlighted earlier were then cut out and placed into the 
respective themes as mentioned earlier. The data are then ready for the final stage of 
analysis, that is, mapping and interpreting; to make sense of the individual quotes, to 
see the relationship between the quotes, and the links between the data as a whole. With 
the quotes highlighted in different colours, it was easier to compare data between 
optometrists from various practice types. As mentioned in the previous section, data 
collection ceased when the same comments were heard several times during the 
interviews, indicating that saturation has occurred. Similarly, saturation has occurred 
when no new codes were generated from the data collected. Themes that were decided 




4.3 Results  
Fifteen fully registered optometrists were interviewed for this research; 3 are from retail 
optical shop, 4 are from clinical optical shops, 5 are from teaching institutions and 3 are 
from eye clinics or eye hospitals. Of these fifteen optometrists, fourteen of them obtained 
a Bachelor of Optometry and one had a Diploma in Optometry.  
 
4.3.1 Singapore optometrists’ perception of nutrition and the eye 
All the optometrists who were interviewed agree that nutrition plays a role in preventing 
and managing, rather than treating certain eye conditions, and the condition that all 
mentioned will benefit from nutrition would be age-related macular degeneration (AMD). 
This is largely due to the Age-Related Eye Disease Study (AREDS)4 that was conducted 
and proved that vitamins such as A, C, E, cooper and zinc minerals and beta-carotene 
are beneficial in slowing the progression of moderate AMD to advanced AMD. In addition, 
AREDS 264 found that antioxidants such as lutein and zeaxanthin are also beneficial for 
AMD patients. Other sources that the optometrists obtained information regarding 
nutrition and the eye include continuing professional education (CPE) programs, 
conferences, online websites such as WebMD or supplement suppliers’ website, journal 
articles as well as brochures from eye hospitals or clinics.  
 
“For AMD, I do read through the AREDS, which is 1 and 2.” (retail optometrist 3) 
“Through articles, reading journals online, conferences.” (institution optometrist 2)  
 
The nutritional advice optometrists provide to AMD patients range from having a 
balanced diet, to consuming foods that are high in antioxidants such as green leafy 
vegetables, kale, spinach, broccoli, eggs, carrots, wolfberries and different kinds of 
coloured fruits, to supplements that either contain the AREDS formulation, lutein or 
antioxidants. Most optometrists do not mention the specific supplement except for two 
optometrists (institution optometrist 4 and clinical optometrist 2) who will recommend 
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Preservision, two (retail optometrist 2 and institution optometrist 5) who would 
recommend Ocuvite and one optometrist (clinical optical shop optometrist 2) who would 
recommend Lutex 15. One optometrist (clinical optometrist 3) will offer Macutec in the 
eye clinic where she is working in. Optometrists recommended Preservision as it 
contains ingredients from AREDS 1 and 2 study; Lutex 15 was recommended by the 
optometrist in this study as clinical trials were done to prove its efficacy. However, it was 
not further explored with optometrists the reasons for recommending Ocuvite. In terms 
of dietary advice, all the optometrists did not advise on the frequency and quantity to be 
consumed, and all optometrists, except for two optometrists, will advise their patients to 
get their supplements outside of their practices, such as the local chemists. Hence they 
do not and are unable to advise patients on the frequency as well as dosage for these 
supplements.  
 
“I didn’t tell them about the frequency, I didn’t tell them how often they should take or 
how much they should take.” (retail optometrist 1)  
“No, I don’t. I think as long as a decent amount of egg every day I think is fine.” (institution 
optometrist 4) 
“So for AMD we are prescribing this lutein supplement known as Lutex 15.” (clinical 
optical shop optometrist 2)  
 
One optometrist (clinical optical shop optometrist 1) mentioned that she will advise all 
her patients aged 50 and above to have a balanced diet and to include more green leafy 
vegetables in their diet. Some optometrists will advise their patients with early AMD on 
dietary modifications, and supplements for patients with moderate AMD, while one 
optometrist will advise supplements for mild to moderate AMD. With more advanced 
AMD, patients are usually seen by the ophthalmologists and optometrists would usually 
advise such patients to seek the ophthalmologists’ opinions on supplements.  
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“Usually from diet first, you do not necessarily have to go for supplements straight away, 
you may go for the antioxidant diet first, then of course lifestyle change, like stop smoking, 
if patients are smoking. If they have been diagnosed of dry AMD by the ophthalmologists 
and they would like to know what they can do, then we will further advise supplements.” 
(retail optometrist 2)  
“I will prescribe when the AMD condition is mild to moderate, but if it is advanced or 
severe, I will refer to the ophthalmologist and they will recommend the supplements 
accordingly.” (clinical optical shop optometrist 2)  
“So I will normally ask them to check with their ophthalmologists, as AMD patients would 
normally be already seen by ophthalmologists. There could be a reason why the doctor 
said yes or no to supplements.” (clinical optical shop optometrist 1) 
 
Following AMD, the next common eye condition that optometrists in Singapore will 
provide nutritional advice is dry eyes. However, as the evidence suggesting that nutrition 
is beneficial for dry eyes is not strong or controversial, most of the optometrists will only 
provide such advice when patients ask.  
 
“For dry eye, some studies say omega-3 or omega-3 & 6 may improve the symptoms, 
but more recent one suggest not so useful. I do not usually advise on this area” (clinical 
optometrist 1) 
“If patients have signs or symptoms of dry eyes, usually the first line of management 
would be ocular lubricants, and if it is a long-standing case of dry eyes, then we can 
include supplements such as omega-3 fatty acids on top of the ocular lubricants.” 
(institution optometrist 4)  
 
The nutritional advice that they will provide for dry eye patients would be to increase their 
intake of omega 3 or 6 fatty acids or to get supplements containing omega 3 or 6. Similar 
to AMD, most optometrists do not advise dry eye patients on the frequency and quantity 
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to be consumed. One optometrist (clinical optical shop optometrist 2) will only prescribe 
omega-3 supplements for dry eyes if it is either the inflammatory or aqueous-deficient 
types, and another (clinical optometrist 3) recommends Lacritec to her dry eye patients.  
 
“I do not have a fixed regime that I will recommend nutritional supplements for every dry 
eye patient. Maybe me myself is not so convinced, but if patients ask me what to take 
for dry eyes then I will mention things like omega 3, omega 6. I do not know of any 
particular brand.” (clinical optical shop optometrist 3)  
 
The other eye conditions that optometrists provide nutritional advice are refractive errors 
such as myopia, diabetic retinopathy, hypertensive retinopathy and cataract. One 
optometrist would recommend carrots or vitamin A for refractive errors (institution 
optometrist 5) while the another (institution optometrist 3) mentioned that if his patient’s 
parents ask if there is any particular food that could help in myopia, he would advise a 
well-balanced diet, for instance if the child is lacking vitamin A in his daily diet, it would 
be good to increase his intake of foods that are high in vitamin A. Diabetic retinopathy 
and hypertensive retinopathy occur due to systemic conditions such as diabetes, high 
blood pressure or high cholesterol. Therefore if patient controls these systemic 
conditions by controlling their diet or taking supplements, it will also help to control these 
eye conditions. Last but not least , one optometrist (retail optometrist 1) would 
recommend his patients with cataract to increase their intake of antioxidants, if his 
patients ask him for recommendations.  
 
4.3.2 Perception of optometrists providing nutritional advice – optometrists’ and 
patients’ view   
All optometrists felt positive about providing nutritional advice to their patients, and most 
felt that it should be a part of routine management for patients with moderate AMD, as 
currently there is no known treatment for atrophic AMD. Therefore, most optometrists felt 
 102 
that as long as it is proven to be beneficial, AMD patients have the right to know what is 
good for their condition, including from a nutrition point of view.  
 
“I think it is good, I suppose this is the least that we can do, at least you do have some 
form of management for the patient, rather than just send them away.” (clinical optical 
shop optometrist 1)  
“As a practitioner I feel that any advice that can help patient to prevent or slow down or 
treat their eye condition or even actually being able to help them in their lifestyle, it will 
be a good piece of advice to all patients. I am happy to provide the information to the 
patient.” (retail optometrist 3)  
 
To some optometrists, providing nutritional advice can actually help to differentiate 
themselves from other optometrists who are not, as it will give patients an impression 
that they are providing them with a holistic care, rather than just checking their 
prescription and prescribing them with glasses or contact lenses, alike what the opticians 
or some optometrists are currently doing.  
 
“Definitely it does help because it will increase the professionalism of optometrists, and 
also because not all shops do this as well. Having a step forward shows that you are 
more concerned about your patient’s eye health so it will really stand out more compared 
to others.” (clinical optical shop optometrist 3)  
“Yes, definitely, I suppose it will build the trust between you and the patient, and the 
patient will look at you from a different perspective, one who is more clinical and shows 
more concern with regards to their eye health, rather than one who only does refraction 
and dispensing of glasses.” (clinical optical shop optometrist 1)  
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Despite feeling positive about providing nutritional advice, there were also some 
concerns and restrictions for some optometrists. The key challenges will be discussed 
in more details in the next section.   
 
“To me, if you just want to provide advice and then for them (patients) to decide whether 
they want to purchase it from outside, that I am comfortable. But if you are asking me to 
prescribe or sell it, then I might not be as comfortable in that sense.” (institution 
optometrist 1) 
“I feel that it can benefit patients and I should definitely do that. Although I do need some 
brushing up on advice to be given.” (clinical optometrist 2)  
 
The optometrists feel that from patients’ point of view, they are generally quite receptive 
about optometrists providing them with nutritional advice, but there are also some who 
are surprised that optometrists are giving them nutritional advice as to them, as to these 
patients, these advices are usually provided by either doctors or pharmacists. 
Conversely, there are also few patients who are not convinced and feel that optometrists 
are trying to sell another product to them. In a general nutshell, patients have to be 
educated on what the condition is, how it came about, and with concrete evidence, they 
will then be advised on why nutrition will work for them. Some optometrists will provide 
nutritional advice as an option for the patient to explore on their own, rather than to 
prescribe to their patients.  
 
“I think they are usually positive because many people have been giving nutritional 
advice, including the pharmacists, it is quite common to give nutritional advice. I think 
optometrists giving nutritional advice is alright, I think people are quite receptive to it.” 
(institution optometrist 4)  
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“50% of patients who were offered supplements were agreeable with trying them out but 
the other half of them were questioning the benefit of supplements.” (clinical optometrist 
3)  
 
4.3.3 Factors and challenges faced by Singapore optometrists when providing 
nutritional advice in practice  
The main factors that determine whether to provide nutritional advice or information to 
patients will depend on the condition that patient is having, the stage and/or risk factors 
of the condition, as well as patient receptiveness. Some optometrists will be more 
cautious when providing nutritional advice to patients with chronic systemic conditions 
and on medications, and will advise such patients to consult their doctors to evaluate if 
they are suitable to take any form of supplements. Two optometrists from retail consider 
chair time as one of the factors as in a busy practice, optometrists might not be able to 
provide too much nutritional information to their patients when there are other patients 
waiting to be seen. On the other hand, there are also optometrists (from institution) who 
will routinely provide nutritional advice to all their AMD patients.  
 
“It will depend on the diagnosis of the disease, and also during which stage of the disease 
that I will put my emphasis on all these nutritional advice to the patient. Some of the 
factors that may affect is it may take up more chair time in the practice, and also response 
from the patients.” (retail optometrist 3)  
“Whether to elaborate or not I guess will depend on whether the patient is open to it. If I 
sense a bit of resistance, it will be more like a statement rather than asking them to 
consider buying this or that. The first attempt is like planting the idea, and if they are very 
open then we may discuss more.” (clinical optical shop optometrist 2)  
“Generally there is no factor, I think it is like a routine that I will let them know that this 
option is available.” (institution optometrist 1)  
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The key challenge that most optometrists face when providing nutritional advice to AMD 
patients would be their lack of knowledge in this area, such as the type of nutritional 
advice (dietary modification or supplements) for different stages, including the type of 
food, the amount, as well as the frequency. Some optometrists are also concerned if the 
nutritional supplements that they are going to recommend will cause any adverse effect(s) 
to the body if the patient is taking other medications. One of the optometrist (clinical 
optical shop optometrist 3) mentioned that the challenge is actually to get patients to 
have a comprehensive eye examination, as the Singapore population is still not used to 
the concept of having a comprehensive eye examination in an optical shop setting; they 
would usually do it in eye clinics or eye hospitals. Therefore without conducting a 
comprehensive eye examination, it would be impossible to diagnose AMD, moreover to 
provide nutritional advice. Another optometrist further added that patients usually visit 
them for vision correction, therefore if they provide such advice, the patients might doubt 
their competency and their role. Chair-time and patient compliance are also some of the 
challenges that the optometrists face when providing nutritional advice to AMD patients.  
 
“I think telling them is not challenging, the challenging part is whether they take it in or 
not.” (retail optometrist 2)  
“The challenge is, patients see us as vision providers, and they will seek 
ophthalmologists for their AMD condition. They will not see us as being proficient in AMD.” 
(retail optometrist 1)  
“If the patient is rejecting the idea of having a full comprehensive eye exam, which 
comprises of the front and back eye health, but some patients only want a degree check, 
so it will be difficult for us to even move on to the nutritional part if they do not want to 
have a front and back health assessment done.” (clinical optical shop optometrist 3)  
“Most challenging or difficult would be to give them specific examples on how much 
dietary supplements is ideal or sufficient. We are aware that anti-oxidants, green 
vegetables, eggs, fruits and etc are beneficial for AMD, but how much exactly is required. 
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So I don’t usually go into those details as I am not really sure myself. I would just tell 
them (patients) to include those food into their meals.” (clinical optical shop optometrist 
1)  
“Sometimes I find that I don’t think I have enough knowledge, I myself may not be 
competent enough, because ultimately as we mentioned earlier, our exposure to this is 
also quite new, if we have more knowledge, more people giving us the kind of information, 
I think we will be more confident in giving out advice. Also the mindset, because in 
Singapore when patients come to us they are looking for visual correction, refractive 
error correction, I mean if we give them the advice on supplements or even medicine 
advice, they may question on our competency and our role, as in are we stepping into 
the role of a medical practitioner or pharmacists.” (clinical optical shop optometrist 4)  
“First will be the specific food to consume, eg. If I mention green leafy vegetables, which 
type should patients consume? And also in terms of frequency and quantity, it is very 
difficult for me to answer. And also sometimes when I mention to consume more carrots, 
and they will ask me, what about if I drink carrot juice, is it the same? It is very hard for 
me to answer yes or no, because yes, sometimes it is fiber, but we know that some of 
the nutrients could be lost if we blend the food and make it into a juice.” (institution 
optometrist 3) 
“Chair-time. Therefore sometimes it would be helpful if there are pamphlets or brochures 
that can do the explanation.” (institution optometrist 1) 
 
There were some controversy between optometrists on smoking advice to AMD patients. 
All optometrists agree that smoking is linked to AMD but for some optometrists they will 
only inform their AMD patients on the risk of progressing to advanced AMD if they are 
smokers. They will not reinforce the need to quit smoking as they feel that most of the 
smokers would have been smoking for a long period of time, and getting them to quit 
would be difficult and challenging, especially when there are no visual symptoms during 
the early AMD stages. On the other hand, there are optometrists who will routinely advise 
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AMD patients to quit smoking, but usually by first asking their patients to taper their 
smoking frequency. And for these optometrists, patients’ compliance would be a 
challenge as they usually do not follow up with these patients. One optometrist working 
in clinical optical shop had no issues advising his patients to quit smoking as he feels 
that this is due to his age, and culturally it is acceptable, as compared to a junior 
optometrist in his or her twenties advising his or her patient who is much older to quit 
smoking.  
 
“Usually I will not advise AMD patients to quit smoking directly. Because usually for AMD 
patients they could have been smoking for an extended period of time, so it is just letting 
them know that smoking is one of the trigger factors, but I will not put it down as advice 
to stop smoking.” (institution optometrist 1)  
“I will give, but I will not put it as strongly as nutritional advice, although I know that 
smoking contributes a huge factor in terms of AMD. As I believe most smokers would 
have been advised before me, so why would they listen to me and not to others who 
would have advised them long time ago.” (institution optometrist 3)  
“Yes I do, usually during history taking we will indicate whether the patient is a smoker, 
and if they do, I will ask how long can one pack of cigarettes last. Most patients who have 
drusen-like changes in their retina, I will advise them to slowly cut down, as it is difficult 
for them to put a total stop to it. By tapering down can actually help them, as long as they 
are convinced, I am sure they are able to cut down their smoking habits.” (clinical optical 
shop optometrist 3)  
“No, I don’t think it is a big challenge, because maybe I am old, so if I give advice 
sometimes people will listen, but if the junior optometrist was to tell a senior person not 
to smoke, so sometimes culturally may not be so, it may be a little bit of challenge, it you 
have a twenty-plus optometrist telling an older man not to smoke, sometimes there may 
be a hurdle.” (clinical optical shop optometrist 4)  
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4.3.4 Further support required by Singapore optometrists in the area of nutrition and 
the eye  
All the optometrists have an unanimous conclusion that they have an important role to 
play in providing nutritional advice to their patients, particularly AMD patients and there 
are several ways that can be done to support them further in this area. First and foremost, 
most of the optometrists think that they need to be equipped with deeper knowledge and 
skills in this area; they would like to have more updated evidence-based information so 
that they can be more confident when communicating such advice, which in turn will 
allow their patients to have more confident in them. Also, optometrists should also 
upgrade their skills to diagnose AMD, in which they would be able to manage their 
patients accordingly and appropriately. Secondly, with so many supplements that are 
currently in the market that are marketed to be beneficial for the eye, optometrists would 
like to have a review on all the available products from a neutral party, as well as a 
guideline on the types of nutritional advice for AMD patients at different stages as well 
as the “contraindications” for those with systemic conditions or are taking any form of 
medications. Additionally, educational materials for patients, in the form of brochure, 
pamphlets or even website that caters to the Singapore community would help to save 
some chair time. One optometrist (clinical optical shop optometrist 2) mentioned that 
there should be regular exchange of updates on how ophthalmologists or general 
practitioners (GPs) care for their patients, so that optometrists know whether they are 
co-managing their patients correctly, and also whether their advice is in tune with the 
rest of the health care professionals. Last but not least, the public needs to have more 
awareness and confidence of the capabilities of the optometrists in Singapore that they 
do have the skills and knowledge to diagnose eye conditions and provide management 
that includes nutritional advice.  
 
“If the professional or government bodies come up with a set of practice guidelines, we 
can refer them to advise our patients accordingly.” (clinical optometrist 1) 
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“I suppose public awareness of the optometrists, that we are trained and skilled in 
detecting eye diseases and providing advice to patients, and nowadays I think there are 
more public awareness campaigns going on, like TV shows, news coverage on 
optometrists and what they could do. So I think this is something that has been on-going 
and I think this is good, we just have to educate the public that there is this profession 
that could give advice, and we do know about all these diseases.” (clinical optical shop 
optometrist 1) 
“The general public does not view us as primary eye care provider and therefore less 
willing to pay for our services. Furthermore, based on our demographics, it is not difficult 
to have access to ophthalmologists who can provide them with diagnosis and treatment 
together. The reason why patients allow us to monitor is because of cost (cheaper as 
compared to ophthalmologist).” (retail optometrist 1)  
“I think the Health Promotion Board should also bring out some public awareness on 
what is AMD and what are the foods that they can consume so that the public can have 
a rough idea of if the supplement does help or not, because it is really by authority 
promoting the health, so this will improve the trust on supplementations.” (clinical optical 
shop optometrist 3) 
“I think in terms of information we have to constantly keep updated, because things may 
change, I think most of the time the challenge to me is quantity and any interactions with 
anything else.” (clinical optical shop optometrist 2) 
“Maybe have refresher courses for optoms and public education to convince patients 
that our advice can be trusted!” (clinical optometrist 2) 
“I think pharmaceutical companies are not reaching out to the optometrists to provide 
them with the brochures, and to let them sell the supplements. If pharmaceutical 
companies can recognize the optometrists are doing a lot to detect AMD, and doing a lot 
of screening for AMD, then pharmaceutical companies will approach optical 
establishments to let them sell their nutritional products.” (institution optometrist 4)  
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“I believe there are a few ways. 1) There could be more education in this part, so that 
everyone in Singapore would have a general guideline to say to patients in terms of 
different stages of AMD. 2) If there are certain websites or brochures or pamphlets that 
dedicate to this portion, and preferably be in multi-languages and that will help in 
Singapore context as most of the people above 50 sometimes are unable to speak 
English.” (institution optometrist 3) 
  
4.4 Discussion 
Nutritional supplements are becoming more common among consumers as not only can 
they supplement the nutrients that people are lacking in our diet, they are also useful for 
certain ailments and patients are seeking for a ‘natural’ remedy rather than to depend on 
medication. The sale of vitamins and supplements in Singapore was SGD490 million in 
2017, up by nearly SGD40 million in 2012239.  According to the newspaper report, the 
increase in sales was contributed by busy young adults, parents and the elderly. Busy 
young adults typically buy vitamins and dietary supplements to obtain the necessary 
nutrients as they are usually too busy to eat proper meals, parents tend to buy probiotics 
as well as brain and immunity-boosting supplements for their children and seniors buy 
glucosamine for joints or eyecare products. From this study, the two most common eye 
conditions that optometrists provide nutritional advice are AMD and dry eyes. This is 
similar to the study conducted by Downie210 whereby 91.2% and 63.9% of the Australian 
optometrists recommend nutritional supplements to patients with AMD and dry eyes 
respectively.  
Despite strongly believing that nutrition plays a part in eye health, Singapore optometrists 
feel that they are lacking knowledge in this area and therefore are unable to provide 
adequate nutritional advice to their patients. This include the specific type of food or 
foods to consume, the amount as well as the frequency. In addition, the type of food that 
is available in Singapore could be different from Western countries. In Singapore, when 
Chinese patients are asked to consume green leafy vegetables, the type of vegetables 
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that Chinese usually consume are different from the kale or spinach that Caucasians 
consume in Western countries. Hence the nutritional value may no longer be the same 
and may not serve the same purpose. AMD patients are usually the elderly and they 
could also suffer from other chronic systemic conditions or are taking other medications, 
therefore optometrists feel that it will be better if they could have more knowledge on the 
type of medical conditions or medication that can be affected by nutritional supplements. 
This additional knowledge on nutrition and the eye could be provided to the optometrists 
through training, continuing education programs or a website that all optometrists could 
have access to. All the optometrists who participated in this study are aware of the link 
between smoking and AMD but not all will actively advise AMD patients to stop smoking 
as they feel that it is a relatively difficult habit to kick and patients might not be compliant. 
On the other hand, based on the previous study, only 20% of Singapore optometrists 
always take a smoking history in follow-up patients, hence there is also a low chance for 
Singapore optometrists to follow-up on patients who were compliant and really did quit 
smoking.  
The optometrists in this study were recruited from different practice settings to compare 
if optometrists working in different setting will have a different perspective on nutrition 
and the eye. However from this study, the views on the themes did not differ much 
between optometrists from the four practice settings. The only difference highlighted 
would be for optometrists working in retail setting, chair time is one of the determining 
factors whether they will provide nutritional advice to their patients. If there are patients 
waiting to be seen, optometrists in retail optical shops might not provide nutritional advice 
to their patients. Singapore optometrists are willing to be trained and enhance their 
knowledge in this domain but at the same time they will be even more confident if there 
is a guideline for them. In situations whereby chair time is limited, brochures or pamphlets 
for patients will come in handy. Nonetheless, the public needs to be more aware of the 
competency of the optometrists in Singapore, to know that they are capable of 
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diagnosing and managing certain eye conditions, and not only checking their refractive 
status and offering visual corrections.   
From the previous study (chapter three), it was learnt that Singapore optometrists are 
not providing dietary and smoking advice to AMD patients as frequently as they should. 
Through this study, it was found that Singapore optometrists believe that nutrition does 
play a part in promoting eye health but most felt that they lack the knowledge to provide 
such information to their patients. Through the in-depth interviews, some optometrists 
would like to have a guideline that could assist them when providing nutritional advice to 
AMD patients. Therefore in the next study, that will be discussed in the coming chapter, 
the efficacy of a clinical decision-making aid will be evaluated on whether it can assist 
optometrists when providing nutritional advice to AMD patients.  
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Chapter Five: Evaluation of a clinical decision-making aid for qualified and student 
optometrists when providing nutritional advice for patients with or at risk of age-
related macular degeneration  
In the previous chapter, Singapore optometrists’ views on nutrition and the eye was 
explored through in-depth interviews. In this chapter, the efficacy of a clinical decision-
making aid (CDMA) for qualified and student optometrists when providing nutritional 
advice for patients with or at risk of AMD will be evaluated.  
 
5.1 Introduction  
As AMD has been found to be highly linked to oxidative stress, there has been much 
interest among researchers in the use of antioxidant supplementation for reducing the 
risk of progression. The first large clinical trial was the Age-Related Eye Disease Study 
(AREDS)4  conducted in 2001 and since then, carotenoids such as lutein and zeaxanthin 
have been identified as nutrients that can provide a protective role against progression 
of AMD due to their antioxidant and photo-protective properties240, but these nutrients 
are only made available through diet and the levels could be affected by the digestive 
and absorptive systems240. More recently, the Age-Related Eye Disease Study 2 
(AREDS 2) found that AMD patients who took a supplement containing lutein and 
zeaxanthin had their risk of progression reduced by 18%64. 
Despite results from both AREDS and AREDS 2, there remains confusion among AMD 
patients and eye care practitioners about when and what supplements should be taken 
and the type of foods to be consumed83. Following the results of AREDS 2, the Macular 
Society, a UK charity, have advocated the use of AREDS 2 formulation, where 
appropriate, and eating vegetables that are lutein and zeaxanthin rich; such as eggs, 
spinach and kale241, but recent surveys of its members found that many were not taking 
a clinically proven nutritional supplement84 or consuming adequate amounts of lutein and 
zeaxanthin242. In Singapore, unlike medicines, health supplements are currently not 
subject to approval, licensing or registration before they can be sold locally. Additionally, 
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they are not assessed for their effectiveness by the Health Sciences Authority (HSA), 
unlike medicines which are studied for their efficacy based on data from stringent clinical 
trials before they are granted approval to be administered to patients. Therefore there 
are at least twenty different types of nutritional supplements for the eye in a local chemist 
and aggressive marketing of particular nutritional formulations makes it difficult for, 
especially AMD patients, and eye care practitioners to make research-based choices, 
and research has shown that given more choices, patients can become overwhelmed83. 
Online platforms are another source where patients can obtain information but some 
unreliable sources might provide conflicting information as to which are the best dietary 
sources of lutein and zeaxanthin. Other barriers that prevent patients from taking 
preventive measures for AMD progression include poor communication with eye care 
practitioners, misinformation in the marketplace, and age-related compliance problems83. 
Patients reported that eye care practitioners were not giving consistent advice regarding 
nutrition and reported confusion as to what advice, if any, to follow213. However, there 
are currently no guidelines for eye care practitioners to follow when advising patients 
about nutrition, and from the qualitative study presented in the previous chapter, eye 
care practitioners would like to have a guide in this area. Eye care practitioners are often 
unsure, or lack confidence, when giving advice outside of their area of expertise, even 
when this advice is consistent with general health advice243. A study conducted by 
Downie at al244. shows that Australia optometrists need to enhance their knowledge on 
nutritional supplementation in managing their own health, particularly improving their 
understanding of what a healthy diet is and its role in eye health.  
 
5.2 Methods 
This is an interventional study to evaluate whether a clinical decision-making aid (CDMA) 
(Figure 5.1) in the form of a flowchart will boost an optometrist’s (qualified or student) 
confidence and self-efficacy when providing nutritional advice to patients with or at risk 
of AMD.  
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Design of the clinical decision-making aid  
When eye care practitioners provide clinical care to patients, they are required to rapidly 
analyse information acquired during the eye examination. This process of clinical 
reasoning is inherently linked to decision making, being a fundamental aspect of care 
delivery. Decision making can range from fast, intuitive or heuristic decisions through to 
well-reasoned, analytical, evidence-based decisions that drive patient care245. There is 
a spectrum of decision making – at one end of the spectrum eye care practitioners use 
their intuition and experience to decide clinical care for patients with simple, common 
conditions. At the other end of the spectrum where complex decisions with a high level 
of uncertainty need to be made, eye care practitioners will adopt a more methodical 
approach in order to feel supported, and these include clinical guidelines, rules-based 
heuristics,  evidence-based principles or even previous experience gained in ‘similar’ 
situations245. When making clinical decisions, particularly under time constraints, eye 
care practitioners often rely on “heuristics”, cognitive shortcuts that reduce cognitive 
burden by focusing on certain pieces of information rather than considering the full range 
of available information246. Although heuristics may lead to accurate decisions, they can 
also be associated with systematic cognitive errors, known as “cognitive biases”, which 
can result in incomplete or inaccurate reasoning. Eye care practitioners are susceptible 
to a range of cognitive biases, which can result in misdiagnoses, delayed clinical care, 
and/or patient mismanagement.  
Similar to other healthcare practices, an evidence-based approach is considered the 
essential foundation for making clinical decisions in eye care practice. Evidence-based 
medicine/practice can be defined as integrating the judicious use of current best 
evidence in clinical decision making, together with patient values and clinical expertise247. 
When managing an individual patient, a series of steps can be applied to formulate a 
strategy for him. These steps include articulating a clinical question, gathering evidence 
to answer the questions, evaluating the quality and validity of the evidence, and finally 
deciding how to apply the evidence to the care of a given patient248. However this type 
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of decision making mitigates the use of unnecessary resources and can be time 
consuming. Therefore it is often reserved for only the very complex clinical cases248 as 
the pressures of current health systems continue to increase.  
Clinical decision making models have been described in medicine for many years, 
particularly for front-line doctors and nursing staff. Researchers in the field of nursing 
Banning et al.249 proposed that there are three main types of clinical decision making 
models: information processing, intuitive-humanist and O’Neills multidimensional model. 
The information processing model uses a scientific or hypothetical-deductive approach 
to assist metacognitive reasoning that is essential to medical diagnosis250,251. In this 
model, decision trees are used to numerically assess potential outcomes; for each 
decision tree, possible outcomes are assigned a numerical value and the probability of 
attaining an outcome is assessed. In the intuitive-humanist model, practitioners use their 
experience and intuition to make clinical decisions instead of relying on guidelines or 
scientific reasoning. The O’Neills multidimensional model is a theoretical model based 
on a computerised decision support system that uses both hypothetico-deduction and 
pattern recognition as a basis for decision making249. This key elements of this model 
include pre-encounter data, anticipating and controlling risk, the provision of standard 
nursing care, client and situational modifications, and finally hypothesis generation and 
action. This model takes into consideration the many variables that could exist in life 
which makes a guideline inappropriate, and inexperienced practitioners can easily input 
the data to generate an answer.  
Organizations such as the National Institute for Health and Care Excellence (NICE) and 
World Health Organization (WHO) have created clinical guidelines according to evidence 
based principles and the consensus of a panel of experts. Patients are often put into a 
category or group, and the guideline will follow a ‘if, then’ rule with a number of multi-
steps for questions that are particularly complex248. These guidelines are often inflexible 
and at times can be difficult to place some patients into specific categories, but can be 
invaluable for a busy overstretched clinical practice. Sometimes these clinical guidelines 
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are depicted using decision-making aids such as decision trees, flow charts, and 
brainstorm and mind map diagrams.  
In medicine, flowcharts have been used to aid diagnosis, treatment options and advice 
given to patients252. As symbols or diagrams are used in flowcharts, users can process 
information quickly and therefore are ideal in settings where time is limited. In addition, 
flowcharts are often space efficient and can be placed on clinic walls or work desk such 
that practitioners can have easy access. As such, a flowchart makes an ideal CDMA for 
all eye care practitioners to use and an ideal way to implement an intervention for 
consistent nutritional advice for patients with or at risk of AMD. A flowchart was designed 
by researchers at Aston University, School of Health Sciences213 to take eye care 
practitioners through a decision-making process that would determine whether a patient 
matched the AREDS 2 eligibility criteria for supplementation. The flowchart helps eye 
care practitioners to answer the following question: ‘what nutritional advice should be 
given to patients with, or at risk AMD?’ The most recent large-scale clinical research 
available to answer this question is the AREDS 264; the study’s inclusion and exclusion 
criteria can be used to decide when it is appropriate to advise the AREDS 2 nutritional 
formulation.  
The flowchart was designed in the following manner: the top of the flowchart begins with 
consideration of the retinal examination. If a patient has normal macula, but with a family 
history of AMD, a branch of decisions will help to determine whether they would benefit 
from dietary modification. If a patient does not have a normal macula, the branches 
following will determine whether the patient fitted into the AREDS 2 inclusion criteria or 
whether they would benefit from dietary modification only. If the retinal findings were not 
related to AMD, referral for an ophthalmological opinion was advised. The final outcomes 
were split into either dietary modification (advice one) or supplementation (advice two).  
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Figure 5.1: Clinical decision-making aid in the form of flowchart213 to assist eye care practitioners 
when providing nutritional advice to patients with, or at risk of AMD  
Evaluation of the flowchart 
A key outcome of using the flowchart is to increase the confidence of eye care 
practitioners when providing dietary advice to AMD patients and this can be achieved 
using self-efficacy surveys. Self-efficacy refers to a person’s estimate of his or her ability 
to perform a specific task successfully253, including a measure of the confidence that a 
person has in their ability to perform a behaviour, such as to give dietary advice to AMD 
patients254. In this study, self-efficacy is measured to assess if the flowchart could boost 
an eye care practitioner’s confidence, and evaluating self-efficacy using scales give 
researchers an idea of whether a subject is likely to accomplish a task in the future. 
Organisational research has shown that self-efficacy is a valuable way of evaluating 
healthcare practitioners’ behaviours as it can predict the performance of an individual255. 
Self-efficacy scales have been used in many surveys when evaluating healthcare 
practitioners’ confidence in performing certain procedures or giving advice to 
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patients243,254,256. Moreover, a survey of clinicians perceptions of computerised protocols 
demonstrated that the biggest predictor of intention to use a computerised protocol was 
beliefs about self-efficacy64, highlighting how important self-efficacy is in providing advice 
for practitioners. 
As mentioned, self-efficacy is concerned with perceived capability, therefore efficacy 
items should accurately reflect the construct257. As described by Bandura that in the 
standard methodology for measuring self-efficacy beliefs, “individuals are presented with 
items portraying different levels of task demands, and they rate the strength of their belief 
in their ability to execute the activities” 257. A survey was created that asked participants 
to rate their confidence and self-efficacy out of 100 (in 10 increment steps) when 
performing certain tasks such as giving nutritional advice to patients or classifying the 
type of AMD seen in a patient. As people usually avoid the extreme positions, so a scale 
with only a few steps may in actual use shrink to one or two points257. In addition, too few 
steps in a scale loses differentiating information as people responding to a category may 
differ if intermediate steps were included. Hence an efficacy scale with the 0 to 100 
response format is a stronger predictor of performance than one with a 5-interval scale258. 
The items in this survey was taken with reference to the study done by Stevens et al.213, 
and further details of the study will be discussed in the next section. These items were 
chosen because they cover all decisions that need to be contemplated when determining 
when and what nutritional advice should be given to a patient based on the AREDS 2 
criteria213, that is, determining that a patient had drusen and geographic atrophy, advising 
a patient that AMD and nutrition are linked, determining what foods are beneficial and 
how much, knowing which patients require supplementation, which supplements to take 
(and how much) and advising those who have a family history of AMD or are at risk. 
Demographic information such as age, gender, and the number of years practising 
(where appropriate) were also obtained. A self-efficacy was repeated by participants 
after using the flowchart. This survey was the same as the initial survey before using the 
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flowchart and utilized the same items to rate the participant’s confidence and self-efficacy 
from 0 to 100 in 10 increment steps. 
 
A. I am confident that I could classify the type of AMD a patient has based on 
retinal signs                         
B. I am confident that I can advise a patient with AMD on the relationship between 
AMD and nutrition                          
C. I am confident that I can advise a patient with AMD on what foods to eat that 
might be beneficial for their condition                         
D. I am confident that I can advise a patient with AMD on the quantities of foods 
that might be beneficial for their eye health                         
E. I am confident that I can advise a patient with AMD on when nutritional 
supplementation may be beneficial                         
F. I am confident that I can advise a patient with AMD on what supplements to 
take and what dosage to recommend                         
G. I am confident with talking about nutrition to those at risk of AMD   
Table 5.1: Seven-item survey to assess confidence and self-efficacy  
 
Hypothetical case scenarios or vignettes 
Hypothetical case scenarios or vignettes partially describes real-life situations and are 
used in research and education as a strategy to elicit participants’ attitudes, judgements, 
beliefs, knowledge, opinions or decisions259. Hypothetical case scenarios or vignettes 
offer a relatively low cost and flexible strategy for describing and understanding 
hypothetical decision-making in any national or international context, regardless of 
whether they may or may not reflect actual decision-making259.  Vignettes can be 
incorporated with a wide range of behavioural, psycho-social, clinical, environmental or 
health system factors259; and when it is not possible to include all relevant combinations 
of factors in the vignettes, the use of unbiased methods for choosing what factors to 
include will be needed. The use of clinical case scenarios or vignettes is central to 
problem-based learning in healthcare education and common in practice guideline and 
decision support studies260.  
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There are two main methods of scenario or vignette development that can be 
distinguished in the field of healthcare and social sciences: the factorial and the 
storytelling method259. The factorial method involves creation of vignettes based on a set 
of predefined factors that describe all or a subset of possible combinations seen in a 
situation or decision problem. As more levels and factors are considered, the number of 
combinations of factor categories increases very rapidly, making this method challenging 
to be applied practically. In contrast, the storytelling method involves creation of one or 
more ‘typical’ or ‘illustrative’ scenarios by members of the research team, often based 
on their experience. The five clinical case scenarios utilised in this study was created 
with the storytelling method.  
Previous use and validation of flowchart/ CDMA 
The objective of the flowchart was to create a clinical decision making aid that increases 
practitioner knowledge on nutrition and AMD, as well as less inter-practitioner variability 
when giving nutritional advice to AMD patients. This CDMA was created by Stevens et 
al.213 and modified following a pilot with 25 optometrists. Thereafter, the CDMA was 
tested and validated on qualified and student optometrists from the UK, with the results 
published in 2017.  
In the study, 46 qualified optometrists completed the self-efficacy surveys before and 
after using the CDMA and 51 student optometrists were also recruited for this study. Out 
of the 51 student optometrists, 25 of them were given an article on AREDS, while 26 
were given the CDMA as the intervention of the study. Qualified optometrists showed a 
significant increase in confidence scores from the initial survey (M=69.7%, SD=16.2%) 
to the second survey after use of the CDMA for 2 weeks in their practices (M=82.1%, 
SD=11.6%; t(45) = 7.33, p<.001). The student optometrists also increased confidence 
scores after receiving the CDMA (M of first survey = 41.7%, SD = 14.6%; M of second 
survey = 69.1%, SD = 1.7%; t(25) = 7.92, p<.001), and increased the number of correct 
answers on five clinical scenarios.  
 122 
Ethical approval 
This study has been reviewed and approved by the Parkway Independent Ethics 
Committee (PIEC) reference number PIEC/2017/004 (Appendix E) based in Singapore 
and the Aston University Research Ethics Committee (AUREC) application number 2010 
based in the UK.  
 
Recruitment and delivery protocol 
This study is sub-divided into two parts as it was conducted on two different groups of 
participants: qualified optometrists and student optometrists.  
 
Qualified optometrist recruitment. Optometrists who participated in the first study 
“Nutritional and smoking advice to patients with or at risk of AMD by optometrists in 
Singapore” as presented in chapter three were asked to indicate if they are interested to 
participate in this study. Participants who were interested left their contact details such 
as email address or contact number. Using the GPower software, the sample size 
required for this group of qualified optometrists is 27, based on the effect size from the 
study done by Stevens213. This sample size was also confirmed by manually calculating 
using a mathematical formula. In order to compare if years of experience would affect 
the results, the target sample size is 27 for experienced optometrists (with more than 
twelve years of experience) and 27 for non-experienced optometrists (less than or equal 
to twelve years of experience)  
Delivery protocol. Participants who indicated their interest to participate in this study were 
contacted for a meeting with the principal researcher of this study. Before commencing 
the study, contents of the study information sheet (Appendix J) was discussed and 
consent form (Appendix K) was signed. Five hypothetical clinical scenarios of patients in 
different AMD stages (Figure 5.2) was presented to the participant. For each case 
scenario, retinal photographs were provided, together with information about the 
patient’s age, the type of AMD they had, and if there was any family history of AMD 
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underneath the photographs. Each case was designed to simulate possible scenarios 
that practitioners could encounter in real practices, and also taking into consideration 
recommendations from AREDS 1 and 2 that only category 3 or 4 AMD patients will 
benefit from supplements. The clinical scenarios were also cross-referenced to the study 
by Stevens et al.213,  and three out of five scenarios (case number 1, 2 and 4) were 
similar. After looking through each case scenario, the participant was asked to indicate 
their nutritional advice for each scenario from a list of ten options: 
1) Consider lifestyle changes to reduce risk, e.g. not smoking, wearing sun 
protection etc. 
2) Consider increasing your intake of lutein. For example, you could try to eat either 
a large cup (150g) of cooked spinach OR kale, OR two eggs every day 
3) Consider increasing your intake of lutein. For example, you could try to eat either 
a large cup (150g) of uncooked spinach OR kale, OR two eggs every day 
4) Consider increasing your intake of lutein. For example, you could try to eat either 
a small cup (75g) of cooked spinach OR kale every day 
5) Consider dietary modification by eating 2 bananas or 2 mangos every day 
6) Consider taking supplementation of vitamin C 500mg, vitamin E 400IU, lutein 
10mg, xeaxanthin 2mg, zinc 25mg, copper 2mg every day. Consult GP if taking 
prescribed medication. 
7) Consider taking the vitamin C 250mg, vitamin E 800IU, lutein 1mg, xeaxanthin 
5mg, zinc 250mg, copper 20mg every day. Consult GP if taking prescribed medication. 
8) Consider taking supplementation of lutein 10mg and xeaxanthin 2mg every day. 
9) Consider taking supplementation of gingko biloba and cod liver oil every day. 
10) Refer immediately for wet AMD treatment. 
The participant was then briefed on the usage of the CDMA by the principal researcher 
and to indicate their nutritional advice for the five clinical scenarios again, but with the 
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assistance of the CDMA. As mentioned previously, participants also completed the self-
efficacy survey before and after using the CDMA.  
 
Student optometrist recruitment. Final year optometry students studying at Ngee Ann 
Polytechnic pursuing their Diploma in Optometry were invited to take part by the principal 
researcher who is working there as the clinical supervisor, in the knowledge that their 
participation was voluntary and that they were not obliged to take part. Using the GPower 
software and based on the study done by Stevens213 to obtain the same effect size, the 
sample size required for this group of student optometrists is 8. This sample size was 
also confirmed by manually calculating using a mathematical formula. In order to assess 
the difference between the CDMA and standard clinical materials such as an article on 
AREDS, there will be two groups of student optometrists.  
Delivery protocol. Student optometrists were arranged to meet with the principal 
researcher based on the students’ schedule. The study information sheet (Appendix L) 
and consent form (Appendix L) were given to the students prior to the meeting and the 
consent form has to be signed by the parent or guardian of the student, as the students 
are below the age of 21. The students were randomly assigned to either the CDMA group 
or the ‘article’ group, and the protocol was the same as the qualified optometrists, except 
for the ‘article’ group whereby the students were given an article to read instead of the 
CDMA.   
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Figure 5.2(a): Five hypothetical clinical scenarios of patients in different AMD stages 
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A total of 50 qualified optometrists participated in this study; 23 males and 27 females 
with a mean age of 36.3 ± 9.4 years old. The average number of years practicing as a 
fully registered optometrist for these participants is 13.4 ± 8.8 years. The Kolmogorov-
Smirnov one-sample test showed that the data of the qualified optometrists did not 
exhibit a normal distribution (p=0.047), therefore the non-parametric Wilcoxon signed-
rank test was used for data analysis. 
A total of 15 student optometrists participated in this study; consisting of 7 males and 8 
females with a mean age of 19.1 ± 0.7 years old. Of the 15 student optometrists, 7 were 
allocated to the CDMA group and 8 were allocated to the AREDS 2 article group. The 
Kolmogorov-Smirnov one-sample test showed that the data of the student optometrists 
exhibited a normal distribution (p=0.200). However, due to the low sample size, the 
paired t-test and Wilcoxon signed-rank test will be run and compared for this group of 
participants.  
 
Qualified optometrists study: results 
Reliability of the scale items in the surveys was confirmed using Cronbach’s alpha 
coefficient (a measure of internal consistency, i.e., how closely related a set of items are 
as a group). Alpha values were high on each occasion = 0.957 for the first survey, alpha 
=0.97 for the second survey. Test-retest correlations between scores at both time points 
confirmed the reliability of the scale (r = 0.8, p<0.01) 
For average confidence scores, there were no differences found between gender or the 
number of years practising as an optometrist. Hence, these variables did not appear to 




 <= 12 years of experience > 12 years of experience  
Number of participants 21 29 
First survey mean 
confidence score (0-100)  
62.5 ± 9.5 62.9 ± 16.0  
Second survey mean 
confidence score (0-100)  
76.0 ± 9.6 76.6 ± 9.5 
Table 5.2: Average confidence scores between number of years practicing as an optometrist. 
(p > 0.05 for both surveys)   
 
 Males Females 
Number of participants 23 27 
First survey mean 
confidence score (0-100)  
62.8 ± 16.1 63.1 ± 21.6  
Second survey mean 
confidence score (0-100)  
75.5 ± 14.0 78.5 ± 15.8 
Table 5.3: Average confidence scores between males and females. (p > 0.05 for both surveys)   
 
Table below depicts the percentage confidence scores for each statement in the self-
efficacy survey, before (first survey) and after (second survey) using the CDMA. A 
Wilcoxon signed-rank test showed there was a significant increase in mean confidence 
scores after the participants used the CDMA for the five clinical scenarios, as compared 
to before (Mean confidence score before = 62.9, SD = 19.1; Mean confidence score after 
= 77.1, SD = 15; p < 0.01).  
Confidence Statement First 
Survey  
(n = 50) 
Second 
Survey  
(n = 50)   
p-
value   
A: I am confident that I could classify the type of AMD 






B: I am confident that I can advise a patient with AMD 






C: I am confident that I can advise a patient with AMD 







D: I am confident that I can advise a patient with AMD 
on the quantities of food that might be beneficial for 






E: I am confident that I can advise a patient with AMD 






F: I am confident that I can advise a patient with AMD 







G: I am confident with talking about nutrition to those at 















Tables 5.5-5.7 depict the answers given to the five clinical scenarios in the initial survey 
and then in the second survey after using the CDMA. For statistical analysis, a correct 
answer was given a value of ‘1’ and incorrect answers were given a value of ‘0’. The final 
value was the sum of the answers, out of a possible 5. An independent t-test shows that 
























A 4% 48% 4% 0% 2% 
B 8% 8% 12% 0% 16% 
C 0% 10% 10% 0% 4% 
D 2% 12% 2% 0% 2% 
E 0% 2% 0% 0% 0% 
F 42% 6% 44% 6% 50% 
G 4% 2% 14% 0% 14% 
H 2% 10% 6% 0% 6% 
I 0% 2% 2% 0% 0% 
J 38% 0% 6% 94% 6% 
Table 5.5: Answers given to five clinical scenarios without the assistance of the CDMA. Shaded 

























A 0% 2% 50% 2% 4% 
B 12% 92% 16% 24% 74% 
C 2% 4% 2% 0% 2% 
D 0% 0% 0% 0% 0% 
E 0% 0% 0% 0% 0% 
F 80% 2% 14% 0% 18% 
G 2% 0% 0% 2% 0% 
H 0% 0% 2% 0% 0% 
I 0% 0% 2% 0% 0% 
J 4% 0% 14% 72% 2% 
Table 5.6: Answers given to five clinical scenarios with the assistance of the CDMA. Shaded 
cells are the correct answers.  
 




One 42% 80% 
Two 8% 92% 
Three 4% 50% 
Four 94% 72% 
Five 16% 74% 




Student optometrists study: results 
Reliability of the scale items in the surveys was confirmed using Cronbach’s alpha 
coefficient; alpha values were high on each occasion = 0.877 for the first survey, alpha 
=0.952 for the second survey. Test-retest correlations between scores at both time points 
confirmed the reliability of the scale (r = 0.51, p = 0.05).  
 
Group Survey 1 mean 
confidence score 
Survey 2 mean confidence 
score 
Article 45.2 ± 16.2  57.7 ± 18.7  
CDMA 32.2 ± 14.3 70.4 ± 14.6 
Table 5.8: Mean confidence score between groups ‘Article’ and CDMA and between survey 1 and 
2 
 
Paired t-tests showed that there is a significant increase in the mean confidence score 
after using the CDMA and article: Group ‘Article’ (p = 0.005), group CDMA (p < 0.001). 
The Wilcoxon signed-ranked test showed the same results: p-value for group CDMA is 
0.018 and the p-value for group ‘article’ is 0.017. There was not a statistically significant 
difference in second survey’s confidence scores between the two groups, although group 








































































Tables 5.10-5.15 depict the answers given to the five clinical scenarios in the initial 
survey and then in the second survey according to each group. For statistical analysis, 
a correct answer was given a value of ‘1’ and incorrect answers were given a value of 
‘0’. The final value was the sum of the answers, out of a possible 5. An independent t-
test showed that the number of correct answers increase significantly (p < 0.05) after 
using the CDMA, but not for the group ‘Article’. An independent t-test also showed that 
there was a significant difference between the two group’s answers in the second survey 

























A 1 (14.3%) 5 (71.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
B 0 (0.0%) 0 (0.0%) 1 (14.3%) 1 (14.3%) 2 (28.6%) 
C 0 (0.0%) 0 (0.0%) 2 (28.6%) 0 (0.0%) 1 (14.3%) 
D 0 (0.0%) 1 (14.3%) 1 (14.3%) 0 (0.0%) 1 (14.3%) 
E 1 (14.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
F 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (14.3%) 2 (28.6%) 
G 1 (14.3%) 1 (14.3%) 0 (0.0%) 1 (14.3%) 1 (14.3%) 
H 0 (0.0%) 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%) 
I 1 (14.3%) 0 (0.0%) 2 (28.6%) 0 (0.0%) 0 (0.0%) 
J 3 (42.9%) 0 (0.0%) 0 (0.0%) 4 (57.1%) 0 (0.0%) 
Table 5.10: Answers given to five clinical scenarios without the assistance of the CDMA. 


























A 0 (0.0%) 0 (0.0%) 2 (28.6%) 0 (0.0%) 0 (0.0%) 
B 4 (57.1%) 5 (71.4%) 0 (0.0%) 2 (28.6%) 3 (42.9%) 
C 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
D 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
E 0 (0.0%) 0 (0.0%) 1 (14.3%)  0 (0.0%) 0 (0.0%) 
F 3 (42.9%) 0 (0.0%) 2 (28.6%) 0 (0.0%) 4 (57.1%) 
G 0 (0.0%) 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%) 
H 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
I 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
J 0 (0.0%) 0 (0.0%) 1 (14.3%) 5 (71.4%) 0 (0.0%) 
Table 5.11: Answers given to five clinical scenarios with the assistance of the CDMA. Shaded 
cells are the correct answers.  
 




One 0.0% 42.9% 
Two 0.0% 71.4% 
Three 0.0% 28.6% 
Four 57.1% 71.4% 
Five 28.6% 42.9% 


























A 1 (12.5%) 4 (50.0%) 1 (12.5%) 1 (12.5%) 0 (0.0%) 
B 2 (25.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 
C 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (25.0%) 
D 0 (0.0%) 0 (0.0%) 2 (25.0%) 0 (0.0%) 0 (0.0%) 
E 0 (0.0%) 1 (12.5%) 1 (12.5%) 0 (0.0%) 1 (12.5%)  
F 4 (50.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 4 (50.0%) 
G 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 
H 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
I 1 (12.5%) 3 (37.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
J 0 (0.0%) 0 (0.0%) 2 (25.0%) 7 (87.5%)  0 (0.0%) 
Table 5.13: Answers given to five clinical scenarios before reading the AREDS article. Shaded 
























A 1 (12.5%) 5 (62.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
B 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 
C 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%) 
D 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 
E 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 
F 4 (50.0%) 1 (12.5%) 2 (25.0%) 0 (0.0%) 3 (37.5%) 
G 1 (12.5%) 0 (0.0%) 2 (25.0%) 0 (0.0%) 3 (37.5%) 
H 1 (12.5%) 1 (12.5%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 
I 0 (0.0%)  1 (12.5%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
J 1 (12.5%) 0 (0.0%) 0 (0.0%) 8 (100%) 0 (0.0%) 
Table 5.14: Answers given to five clinical scenarios after reading the AREDS article. Shaded 












One 50.0% 50.0% 
Two 0.0% 0.0% 
Three 12.5% 0.0% 
Four 87.5% 100% 
Five 0.0% 0.0% 
Table 5.15: Percentage of correct answers for case scenarios before and after reading the 
AREDS article.  
 
5.4 Discussion 
Within the qualified optometrists, the mean confidence scores increased significantly for 
each statement after using the CDMA. An interesting finding was discovered from the 
results. Even though the CDMA did not assist the participants to classify the type of AMD 
a patient has based on retinal signs, there was a statistically significant increase in mean 
confidence score for that statement. This shows that with the aid of a guideline, the 
confidence level of a practitioner generally improves. The number of correct answers for 
the five clinical scenarios also increased significantly after using the CDMA, except for 
case number 4, where the patient presented with neovascular AMD in one eye. Some 
optometrists were too focused on utilizing the CDMA and neglected the fact that the 
patient should be referred immediately for treatment. Hence, it should be emphasized 
that the CDMA serves only as a guide for atrophic AMD and optometrists are advised to 
use their clinical judgement when managing their patients. Overall, the CDMA is useful 
in boosting the optometrists’ confidence when providing nutritional advice to patients with 
or at risk of AMD and it also help optometrists to provide the appropriate nutritional advice. 
The results would be even more convincing if the optometrists were to use it in their 
practices, but because the number of AMD patients seen by Singapore optometrists is 
quite low, hence this study is designed using clinical scenarios instead.  
Within the student optometrists, the mean confidence scores increased significantly for 
each statement for both groups. However, the number of correct answers for the clinical 
scenarios increased significantly only for the group CDMA. In addition, the number of 
correct answers increased for all five scenarios after using the CDMA, but for group 
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‘article’, the number of correct answers reduced for scenario three, and there was no 
difference in the number of correct answers for scenarios one, two and five. The 
confidence level increased among the student optometrists after using some form of aid 
(CDMA or article), but the appropriate advice was only provided by the group CDMA. 
This shows that the CDMA is beneficial for both qualified and student optometrists when 
providing nutritional advice to patients with or at risk of AMD.  
The study done by Stevens et al. 213 evaluated the efficacy of the same CDMA with the 
same self-efficacy survey that were utilized in this study and the results also show that 
the CDMA does increase the confidence of both qualified and student optometrists in the 
UK when providing nutritional advice to patients with or at risk of AMD. The qualified 
optometrists in the UK completed the self-efficacy survey after using the CDMA in a real 
practice setting, whereas the qualified optometrists in Singapore completed the self-
efficacy survey based on simulated clinical case scenarios. The clinical case scenarios 
in this study were created using the storytelling method and while efforts were made to 
simulate real-life situations as closely as possible and to test all the possible clinical 
scenarios, there still remain some areas of improvement. A modified factorial method 
could be adopted; the factors to consider can include patient’s smoking history, presence 
of any chronic systemic conditions, visual acuity, and other relevant test results such as 
Amsler or OCT. With these additional information, the optometrist would be able to 
provide a more holistic management for the patient. Testing the efficacy of the CDMA in 
a real practice setting would be ideal, but for some practices, optometrists might not be 
seeing AMD patients as frequent as other optometrists, and therefore would not be able 
to give an accurate feedback on the CDMA. Nonetheless, the studies conducted in the 
UK and Singapore show that the CDMA does improve the confidence of qualified and 
student optometrists when providing nutritional advice to patients with or at risk of AMD, 
proving that this CDMA is beneficial for optometrists around the world, regardless of 
geographic location.   
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There were other studies in the field of healthcare that have shown that clinical guidelines 
improved the self-efficacy of healthcare professionals. In the study by Farrell et al.261, the 
implementation of evidence-based deprescribing guidelines increase clinicians’ self-
efficacy in developing and implementing a deprescribing plan for specific drug classes. 
Maas et al. 262 also described increased self-efficacy for physical therapists following 
guideline exposure and peer feedback. Cloutier et al. 263 highlighted increased physician 
self-efficacy following a multi-faceted guideline implementation but no corresponding 
change in the desired behaviour. This highlights the importance that eye care 
practitioners need to regularly use the CDMA when providing nutritional advice to 
patients with or at risk of AMD so that they familiarise themselves on the usage, as 
repeated use lends itself to mastery and is consistent with Bandura’s theory264 that such 
experiences contribute to self-efficacy.  
This study has proven the efficacy of a CDMA in the form of a flowchart that was 
developed by Stevens et al. 213 when providing nutritional advice to patients with or at 
risk of AMD. The efficacy was tested using self-efficacy surveys and it has shown to 
increase confidence and self-efficacy scores among fully registered and student 
optometrists when providing nutritional advice to AMD patients in simulated case 
scenarios. In addition, the number of correct answers (appropriate nutritional advice to 
each case scenario) increased significantly with the use of the CDMA. In the next chapter, 
a summary of the findings of the three studies conducted in this thesis will be discussed, 
including the limitations for each study and recommendations for future research.   
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Chapter Six: Discussion 
6.1  Summary  
AMD is a multi-factorial eye condition affecting those aged 50 years and above. With the 
increasing greying population in developed countries and also in Singapore, the 
prevalence of AMD will increase concurrently. Other than being multi-factorial, the exact 
pathogenesis of AMD is also unknown, but recent research has found oxidative stress 
to be one of the major contributory factors. As there are currently no treatment available 
for atrophic AMD, reducing the amount of reactive oxygen intermediates (ROIs) that are 
produced via oxidative stress is one of the methods to prevent atrophic AMD from 
progressing to the more advanced stages or to neovascular AMD. ROIs can be 
scavenged with anti-oxidants such as vitamins A, C and E and substances such as lutein, 
zeaxanthin and polyunsaturated fatty acids (omega-3 and 6) have also shown to be 
protective against AMD as discussed in previous chapters.  
 
Study One: Nutritional and smoking advice to patients with or at risk of AMD by 
Singapore optometrists 
The first study “Nutritional and smoking advice to patients with or at risk of AMD by 
Singapore optometrists” is the first to systematically investigate the extent to which 
optometrists in Singapore provide advice on modifiable risk factors for AMD. The 
response rate of this study is 18.2%, similar to Lawrenson and Evan’s209 study with a 
response rate of 16.2% for the optometrists. Data from Singapore’s Optometrists and 
Opticians Board (OOB) shows that approximately 20% of the Singapore optometrists are 
degree-trained and 60% of these optometrists are working in retail sector. From our study, 
almost 40% of the respondents are degree-trained and 60% are working in the retail 
sector (retail optical shops and clinical optical shops). The percentage of degree-trained 
optometrists are over-represented in our study but the percentage of optometrists 
working in retail sector matches the statistic provided by OOB. Attempts were made to 
obtain more demographic information such as gender and years of experience on 
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Singapore optometrists from OOB but to no avail, therefore we were unable to establish 
further on whether the demographics of the respondents are representative of the fully 
registered optometrists practicing in Singapore. In the UK209, 67.9% of the optometrists 
provide dietary advice to patients with advanced AMD most of the time, 52.9% of the 
Singapore optometrists do that and 28% of the optometrists in Sweden208 do the same. 
One of the main reasons Singapore optometrists are not providing dietary advice to 
patients with advanced AMD is because they seldom see such patients. For patients 
considered to be at risk of AMD, 53.6% of optometrists in the UK209 provide dietary advice 
most of the time, while 31.7% and 25% of the optometrists in Singapore and Sweden208 
respectively provide dietary advice most of the time. 80% of the optometrists in 
Singapore will advise patients with early, advanced or at risk of AMD to consume green 
leafy vegetables; most will advise patients to consume daily but did not advise on the 
amount to consume. Approximately 60% of the optometrists in Singapore will advise 
patients with early, advanced or at risk of AMD to consume oily fish; most will advise 
patients to consume daily and will either not advise on the amount or advise patients to 
consume one serving.  
42.3% of optometrists in Singapore will take a smoking history in new or first time patients 
most of the time and 32.3% and 17% of optometrists in the UK209 and Sweden208 
respectively will do the same. Conversely, a slightly lesser percentage of optometrists in 
Singapore (16.5%) will take a smoking history in non-first time or review patients as 
compared to the optometrists in the UK209 (21.2%). Slightly more than one third of the 
optometrists in Singapore will inform smokers of the link between smoking and AMD 
most of the time and almost half of the optometrists in the UK209 will advise smokers of 
the link most of the time. On the other hand, slightly more than half of the optometrists 
in Singapore will advise AMD patients to stop smoking most of the time and slightly more 
than a third of the optometrists in the UK209 will advise AMD patients to stop smoking. 
While not many optometrists in Singapore will advise smokers of the link between 
smoking and AMD, a considerable percentage of them will advise them to stop smoking 
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and this could imply that Singapore optometrists are concerned of the health risks that 
smoking can bring to their patients.  
For all case scenarios except for case scenario two (65 year old patient with advanced 
AMD in one eye and early AMD in the other), a higher percentage of optometrists in 
Singapore will recommend supplements as compared to optometrists in the UK209 and 
Sweden208. The percentage of Singapore optometrists recommending supplements for 
case scenario two is similar to the percentage of optometrists in the UK209 who will 
recommend supplements. In case scenario one, most optometrists in Singapore and 
UK209 would recommend supplements containing antioxidant vitamins, lutein and 
zeaxanthin. In case scenarios two and three, most optometrists in Singapore would 
recommend AREDS 2 but most optometrists in the UK would recommend a supplement 
containing macular carotenoids.  
There is no difference in self-efficacy scores between optometrists with different years 
of experience. Nonetheless, there is a significant difference in self-efficacy scores for 
almost all statements between optometrists working in retail and optometrists working in 
clinical setting, as well as between optometrists with a Diploma and optometrists with 
higher qualification. The only statement that did not show a significant difference is “I am 
confident that I can advise a patient with AMD on the quantities of food that might be 
beneficial for their eye health.” This shows that regardless of practice setting or 
qualification, most optometrists in Singapore are not too confident when advising AMD 
patients on the quantities of food that might be beneficial for their eye health.  
 
Study Two: What do Singapore optometrists feel about providing nutritional and smoking 
advice to patients with or at risk of AMD? 
From this qualitative research, all the optometrists who were interviewed think that 
nutrition is beneficial for the eye health and the two most common conditions that they 
provide nutritional advice to their patients are AMD and dry eyes. Nonetheless, most 
optometrists do not provide further information on the amount and frequency of food or 
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supplement that they recommended to their patients. All optometrists felt positive about 
providing nutritional advice to their patients and some felt that it could help to differentiate 
them from other optometrists who are not providing such advice. From the optometrists’ 
view, they felt that patients are generally quite receptive on optometrists providing them 
with nutritional advice, even though there may be a few who felt that providing nutritional 
advice is not within the job scope of optometrists in Singapore. Besides the eye condition, 
stage and/or risk factors of the condition, the other factors that determine whether 
Singapore optometrists provide nutritional advice include patient receptiveness, as well 
as presence of other systemic conditions or medications that the patient is currently 
taking. As such, Singapore optometrists find it challenging to provide nutritional advice 
to AMD patients as they feel that their knowledge in this area is insufficient to provide 
such advice. In addition, many members of the public in Singapore are still unaware of 
the capabilities of optometrists; that they are proficient in performing many eye tests to 
diagnose eye diseases and manage them appropriately. To further support Singapore 
optometrists, their capabilities should be made known to more members of the public so 
that they could perform a comprehensive eye examination on every patient. Additionally, 
optometrists felt that they need a guideline when providing nutritional advice to AMD 
patients so that they can be more assured that the advice that they provide are accurate 
and based on the most recent research results.  
 
Study Three: Evaluation of a CDMA for qualified and student optometrists when 
providing nutritional advice for patients with or at risk of AMD  
In this interventional study, the efficacy of a CDMA was evaluated among qualified and 
student optometrists and the results show that the self-efficacy scores for both groups of 
optometrists were improved significantly after using the CDMA. Furthermore, the number 
of correct answers for the hypothetical case scenarios increased significantly after using 
the CDMA for both qualified and student optometrists. This shows that the CDMA is 
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beneficial for qualified and student optometrists when providing nutritional advice to AMD 
patients.  
 
6.2  Conclusions 
With the increasing greying population in Singapore, the prevalence of AMD will increase, 
but this condition could be undiagnosed unless patient’s vision has been affected or if 
patient go for a comprehensive eye examination regularly. Therefore, optometrists, 
especially those working in the retail optical shops, should routinely perform fundus 
examination on all patients aged 50 and above in order to diagnose AMD early. On the 
other hand, the general public in Singapore needs to have a much better understanding 
on optometrists’ roles and capabilities. Singapore optometrists need to perform more 
comprehensive eye examinations in order to diagnose more AMD patients so that they 
could give nutritional advice to these patients before their conditions start to deteriorate. 
Whilst not a big percentage of Singapore optometrists routinely take a smoking history 
on new and review patients and inform smokers of the link between smoking and AMD, 
about half of them would advise AMD patients to stop smoking and more optometrists 
should routinely take a smoking history on all patients and advise AMD patients who are 
currently smoking to quit smoking as smoking is strongly related to AMD. Singapore 
optometrists could adopt the 3A1R protocol: “Ask about smoking, Advise to quit, Assess 
willingness to quit, Refer to tobacco quitlines” as it has been shown to effectively improve 
eye care practitioners’ smoking cessation counseling practices in the U.S265.    
Singapore optometrists believe in nutrition and the eye, especially for AMD but they feel 
that they lack the knowledge to provide nutritional advice for AMD patients. As a starting 
point to explore further in this area, they could utilize the CDMA that was evaluated in 
this study, as it has been shown to be beneficial for optometrists in Singapore as well as 
in the UK213. Alternatively, Singapore optometrists could also consider to co-manage 
AMD patients in this area with pharmacists or ophthalmologists if they do not feel too 
confident in providing nutritional advice to AMD patients. In conclusion, optometrists in 
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Singapore should be providing nutritional and smoking advice to more AMD patients as 
currently this is the most feasible option and with the projected increasing prevalence of 
AMD in the years to come, this will be the best option. One of the ways to encourage 
Singapore optometrists to provide nutritional and smoking advice to more AMD patients 
is through continuing professional education seminars to increase their knowledge and 
hence confidence when providing such advice to their patients. Another alternative 
method is to publish these results for Singapore optometrists to be more aware of the 
current situation in Singapore.  
 
6.3 Limitations and recommendations for future research  
Study One: Nutritional and smoking advice to patients with or at risk of AMD by 
Singapore optometrists 
Despite having a good response rate of 18.2% in this study, the demographics of 
respondents represent more degree-trained optometrists as almost 40% of the 
respondents are degree-trained, whereas statistics from OOB state that approximately 
20% of Singapore optometrists are degree-trained. Therefore, more responses from 
optometrists with a diploma qualification should be included. The use of questionnaire in 
this study is subject to response and recall bias, and as shown in the response rate, 
there were 217 respondents initially via the Survey Monkey platform but only 111 
completed the questionnaire as those who did not complete might feel that they are not 
too familiar with the topic of nutrition and AMD, or this area is not quite relevant to their 
practice. All the responses for this questionnaire was made anonymous to protect the 
identities of the respondents, but this could result in possible duplications of responses 
from the same respondent. However, this has been looked into prior to data analysis as 
the principal researcher manually browsed through all the respondents’ demographics 
to ensure there are no duplications. As AMD patients are mostly seen by 
ophthalmologists in Singapore, future research could recruit ophthalmologists to share 
their views on nutrition and AMD.  
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Study Two: What do Singapore optometrists feel about providing nutritional and smoking 
advice to patients with or at risk of AMD? 
In this study, the optometrists were recruited from different practices: retail optical shops, 
clinical optical shops, institutions and eye hospitals or eye clinics and there was not much 
difference in their views and opinions. For future research, more optometrists with 
diploma qualification should be recruited as about 80% of optometrists in Singapore 
graduated with a diploma in optometry, and their opinions could be compared with the 
optometrists with higher qualifications. Besides, more could be explored from 
optometrists the reason(s) behind recommending a particular supplement for their AMD 
patients as this has not been fully established from this study. 
 
Study Three: Evaluation of a CDMA for qualified and student optometrists when 
providing nutritional advice for patients with or at risk of AMD  
The CDMA has shown to be beneficial for both qualified and student optometrists in this 
study but it will be even more significant if the qualified optometrists were to use it in their 
practices, as case scenarios will not be able to replace real-life clinical situations. 
Furthermore, it will be more ideal if the sample size in the non-experienced group could 
be increased to 27 (the sample size required following GPower calculation), even though 
the results in this study has proven to be significant. This thesis also highlights the need 
to educate Singapore optometrists about discussing smoking cessation with their 
patients. For future research, an evidence-based smoking cessation protocol could be 
tested with Singapore optometrists to evaluate if it will increase and improve smoking 
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Survey on nutritional and smoking advice to patients with or at risk of age-related 
macular degeneration (AMD) by optometrists in Singapore 
 
Kindly answer all questions, based on your practice as an optometrist in Singapore.  
 
Section 1: Demographic Information  
 
Your current age:  
Gender:  
Number of years practicing as a 
fully registered optometrist: 
 
Highest qualification attained in 
the field of optometry: 
Diploma/ Advanced diploma/ Bachelor/ Masters/ PhD/ 
Others _____________________________ 
(Circle one) 
Type of practice (A): Retail optical shop/ Clinical (Includes hospitals and eye 
clinics)/ Clinical optical shop* 
(Circle one) 
Type of practice (B):  Independent or Private/ Chain/ Government 
(Circle one) 
Location of current practice 
(A): 
North/ South/ East/ West/ Central 
(Circle one) 
Location of current practice 
(B): 
Shopping malls/ Neighbourhood areas/ Hospitals/ Eye 










*Your practice is defined as clinical optical shop if slit-lamp examination and ophthalmoscopy is routinely performed 
on all patients/ customers 
 
Section 2: Tests routinely performed on patients/ customers aged 50 and above  
 
2.1  Average number of patients/ customers aged 50 and above seen per week in your practice:  
 ____________________________ 
2.2 Which of the following tests are routinely performed on patients/ customers aged 50 
and above in your practice? (You may tick more than one) 
o History taking 
o Objective refractive 
o Subjective refraction 
o Pupillary assessment 
o Ocular motility 
o Cover test 
o Confrontation 
o Colour vision assessment 
o Anterior segment examination (Slit-lamp bio-microscopy) 
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o Poster segment examination (Fundus examination) 
o Tonometry 





Section 3: Number of AMD patients/ customers seen per year  
 
3.1 Average number of patients/ customers seen with category 1 or 2* AMD per year: 
 _______________________ 
*Category 1: less than 5 small drusen (<63 microns: approximately the width of a retinal artery near the optic nerve 
head)  
Category 2: multiple small drusen or nonextensive intermediate drusen (63-124 microns), pigment abnormalities, or 
a combination of the two (refer to appendix A for sample images) 
 
3.2 Average number of patients/ customers seen with category 3 or 4* AMD per year: 
 _______________________ 
*Category 3: no advanced AMD but had ≥ 1 large drusen (125 microns), extensive area of intermediate drusen, or 
geographic atrophy (GA) not involving the center of macula 
Category 4: advanced AMD, central GA or neovascular AMD in one eye (refer to appendix A for sample images) 
 
Section 4: Perspective on AMD and nutrition  
 
4.1 Are you aware of the link between AMD and nutrition?  
o Yes 
o No  
 
4.2 Is your nutritional advice to patients/ customers with or at risk of AMD restricted by 
your current practice? 
o Yes 
o No  
 
Section 5: Dietary advice to patients/ customers with early (category 1 or 2) AMD  
 
5.1  Frequency of dietary advice for patients/ customers with early (category 1 or 2) AMD 
o Never 
o Rarely (10% of the time) 
§ What is/ are your main reason(s) for not/rarely advising? 
o Insufficient evidence that nutrition is beneficial for patients/ 
customers with category 1 or 2 AMD 
o Do not believe that nutrition is beneficial for patients/ customers 
with category 1 or 2 AMD 
o Not aware that nutrition is beneficial for patients/customers with 
category 1 or 2 AMD 
o Insufficient time  





o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
5.2  Kindly indicate if the following dietary advice was provided for patients/ customers with 
early (category 1 or 2) AMD 
o Eat plenty of leafy green vegetables 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
 
o Eat oily fish, such as salmon 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
o Other:  _________________________________________ 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
 
5.3 Do you think that optometrists in Singapore should be providing dietary advice to 
patients/ customers with early (category 1 or 2) AMD?  
o Yes 




Section 6: Dietary advice to patients/ customers with advanced (category 3 or 4) AMD  
 
6.1  Frequency of dietary advice for patients/ customers with advanced (category 3 or 4) 
AMD 
o Never 
o Rarely (10% of the time) 
§ What is/ are your main reason(s) for not/rarely advising? 
o Insufficient evidence that nutrition is beneficial for patients/ 
customers with category 3 or 4 AMD 
o Do not believe that nutrition is beneficial for patients/ customers 
with category 3 or 4 AMD 
o Not aware that nutrition is beneficial for patients/customers with 
category 3 or 4 AMD 
o Insufficient time  
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o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
6.2  Kindly indicate if the following dietary advice was provided for patients/ customers 
with advanced (category 3 or 4) AMD 
o Eat plenty of leafy green vegetables 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
o Eat oily fish, such as salmon 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
o Other:  _________________________________________ 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
 
6.3 Do you think that optometrists in Singapore should be providing dietary advice to 
patients/ customers with advanced (category 3 or 4) AMD?  
o Yes 




Section 7: Dietary advice to patients/ customers considered to be at risk of AMD 
 
7.1  Frequency of dietary advice for patients/ customers considered to be at risk of AMD 
o Never 
o Rarely (10% of the time) 
§ What is/ are your main reason(s) for not/rarely advising? 
o Insufficient evidence that nutrition is beneficial for patients/ 
customers at risk of AMD  
o Do not believe that nutrition is beneficial for patients/ customers 
at risk of AMD  
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o Not aware that nutrition is beneficial for patients/customers at 
risk of AMD  
o Insufficient time  




o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
7.2  Kindly indicate if the following dietary advice was provided for patients/ customers 
considered to be at risk of AMD  
o Eat plenty of leafy green vegetables 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
o Eat oily fish, such as salmon 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
o Other:  _________________________________________ 
Frequency:  _________________________________________ (Advised to consume 
daily, once a week, etc., or not mentioned) 
Amount:  _________________________________________ (Please indicate if it is in 
servings, grams, others, or not mentioned) 
 
 
7.3 Do you think that optometrists in Singapore should be providing dietary advice to 
patients/ customers considered to be at risk of AMD?  
o Yes 




Section 8: Smoking and AMD 
 





8.2 Frequency of taking a smoking history in new or first time patients/ customers 
o Never 
o Rarely (10% of the time) 
o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time) 
 
8.3  Frequency of taking a smoking history in non-first time review patients/ customers 
o Never 
o Rarely (10% of the time) 
o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
8.4  Frequency of informing smokers of the link between smoking and AMD 
o Never 
o Rarely (10% of the time) 
o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
8.5  Frequency of advising patients/ customers with AMD to stop smoking  
o Never 
o Rarely (10% of the time) 
o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
8.6  Frequency of advising patients/ customers at risk of AMD to stop smoking 
o Never 
o Rarely (10% of the time) 
o Sometimes (20-40% of the time) 
o Often (50-70% of the time) 
o Most of the time (80-90% of the time) 
o Always (100% of the time)  
 
Section 9: Recommendations on nutritional supplements in patients with established or at risk of 
developing AMD 
Kindly indicate the type of supplements (if any) that will be recommended to your patients/ 
customers based on the following scenarios during your practice.  
 
Scenario 1: 
55 year old patient with no evidence of AMD but with one or more parents and/or siblings affected 
by AMD 
o NO supplement recommended 
o AREDS formula 
o AREDS 2 formula 
o Supplements containing macular carotenoids 
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o Supplements containing antioxidant vitamins, lutein and zeaxanthin 
o Supplements containing omega 3 fatty acids 




65 year old patient with advanced AMD in one eye and early AMD in the other 
o NO supplement recommended 
o AREDS formula 
o AREDS 2 formula 
o Supplements containing macular carotenoids 
o Supplements containing antioxidant vitamins, lutein and zeaxanthin 
o Supplements containing omega 3 fatty acids 




75 year old patient with advanced AMD in both eyes 
o NO supplement recommended 
o AREDS formula 
o AREDS 2 formula 
o Supplements containing macular carotenoids 
o Supplements containing antioxidant vitamins, lutein and zeaxanthin 
o Supplements containing omega 3 fatty acids 
o Others (please specify)  
___________________________________________________________ 
 
9.2  Would you consider the smoking status or history of your patients/ customers when 




9.3  Which of the following sources of evidence provide you with information on nutritional 
supplements and AMD? (You may tick more than one) 
o Articles in professional journals 
o Conference presentations, CPE events 
o Reference to specific studies, eg. AREDS 
o Scientific/ Research literature 
o Manufacturers literature 
o Expert opinion 










Section 10: Confidence in classifying AMD and providing nutritional advice to patients with or 
at risk of AMD 
Kindly rate your confidence level from 0 to 100 (in 10 increment steps) for the following 
statements.  
(0=least confident, 100=most confident) 
 
 0 = least 
confident;  
100 = most 
confident 
10.1 I am confident that I could classify the type of AMD a patient has 
based on retinal signs. 
 
 
10.2 I am confident that I can advise a patient with AMD on the 
relationship between AMD and nutrition. 
 
 
10.3 I am confident that I can advise a patient with AMD on what foods to 
eat that might be beneficial for their condition.  
 
 
10.4 I am confident that I can advise a patient with AMD on the quantities 
of food that might be beneficial for their eye health. 
 
 
10.5 I am confident that I can advise a patient with AMD on when 
nutritional supplementation may be beneficial. 
 
 
10.6 I am confident that I can advise a patient with AMD on what 
supplements to take and what dosage to recommend. 
 
 






Would you be interested to participate in evaluating a clinical decision making aid 
for advising patients with or at risk of AMD? 
 
Yes / No  
 
If yes, kindly fill in the following:  
 
Email address: ________________________________________ 
  












RE: Invitational letter to participate in research study titled: “Nutritional and smoking 
advice given to patients with or at risk of age-related macular degeneration by 
optometrists in Singapore 
 
Dear fellow optometrist,  
 
As we are all aware, Singapore has a rapidly greying population and with this trend, the 
prevalence of age-related macular degeneration (AMD) is expected to increase. While 
treatment is currently available for wet AMD, there is no treatment for dry or moderate 
AMD and the only available and most appropriate option is to target the modifiable 
factors such as diet and smoking.  
 
As part of my PhD research study, I would like to understand the nutritional and smoking 
advice that is given by you, as an eye-care professional to your patients with or at risk of 
AMD. More information on the research study can be found in the attached “Study 
Information-Phase 1” document.  
 
Therefore I would really appreciate if you could spend approximately fifteen minutes of 
your time to complete the attached questionnaire, together with the signed informed 
consent form, and mail it back to me in the return envelope.  
 
Alternatively, if you prefer to complete this questionnaire online, you may access it via 
this website:   
 
Kindly complete the questionnaire only once, latest by 31 March 2018.  
 
I look forward to your response and feel free to contact me at should you have 
any questions on the research study.  
 
Thank you for your time.  
 
 






Stacy Chan Hsiao Lan  
Diploma in Optometry (Singapore Polytechnic, 2003) 







STUDY INFORMATION – Phase 1 
Version Five 13/10/17 
Nutritional and smoking advice given to patients with or at risk of age-related 
macular degeneration by optometrists in Singapore 
 
Purpose of the study  
Age-related macular degeneration (AMD) is the leading cause of visual impairment and 
blindness registration in the developed world and in countries with an ageing population 
such as Singapore, the prevalence of AMD is expected to rise. While the treatment for 
“wet” AMD seems promising, there is currently no treatment available for “dry” AMD, and 
the only available and most appropriate option is to target the modifiable factors such as 
diet and smoking. The results from AREDS 1 and AREDS 2 have shown that the intake 
of antioxidants such as vitamins E and C, beta-carotene or lutein and zeaxanthin and 
zinc could reduce the risk of developing advanced AMD. Additionally, there is also 
increasing evidence that smoking is casually linked to the development of AMD.  
This study consists of two phases and this study information relates to Phase 1. In Phase 
1 of this study, we aim to investigate the nutritional and smoking advice that optometrists 
in Singapore are currently providing to their patients with or at risk of AMD through a 
questionnaire. At the end of the questionnaire, you will be asked to indicate your interest 
to participate in Phase 2 of this study, which is to evaluate the effectiveness of a clinical 
decision-making aid.  
 
Why have I been chosen? 
This study is open to any optometrist who is fully registered under the Optometrists and 
Opticians Board (OOB) and is currently practicing in Singapore.  
 
Do I have to take part? 
No, you do not have to participate if you do not wish to do so.  If you decide to participate, 
you are free to withdraw from the study at any time without penalty.  
 
What does the study involve? 
You will be requested to complete a questionnaire on AMD either through an online link 







The questionnaire includes the following questions: 
• Demographic information including age, gender, number of years practicing as a fully 
registered optometrist, highest qualification attained in the field of optometry as well 
as the type and location of practice currently working in.  
• Tests routinely performed on patients aged 50 and above (2 questions)  
• Number of AMD patients seen per year (2 questions) 
• Perspective on AMD and nutrition (2 questions)     
• Dietary advice to patients with early (Category 1 or 2) AMD (3 questions)  
• Dietary advice to patients with advanced (Category 3 or 4) AMD (3 questions)  
• Dietary advice to patients considered to be at risk of AMD (3 questions)  
• Smoking and AMD (6 questions) 
• Recommendations on nutritional supplements in patients with established or at risk 
of developing AMD (5 questions)  
• Confidence in classifying AMD and providing nutritional advice to patients with or at 
risk of AMD (7 questions)  
 
At the end of the questionnaire, you will be invited to indicate if you would like to 
participate in Phase 2 of this study, that is to validate a clinical decision making aid when 
providing nutritional advice for patients with or at risk of AMD. If interested, you will be 
asked to provide your contact details.  
 
What are the benefits of taking part? 
It is anticipated that the results in this study can help to identify the areas that 
optometrists in Singapore are lacking in when providing nutritional and smoking advice 
to patients with or at risk of AMD, and subsequently be trained on these areas during 
conferences or continuing professional education seminars.  
 
Are there any risks or disadvantages of taking part? 
This study does not involve any known physical risks and optometrists are requested to 
spend approximately fifteen minutes of their time to complete the questionnaire and to 
mail it should they choose to complete the hardcopy version. There is a risk of breaching 
privacy and confidentiality in relation to your survey results but this risk will be minimised 
by keeping your data anonymous at all times. Ms. Stacy Chan will be responsible for 
putting your survey results onto a database and maintaining your privacy and 
confidentiality. Only Ms. Stacy Chan will have access to the database that is password 
protected.  
 
What will happen to the results of the study? 
We aim to publish the results of this research study.  However, there will be no reference 
to any optometrist’s survey results in any publication. A copy of the published research 




Who has reviewed the study? 
The study has been reviewed by Aston University Research Ethics Committee and 
Parkway Independent Ethics Committee.  
  
Researchers 
Stacy Hsiao Lan Chan 





Optometrist. Senior Lecturer. Vision Sciences department, Aston University. 
Contact:  
 
Where can I get more information? 
Please contact Rebekah Stevens if you would like any more 
information about the study. 
What if there is a problem? 
If you have any concerns about anything to do with this study, you should speak to the 
research team and they will do their best to answer your concerns. You may contact 
either Stacy Chan at , or Hannah Bartlett at  
telephone 0121 204 4182. If they cannot help you and you still have concerns or wish 
to make a complaint about the way in which the study has been conducted, then you 








CONSENT FORM (PHASE 1)  
Version 4: 13 October 2017 
 
 
Project Title: Nutritional and smoking advice given to patients with or at risk of 
age-related macular degeneration (AMD) by optometrists in Singapore  
 
Name of Researcher(s): Hannah Bartlett and Stacy Chan  
 
  Initial 
1 I confirm that I have read and understand the information sheet 
(Version 5 dated 13 October 2017) for the above study. I have had 
the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal 















Name of volunteer 
___________________ 








Name of researcher 
___________________ 









Appendix A: Sample images for AMD categorization 
Category 2: multiple small drusen or nonextensive intermediate drusen (63-124 microns), pigment 
abnormalities, or a combination of the two 
Category 3: no advanced AMD but had ≥ 1 large drusen (125 microns), extensive area of intermediate 
drusen, or geographic atrophy (GA) not involving the center of macula 
Category 4: advanced AMD, central GA or neovascular AMD in one eye 
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Appendix F 
Dear fellow optometrist,  
 
As we are all aware, Singapore has a rapidly greying population and with this trend, the 
prevalence of age-related macular degeneration (AMD) is expected to increase. While 
treatment is currently available for wet AMD, there is no treatment for dry or moderate 
AMD and the only available and most appropriate option is to target the modifiable 
factors such as diet and smoking.  
 
As part of my PhD research study, I would like to understand the nutritional and smoking 
advice that are given by you, as an eye-care professional to your patients with or at risk 
of AMD. More information on the research study can be found here. (Link to Study 
Information-Phase 1 document) 
 
Therefore I would really appreciate if you could spend fifteen minutes of your time to 
complete a questionnaire by clicking on this link. (Link to consent form and questionnaire)  
Kindly complete the questionnaire only once.  
 
I look forward to your response and feel free to contact me at should you have 
any questions on the research study.  
 























STUDY INFORMATION – Phase 1b 
Version One – 05/02/19 
Nutritional and smoking advice given to patients with or at risk of age-related 
macular degeneration by optometrists in Singapore 
 
Purpose of the study  
Age-related macular degeneration (AMD) is the leading cause of visual impairment and 
blindness registration in the developed world and in countries with an ageing population 
such as Singapore, the prevalence of AMD is expected to rise. While the treatment for 
“wet” AMD seems promising, there is currently no treatment available for “dry” AMD, and 
the only available and most appropriate option is to target the modifiable factors such as 
diet and smoking. The results from AREDS 1 and AREDS 2 have shown that the intake 
of antioxidants such as vitamins E and C, beta-carotene or lutein and zeaxanthin and 
zinc could reduce the risk of developing advanced AMD. Additionally, there is also 
increasing evidence that smoking is casually linked to the development of AMD.  
This study consists of two phases and this study information relates to Phase 1b. In 
Phase 1b of this study, we aim to understand optometrists’ views on nutrition and the 
eye via a face-to-face interview.  
 
Why have I been chosen? 
This study is open to any optometrist who is fully registered under the Optometrists and 
Opticians Board (OOB) and is currently practicing in Singapore.  
 
Do I have to take part? 
No, you do not have to participate if you do not wish to do so.  If you decide to participate, 
you are free to withdraw from the study at any time without penalty.  
 
What does the study involve? 
You will go through a face-to-face interview with the main researcher, Stacy Chan, and 
this interview will take approximately thirty to forty-five minutes of your time at a location 
of your convenience.  
 
The interview will include the following questions: 
• Do you think nutrition plays a role in preventing or treating certain eye conditions? 
What are the eye conditions that you think will benefit from nutrition? (For each eye 
condition, what nutritional advice/information have you given to patients? Or for each 
eye condition, what kind of nutritional advice/information do you think is appropriate 
for patients?) Where do you get the information regarding nutrition and the eye from?  
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• What were your patients’ reactions to you offering this advice/information? (If 
participants have not engaged in this scenario, ask whether participants believe that 
patients would expect optometrists to be involved in this type of activity and why?)  
• How do you feel about including nutritional advice/information within your patient 
management?  
• What factors influence whether or not you give nutritional advice/information to your 
patients? What do you think is most challenging/difficult when providing nutritional/ 
smoking advice to AMD patients?  
• Do you routinely screen for age-related macular degeneration (AMD) in your practice 
for patients aged 50 years and above? (If yes, ask how is AMD diagnosed in your 
practice? If no, ask what is/are the main reasons for not routinely screening?) 
Currently the use of diagnostic drugs has not been legalized in Singapore, but do 
you think the use of these drugs will aid in your diagnosis of AMD?  
• If you agree that you have an important role to play in the health promotion and 
dietary advice giving to patients, what can be done to support you further in your 
professional development relating to this aspect of your role?  
• Are there any other comments you would like to make in relation to this area of patient 
care and management?  
 
For analysis of the research data, the entire interview will be voice recorded.  
 
What are the benefits of taking part? 
It is anticipated that the results in this study can help to understand Singapore 
optometrists’ view on nutrition and the eye, particularly the areas that optometrists in 
Singapore are lacking in when providing nutritional and smoking advice to patients with 
or at risk of AMD. Optometrists in Singapore can then be subsequently trained in these 
areas during conferences or continuing professional education seminars.  
 
Are there any risks or disadvantages of taking part? 
This study does not involve any known physical risks and optometrists are requested to 
spend approximately thirty to forty-five minutes of their time for the interview. There is a 
risk of breaching privacy and confidentiality in relation to your survey results but this risk 
will be minimised by keeping your data anonymous at all times. Ms. Stacy Chan will be 
responsible for recording the interview, downloading it into a database, and maintaining 
your privacy and confidentiality. Only Ms. Stacy Chan will have access to the database 
that is password protected.  
 
What will happen to the results of the study? 
We aim to publish the results of this research study.  However, there will be no reference 
to any optometrist’s interview results in any publication. A copy of the published research 
will be provided to you once the research study has been approved for publishing.   
 
Who has reviewed the study? 
The study has been reviewed by Aston University Research Ethics Committee and 





Stacy Hsiao Lan Chan 





Optometrist. Senior Lecturer. Vision Sciences department, Aston University. 
Contact:  
 
Where can I get more information? 
Please contact Rebekah Stevens if you would like any more 
information about the study. 
 
What if there is a problem? 
If you have any concerns about anything to do with this study, you should speak to the 
research team and they will do their best to answer your concerns. You may contact 
either Stacy Chan at , or Hannah Bartlett at  or 
telephone . If they cannot help you and you still have concerns or 
wish to make a complaint about the way in which the study has been conducted, then 
you should contact the Aston University Director of Governance,  
. 
If you want an independent opinion of your rights as a research subject you may 









CONSENT FORM (PHASE 1b)  
Version 1: 5 February 2019 
 
 
Project Title: Nutritional and smoking advice given to patients with or at risk of 
age-related macular degeneration (AMD) by optometrists in Singapore  
 
Name of Researcher(s): Hannah Bartlett and Stacy Chan  
 
  Initial 
1 I confirm that I have read and understand the information sheet 
(Version 1 dated 5 February 2019) for the above study. I have had 
the opportunity to consider the information, ask questions and 
have had these answered satisfactorily. 
 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal 















Name of volunteer 
___________________ 








Name of researcher 
___________________ 









STUDY INFORMATION – Phase 2 
Version Seven 31/10/17 
Nutritional and smoking advice given to patients with or at risk of age-related 
macular degeneration by optometrists in Singapore 
 
Purpose of the study  
Age-related macular degeneration (AMD) is the leading cause of visual impairment and 
blindness registration in the developed world. In countries with an ageing population 
such as Singapore, the prevalence of AMD is expected to rise and following the AREDS 
1 study, there were many nutritional supplements available in the market that claimed to 
preserve the vision of patients with AMD. However, patients or even some optometrists 
are unaware that the AREDS formulation is only beneficial for patients with moderate 
AMD. It is important for optometrists to know which patients meet the AREDS inclusion 
criteria, and could benefit from this specific formulation. Therefore, a clinical decision-
making aid has been developed in the form of a flowchart to help optometrists choose 
the appropriate nutritional advice for their patients.  
This study consists of two phases and this study information relates to Phase 2, where 
the aim is to validate this clinical decision-making aid.  
 
Why have I been chosen? 
This study is open to any optometrist who is fully registered under the Optometrists and 
Opticians Board (OOB) and is currently practicing in Singapore.  
 
Do I have to take part? 
No, you do not have to participate if you do not wish to do so.  If you decide to participate, 
you are free to withdraw from the study at any time without penalty.  
 
What does the study involve? 
You will be requested to validate a clinical decision-making aid in the form of a flowchart 
by completing a self-efficacy survey before and after using the aid based on case 
scenarios.  
 
Firstly, you will be presented with five AMD scenarios and asked to indicate the nutritional 
advice that you will provide for each case. After which, you will be requested to complete 
a short survey of seven questions that takes approximately five minutes and will assess 
your thoughts on giving nutritional advice to patients with or at risk of AMD. The survey 
will involve answering questions on a scale of 0 – 100.  
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You will then be provided with the clinical decision-making aid and be briefed on how to 
use it. The five case scenarios will then be presented to you again and you will be 
requested to provide the appropriate nutritional advice for each case with the aid. Finally, 
you will be asked to complete the survey again with the seven questions that will take 
another five minutes of your time.  
 
Will I be compensated for my participation? 
You will be reimbursed with S$10 coffee voucher for participation in this study. 
 
Are there any risks of disadvantages of taking part? 
There are minimal potential risks in taking part in this study. Some optometrists may lack 
confidence in the area of nutrition for AMD but participation is anonymous and their 
confidence has the potential to improve after using the clinical decision-making aid. 
There is a risk of breaching privacy and confidentiality in relation to your survey results 
but this risk will be minimised by keeping your data anonymous at all times. Ms. Stacy 
Chan will be responsible for putting your survey results onto a database and maintaining 
your privacy and confidentiality. Only Ms. Stacy Chan will have access to the database 
that is password protected.  
 
What will happen to the results of the study? 
We aim to publish the results of this research study.  However, there will be no reference 
to any optometrist’s survey results in any publication. A copy of the published research 
will be provided to you once the research study has been approved for publishing.   
 
Who has reviewed the study? 
The study has been reviewed by Aston University Research Ethics Committee and 
Parkway Independent Ethics Committee.  
  
Researchers 
Stacy Hsiao Lan Chan 





Optometrist. Senior Lecturer. Vision Sciences department, Aston University. 
Contact:  
 
Where can I get more information? 
Please contact ) if you would like any more 
information about the study. 
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What if there is a problem? 
If you have any concerns about anything to do with this study, you should speak to the 
research team and they will do their best to answer your concerns. You may contact 
either Stacy Chan at , or Hannah Bartlett at  or 
telephone  If they cannot help you and you still have concerns or 
wish to make a complaint about the way in which the study has been conducted, then 
 
 















STUDY INFORMATION – Phase 2b 
Version Two 29/04/2019 
Nutritional and smoking advice given to patients with or at risk of age-related 
macular degeneration by optometrists in Singapore 
 
Purpose of the study  
Age-related macular degeneration (AMD) is the leading cause of visual impairment and 
blindness registration in the developed world. In countries with an ageing population 
such as Singapore, the prevalence of AMD is expected to rise and following the AREDS 
1 study, there were many nutritional supplements available in the market that claimed to 
preserve the vision of patients with AMD. However, patients or even some optometrists 
are unaware that the AREDS formulation is only beneficial for patients with moderate 
AMD. It is important for optometrists to know which patients meet the AREDS inclusion 
criteria, and could benefit from this specific formulation. Therefore, a clinical decision-
making aid has been developed in the form of a flowchart to help optometrists choose 
the appropriate nutritional advice for their patients.  
This study consists of two phases and this study information relates to Phase 2, where 
the aim is to validate this clinical decision-making aid.  
 
Why is my child chosen to participate in this research study? 
This study is open to any final year student optometrist who is currently pursuing his/her 
diploma in optometry in Singapore.  
 
Does my child have to take part in this study? 
No, your child’s participation in this study is voluntary.  Your child may decline to 
participate or to withdraw from participation at any time. You can allow your child to be 
in the study now and change your mind later without any penalty.  
 
What does the study involve? 
Your child will be requested to validate a clinical decision-making aid in the form of a 
flowchart by completing a self-efficacy survey before and after using the aid based on 
case scenarios. As part of the control for this study, he/she may be asked to read an 
article instead of using the clinical decision-making aid.  
 
Firstly, your child will be presented with five AMD scenarios and asked to indicate the 
nutritional advice that he/she will provide for each case. After which, he/she will be 
requested to complete a short survey of seven questions that takes approximately five 
minutes and will assess his/her thoughts on giving nutritional advice to patients with or 
at risk of AMD. The survey will involve answering questions on a scale of 0 – 100.  
 194 
Your child will then be provided with the clinical decision-making aid and be briefed on 
how to use it. Alternatively, he/she may be asked to read an article on AMD 
management. The five case scenarios will then be presented to your child again and 
he/she will be requested to provide the appropriate nutritional advice for each case with 
the aid or article. Finally, your child will be asked to complete the survey again with the 
seven questions that will take another five minutes of his/her time.  
 
 
Will my child be compensated for his/her participation? 
Your child will be reimbursed with S$10 coffee voucher for participation in this study. 
 
Are there any risks or disadvantages of taking part in this study? 
There are minimal potential risks in taking part in this study. Student optometrists may 
not be very confident in providing nutritional advice to AMD patients as they are not well 
versed in this area, or they could also be not seeing many AMD patients. However, their 
confidence may increase with the aid. There is a risk of breaching privacy and 
confidentiality in relation to your child’s survey results but this risk will be minimised by 
keeping your child’s data anonymous at all times. Ms. Stacy Chan will be responsible for 
putting your child’s survey results onto a database and maintaining his/her privacy and 
confidentiality. Only Ms. Stacy Chan will have access to the database that is password 
protected.  
 
What will happen to the results of the study? 
We aim to publish the results of this research study.  However, there will be no reference 
to any student optometrist’s survey results in any publication.  
 
Who has reviewed the study? 
The study has been reviewed by Aston University Research Ethics Committee and 
Parkway Independent Ethics Committee.  
  
Researchers 
Stacy Hsiao Lan Chan 





Optometrist. Senior Lecturer. Vision Sciences department, Aston University. 
Contact:  
 
Where can I get more information? 
Please contact ) if you would like any more 
information about the study. 
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What if there is a problem? 
If you have any concerns about anything to do with this study, you should speak to the 
research team and they will do their best to answer your concerns. You may contact 
either Stacy Chan at , or Hannah Bartlett at  or 
telephone . If they cannot help you and you still have concerns or wish 
to make a complaint about the way in which the study has been conducted, then you 









CONSENT FORM (PHASE 2b)  
Version 2: 29 April 2019 
 
 
Project Title: Nutritional and smoking advice given to patients with or at risk of 
age-related macular degeneration (AMD) by optometrists in Singapore  
 
Name of Researcher(s): Hannah Bartlett and Stacy Chan  
 
  Initial 
1 I confirm that I have read and understand the information sheet 
(Version 2 dated 29 April 2019) for the above study. I have had the 
opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
 
2 I understand that my child’s participation in this study is voluntary 
and that he or she is free to withdraw at any time without giving 














Name of child  
___________________ 







Name of parent or  
Legal Guardian  
___________________ 








Name of researcher 
___________________ 
Signature of researcher 
_________________ 
Date  
 
 
